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Abstract 
 
In eukaryotes, the majority of intracellular proteins are degraded by a 2.5 megadaltons 
multimeric assembly, the proteasome. This giant self-compartmentalizing protease ensures the quality 
of intracellular proteins and controls numerous cellular processes by regulating the break-down of key 
regulatory proteins. Selectively depleting intracellular proteins could open a new avenue for protein 
function analysis and therapeutic applications. It can be achieved by specifically leading the protein of 
interest to the proteasome for degradation. Several protein knock-out techniques were developed, but 
engineered degradation has so far been successfully applied to very few proteins only, and every time 
redesigned case by case. To further assess the potential of protein knock-out, we chose to use a 
common binding scaffold, DARPins, for the design of diverse generalizable effector proteins, meant to 
degrade any kind of target protein.  
The proteasome functions primarily to break down proteins which have been covalently 
modified with a polyubiquitin tag. Ubiquitin protein ligases (E3) are the enzymes responsible for the 
substrate specificity of the ubiquitination reaction. We aimed at altering their recognition function to 
ubiquitinate selected proteins. SCF (Skp1 - Cullin - F-Box protein) ubiquitin ligases, a well characterized 
family of multisubunit E3 enzymes, were exploited to achieve designed degradation. They contain a core 
enzymatic structure and an interchangeable F-Box protein subunit, which is responsible for the SCF 
substrate specificity.  A chimeric F-box protein was engineered using DARPin to provide an artificial 
specificity domain. In S. cerevisiae, a chimeric F-box protein could specifically destabilize a cognate 
target protein in a SCF- and proteasome-dependent manner. The chimeric F box protein was further 
reengineered in order to better investigate how F-box proteins mediate ubiquitination. A deeper 
understanding of the ubiquitination machinery was gained but the target protein degradation efficiency 
stayed limited.  
An ubiquitin free route was also used as an alternative strategy for degrading selected proteins. 
A small subset of proteins is degraded by the proteasome without prior ubiquitination. These proteins 
contain a degradation signal, named degron, enabling a direct interaction with the proteasome. The 
ODC and NYV degron sequences, originating from the mouse ornithine decarboxylase and the G1 
glycoprotein of NY-1V hantavirus, respectively, were evaluated in S. cerevisiae. Different kinds of target 
proteins, among which highly stable ones like DARPins, were very rapidly degraded by the proteasome, 
when the ODC- or NYV-degron was fused to their C termini. We then assessed if a degron could work in 
trans to induce degradation of a binding partner. A DARPin-degron was co-expressed with a cognate 
target protein in S. cerevisiae. Whereas the DARPin-degron was quickly degraded, the levels of the 
target protein were not affected. In mammalian cells, DARPin-degron constructs could be targeted to 
the proteasome with a lower rate than in S. cerevisiae. In spite of more favorable interaction conditions 
and complex formation, a co-expressed cognate target protein was still not co-degraded.  
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Targeted degradation may be very valuable for the complete removal of proteins potentially 
toxic for the cell such as oncoproteins, viral proteins and stabilized proteins in neurodegenerative 
diseases. Our experimental data indicate that targeting a selected protein to the proteasome might not 
be enough to turn it into an eligible substrate. The proteasome might require specific substrate 
characteristics to achieve efficient degradation, making the development of a general protein knock-out 
strategy more challenging than it was previously assumed.   
 
Zusammenfassung 
 
In Eukaryoten wird die Merheit der intrazellulären Proteine vom Proteasom, einem 2.5 
Megadalton multimerischen Komplex abgebaut. Diese gigantische Protease ist verantwortlich für die 
Qualität der intrazellulären Proteine und kontrolliert zahlreiche zelluläre Prozesse durch den Abbau von 
Proteinen mit Schlüsselfunktionen. Der spezifische Abbau von intrazellulären Proteinen könnte einen 
neuen Weg für die Funktionsanalyse von Proteinen eröffnen und zudem eine therapeutische  Anwedung 
haben. Eine Möglichkeit, um ein bestimmtes Zielprotein abzubauen, ist es dieses spezifisch zum 
Proteasom zu führen. Mehrere Protein-knock-out-Techniken/Strategien wurden entwickelt, konnten  bis 
zum jetzigen Zeitpunkt aber nur für ein begrenzte Reihe von Proteinen bewiesen werden. Zudem musste 
das Verfahren für jedes Zielprotein einzeln optimiert werden. Um das Potenzial von Protein-knock-out-
Strategien richtig einzuschätzen, haben wir ein generelles proteinbindendes Molekül, DARPIns, zu Hilfe 
genommen. Mithilfe dieser DARPins wurden verschiedene Effektor moleküle hergestellt, welche den 
Abbau von beliebigen Protein ermöglichen sollten.  
Das Proteasom zerstört hauptsächlich Proteine, an die eine Polyubiquitinkette angehängt 
wurde. Ubiquitin-Protein-Ligasen (E3) sind diejenigen Enzyme, die für die Spezifizität der 
Ubiquitinierungsreaktion verantwortlich sind. Eine Strategie verfolgte die Modifizierung der 
Erkennungsfunktion der E3-Ligasen, so dass diese ein Zielprotein für die Ubiquitinierungsreaktion 
auswählen würden. SCF (Skp1 - Cullin - F-Box protein)- Ubiquitin-Ligasen, eine Familie von 
multimerischen E3-Enzymen, wurden genutzt um spezifischen Abbau zu ermöglichen. Der SCF Komplex 
besteht aus einer enzymatischen Kernstruktur und einem austauschbaren Faktor, dem F-box-Protein. 
Dieses funktioniert wie ein Adaptor, der spezifisch Substrate in der Zelle rekrutiert. Mithilfe von DARPins 
wurde ein chimäres F-box-Protein konstruiert, welches eine künstlichen Substraterkennungsstruktur 
besitzt. In Anwesenheit eines chimären F-box Proteins konnte ein bestimmtes Zielprotein spezifisch 
durch die SCF-Ligase und das Proteasom abgebaut werden, falls beide in S. cerevisiae coexprimiert 
wurden. Das chimäre F-box Protein wurde weiterentwickelt, um genauer zu analysieren, wie F-box-
Proteine den Proteinabbau steuern. Die erhaltenen Ergebnisse führten zu einem besseren Verständnis 
des Ubiquitinierungsprozesses; die Effizienz des Proteinabbaus blieb jedoch begrenzt. 
 
3 
 
Eine alternativer Ansatz nutzte einen Ubiquitin-freien Weg, um ein Zielprotein zum Proteasom 
zu bringen. Eine kleine Gruppe von Proteinen benötigt keine Ubiquitinierung, um abgebaut zu werden. 
Sie erhalten eine kleine Sequenz – Degron genannt - die direkt mit dem Proteasom interagiert. Die 
Effekte des ODC(Maus Ornithine Decarboxylase)-Degrons und des NYV(G1 Glycoprotein des NY-1V 
Hantaviruses)-Degrons wurden im S. cerevisiae untersucht. Verschiedene Proteine, unter diesen hoch 
stabile Proteine wie DARPins, wurden sehr schnell durch das Proteasom abgebaut, falls eine dieser 
Degron-Sequenzen am C-Terminus fusioniert wurde. Ein DARPin-Degron-Fusionsprotein wurde mit 
einem bindenden Zielprotein in S. cerevisiae exprimiert. Das DARPin-degron wurde schnell abgebaut, 
während das bindende Zielprotein stabil blieb. In humanen Zellen wurden die DARPin-degron-Fusionen 
weniger schnell als in S. cerevisiae abgebaut. Die Vorraussetzungen für Interaktionen mit dem 
Zielprotein und den Komplexeinbau waren gegeben, jedoch wurde das Zielprotein dennoch nicht 
abgebaut. 
Gezielter Abbau von Proteinen wäre ein wertvolles Werkzeug um toxische Proteine, die 
Krankheiten verursachen (zum Beispiel Onkoproteine, virale Proteine, oder stabile Proteine typisch für 
neurodegenerative Erkrankungen), zu entfernen. Unsere Ergebnisse zeigen, dass es nicht ausreicht ein 
beliebendes Protein zum Proteasom zu schicken um seinen Abbau auszulösen. Der Proteinabbau durch 
das Proteasom erfordert vielleicht zusätzliche Proteineigenschaften, damit es als Substrat behandelt 
wird. Unter diesen Bedingungen ist die Entwicklung einer generellen Protein-knock-out-Strategie 
herausfordernder als vorausgesetzt. 
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Proteins are in a dynamic state 
 
The concept of protein degradation is about 70 years old. Earlier, dietary proteins were believed 
to function primarily as energy-providing fuel and the protein components of the body were considered 
as stable constituents [1]. Between 1937 and 1941, Rudolf Schönheimer studied protein metabolism; 
using 15N-labelled amino-acids he showed that bodily protein components were turning over. In his 
posthum book “ The Dynamic State of Body Constituents” [2], he proposed the concept of metabolic 
regeneration and wrote: “ The simile of the combustion engine pictured the steady state flow of fuel into 
a fixed system, and the conversion of this fuel into waste products. The new results imply that not only 
fuel, but the structural materials are in steady state of flux. The classical doctrine (of metabolism) must 
thus be replaced by one which takes account of the dynamic state of body structure.” Under 
physiological conditions, whole body protein degradation is approximately equivalent to whole body 
protein synthesis for a human adult [3]. These are mostly intracellular proteins which account for the 
vast bulk of body protein turnover. All intracellular proteins are in a dynamic state, they are continuously 
degraded with half-lives ranging from a few minutes to more than 60 h. Two major intracellular 
proteolysis systems co-exist.  The lysosome, an organelle which contains a broad array of varying 
proteases, is responsible for the non-selective degradation of intracellular proteins.  By a process of 
autophagy, a portion of cytoplasm or organelle is sequestered within a membrane sac which then fuses 
with the lysosome. Lysosomal enzymes disintegrate the sac and digest its content. Regulated 
degradation of intracellular proteins is performed by the proteasome. This multimeric assembly of 
approximately 2.5 megadaltons functions primarily to break down proteins which have been covalently 
modified with a polyubiquitin tag [4]. Polymerization of ubiquitin and conjugation to the target protein is 
achieved by concerted actions of a cascade of enzymes: ubiquitin activating enzyme, ubiquitin 
conjugating enzyme and ubiquitin protein ligase [5]. The mechanism underlying the ubiquitylation 
reaction will be more deeply described in the introduction of chapter 1. The proteasome is a giant self-
compartmentalizing protease which structurally consists of a proteolytic chamber (20S core particle) and 
an ATP dependent regulatory machinery (19S regulatory particle), functionally linked by a gated protein 
translocation channel [6]. Substrates are degraded via a multistep mechanism involving distinct 
proteasome subunits. The 19S regulatory particle (RP) mediates substrate recognition, preparation, 
unfolding and translocation into the 20S core particle [7]. The 20S core particle processively digests 
substrates in a highly heterogeneous mixture of peptides ranging from 3 to 22 residues [8]. An overview 
of the proteasome’s architecture is given; identified subunits give insights into its mechanism. 
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Figure 1: Architecture of the yeast 20S proteasome. (a) Side view of the proteasome. Active sites are 
formed at the N-termini of β1, β2 and β5. (b) Cutaway stereoview showing how the active sites (yellow) 
are sequestered within a central catalytic chamber formed by the two β-rings. Substrates and products 
pass through the α-annulus (green) through the middle of α-rings. (c) Top view of the proteasome in the 
closed conformation. (d) Top view of the proteasome in the open conformation. Adapted from 
Rechtsteiner & Hill, 2005 [9]. 
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The proteasome, an elaborate proteolytic machinery 
 
20S core particle (CP) 
The CP is made of 28 subunits arranged into four stacked heteroheptameric rings: two inner β-rings and 
two α-outer rings made up of seven similar yet distinguishable β- and α-subunits [10] (Fig. 1a). This 
assembly builds a barrel-shaped complex which encloses three internal cavities interconnected by a 
narrow channel with restricted orifices (Fig. 2) [11]. The central cavity formed by the β-rings is the 
proteolytic chamber (Fig. 1b). Three beta subunits harbor the catalytic active sites; β1, β2 and β5 are 
associated with caspase-like, trypsin-like and chymotrypsine-like activities respectively, which confer the 
ability to cleave peptide bonds on the C-terminal side of acidic, basic and hydrophobic residues 
respectively [12]. The two outer cavities are antechambers formed jointly by one α- and one β-ring. 
Antechambers may be used to keep substrates in storage prior to their processive degradation in the 
catalytic chamber [13]. The two α-rings provide a gating mechanism for the degradative chamber (Fig. 
1c). α-subunits converge axially at their N-termini in an interdigitated network that closes the entrance 
of the channel [14]. On the regulatory particle (RP) facing surface of the ring, they form α-pockets; when 
the RP binds on these α-pockets, it triggers opening of the channel (Fig. 1d) [15].  
19S regulatory particle 
The 19S regulatory particle (RP) comprises 19 subunits that are sub-classified in two groups: 6 Regulatory 
particles of triple- ATPase (Rpt) and 13 Regulatory particles of non-ATPase (Rpn) subunits [16]. 
Structurally, it consists of two sub-complexes: the lid and base assemblies, which are distal and proximal 
to the CP, respectively (Glickman, 98).  
The base 
The base is responsible for capturing client proteins, promoting unfolding and opening the CP channel. 
This sub-complex contains six homologous AAA-ATPase (Rpt1-6) and four non-ATPase (Rpn1,2,10,13) 
subunits. Rpts are critical for opening the α-ring channel but also for substrate unfolding. The six ATPases 
are organized in a hexameric ring; the resulting structure has a hexagonal base and on the top of it a 
“mouth” [17]. Three of these subunits (Rpt2,3,5) contain a conserved C-terminal hydrophobic-tyrosine-X 
motif which can insert into the above-described α-pockets of the CP, like a "key in a lock", to induce gate 
opening. Stabilization of the open gate may be achieved through wobbling of the ATPases [15, 17]. AAA-
ATPases are also involved in proteasome assembly, substrate deubiquitination, unfolding and 
translocation into the CP [18]. Several evidences point towards a coupling of unfolding and 
translocations events, which would be driven by a same motor [19]. The substrate is, via an “initiation 
sequence”, pulled within the translocation channel, in an ATP-dependent manner. Unfolding follows, 
resulting from exposure of previously protected domains of the substrate and/or collisions between the 
rest of the substrate chain and the entry port of the narrow channel. 
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Figure 2: Determination of the Drosophila 26S proteasome density by Cryo-electron microscopy. Nickell 
& colleagues collected a large number of 26S images. A first 3D reconstruction was obtained by using a 
standard angular refinement procedure; a plain cylinder model was used as an initial reference to assign 
optimal projection directions and in-plane transformations to all experimental particles, and the model 
was iteratively refined until no further improvements were observed. Seven different views (from top to 
bottom) of the 26S proteasome reconstruction rotated around the pseudo-7-fold axis of the 20S CP are 
presented. The left column shows isosurface representations of the entire 3D reconstruction of the 26S 
proteasome complex; the second column from the left shows isosurfaces of the reconstruction cut open 
along the pseudo-7-fold axis of the core particle to display its inner organization. The second column 
from the right shows central slices in the x–y plane of the density distribution (mass is white) of the 
reconstruction. The right column shows a mesh representation of the reconstruction with an overlay 
isosurface in red highlighting the main variances. Adapted from Nickell & al., 2009 [17]. 
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Rpn1 and Rpn2 function as scaffolding proteins which mediate binding with proteasome associated 
proteins. All known binding factors are involved in ubiquitin chain recognition [20], disassembly [21] or 
extension [22]; it seems then that these two subunits play a major role in the proteasome for chain 
dynamics. Rpn1 and Rpn2 form a stacked double-toroid structure, capable of attaching the CP 
independently of the Rpt ring and aligning its own channel with the CP’s one [23]. It was then proposed 
that these Rpn1/Rpn2 channel may be a part of the substrate translocation channel of the base. Yet 
latest structural data of the 26S proteasome do not support this model [17]. 
Rpn10 and Rpn13 are integral ubiquitin receptors [24, 25]. These subunits respectively trap their 
substrates via an Ubiquitin Interacting motif (UIM) [26] or pleckstrin-like-receptor for ubiquitin (Pru) 
domain [27]. Rpt5, another subunit could be an additional ubiquitin receptor as it was reported to bind 
polyubiquitylated proteins in vitro [28]. In addition to the intrinsic ubiquitin receptors, there are three 
proteasome-associated ubiquitin receptors: Rad23, Dsk2 and Ddi1 [19, 29, 30]. These proteins, called 
UBL-UBA proteins, harbor an N-terminal UBL (ubiquitin-like) domain which binds the proteasome and 
one or two UBA (ubiquitin-associated) domain which bind ubiquitin. These UBL-UBA proteins are 
thought to function as shuttle proteins which may capture remote substrates and escort them to the 
proteasome. UBL-UBA proteins can dock ubiquitylated proteins at the proteasome. Moreover, they can 
interact with ubiquitin ligases, the enzymes involved in the attachment of ubiquitin chains onto the 
substrate. It is unclear whether these shuttle proteins deliver their bound substrate directly to the 
proteasome base or if they first hand them off to the intrinsic receptors as their UBL domain can be 
bound by Rpn10 and Rpn13. Noteworthy, ubiquitin receptors may not have a promiscuous capacity to 
bind ubiquitylated proteins as UBL-UBA proteins and Rpn10 showed significant substrate selectivity in 
vivo. What’s more, as the five identified ubiquitin receptors are non-essential in yeast, additional 
receptors remain to be discovered.  
The lid 
The lid complex is composed of nine non-ATPase subunits (Rpn3,5,6,7,8,9,11,12,15) but only one has a 
known function. Rpn11 is a deubiquitinating enzyme (DUB), it separates the polyubiquitin chains from 
the substrate by cleaving them at a proximal site [31, 32]. Its deubiquitination activity requires 
association with the lid and ATP, suggesting that Rpn11 does only act on substrates which are already 
proceeding on the pathway of degradation. How the deubiquitination and degradation mechanisms are 
exactly coupled is unknown but proteasomes function poorly in the absence of Rpn11. It is assumed that 
ubiquitin chains would obstruct substrate translocation and/or slow down unfolding processes. However 
it appeared lately that ubiquitin can be degraded along with the substrate protein in a “piggyback” 
mechanism [33]. Perhaps more importantly, ubiquitin homeostasis is essential for cell viability, and as 
this protein is transcribed at relatively low levels, it might be crucial to recycle it.   
Additionally, ubiquitin chains can be trimmed at their distal end by two other DUBs: Ubp6 (Usp14) and 
Uch37 [34]. Ubp6 reversibly associates with the proteasome while it is still under debate if Uch37 does 
so as well or is a stoichiometric component of the 26S proteasome. Associated DUBs may provide an 
editing function to spare inappropriately or poorly modified substrates from destruction [35]. Besides, 
these ATP-independent enzymes seem to complement the action of Rpn11, possibly by clearing the 
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proteasome of bound polyubiquitin chains to create occupancy for new rounds of polyubiquitylated 
protein binding and proteolysis [34] 
Compositional variants of the proteasome 
The proteasome has been highly conserved during evolution. However, it appears that its function can 
be modulated through association of the regulatory particle (RP) with a constellation of specific 
proteasome interacting proteins. Another regulation mechanism relies on its assembly. The core particle 
(CP) can associate with different proteasome activators and even some of its subunits can be specifically 
replaced.  
Proteasome interacting proteins (PIPs) 
Recent proteomic analyses have led to the discovery of large numbers of auxiliary factors which are 
physically and /or transiently associated with the 26S proteasome [36, 37]. Many of these proteasome 
interacting proteins (PIPs) are related to the ubiquitylation system. In addition to the above-discussed 
UBL-UBA proteins and Ubp6 and Uch37 deubiquitinases, the ubiquitin ligase Hul5 (or E3a) appears to be 
an additional major component [21]. Hul5 may be acting on ubiquitin conjugates that associate with the 
proteasome. As longer ubiquitin chains associate more tightly with the proteasome [38], chain extension 
should increase the residence time of substrates and enhance their degradation. Hul5 chain-extending 
activity opposes Ubp6 chain-trimming activity in an intimate way as both proteins associate with Rpn2 
and Rpn1, respectively [22]. Through dynamic remodeling of ubiquitin chains, proteasomes might 
actively regulate substrate commitment to degradation. Certain ubiquitin conjugating enzymes and 
ubiquitin protein ligases also associate with the proteasome, e.g. SCF ubiquitin ligase and its associated 
ubiquitin conjugating enzyme: cdc34 [39]. Finally, other PIPs seem to regulate the proteasome function 
or its assembly via direct binding [40]. For instance, Ecm29 enhances the proteasome stability by 
tethering the CP to the 19S RP [21]. 
 
Proteasome activators 
In addition to 19S regulatory particle, several other proteasome activators can bind to one or both α-
rings of the CP to open its channel [40]. Three are known: PA28 (also called PA28αβ, 11S or REG), REGγ 
(also called PA28γ) and PA200 (also called Blm10). They do not recognize ubiquitin nor utilize ATP.  
PA28 
PA28 is mostly observed in the cytoplasm in association with CP or CP-RP complex to form a so-called 
hybrid proteasome. Several observations suggest that it functions in the immune system. It is enriched in 
immune tissues, its expression is induced by interferon-γ and infection and its presence influences the 
production of some class I epitopes. The hybrid proteasome enhances the hydrolysis of small peptides 
but not proteins and generates a pattern of peptides different from those produced by the 26S, without 
altering the mean product length. This change in peptide profile might account PA28 capacity to enhance 
antigen presentation.  
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  REGγ 
REGγ is most heavily expressed in brain and confined to the nucleus. Its function remains largely 
unknown; it seems to be involved in apoptosis and cell-cycle regulation. REGγ promotes degradation of 
loosely folded substrates such as p21 CIP and the steroid receptor co-activator 3 (SRC-3).  
 
PA200 
PA200 is a large nuclear protein which in contrast to the three previously described activators, binds to 
the CP as a monomer. It is predominantly found as a complex with CP-RP. Like PA28, it stimulates 
proteasomal hydrolysis of peptides but not proteins. PA200 was suggested to be involved in proteasome 
assembly and DNA repair but its true role is still an open question and requires further clarification.  
As a conclusion, proteasomes can be labile. There is still much to be resolved concerning the biology and 
biochemistry of proteasome activators, it is possible that they might function primarily in the context of 
hybrid proteasomes, which tether CP-RP complexes to specific intracellular locations or substrate 
complexes. In this model, their primary role would be to define a location or association. 
Subunit variation 
Structural variation can also be achieved at the subunit level, through the replacement of one subunit for 
another during proteasome de novo assembly [40]. In response to interferon-γ, the active subunits of 
the CP: β1, β2, β5 are replaced by β1i, β2i, β5i. The resulting proteasomes are called 
immunoproteasomes and might be more adapted for the immunological processing of antigens. The 
induced proteolytic subunits have indeed altered cleavage properties; the chymotrypsin- and trypsin-like 
activites are increased while the caspase-like activity is decreased. The product peptides are more likely 
to bind in the peptide-binding pocket of MHC class I molecules where peptides usually anchor via basic 
or mostly hydrophobic carboxyl terminal residues. Similarly, another subunit β5t is assembled with β1i 
and β2i to form the thymoproteasome, the predominant proteasome species in cortical thymic 
epithelium. In this case, a more hydrophilic ensemble of peptides is generated, which bind with less 
affinity to MHC class I clefts. Remarkably, thymoproteasomes are expressed in thymic cortical epithelial 
cells (cTECs) whereas immnuoproteasomes are constituvely present in thymic medullary epithelial cells 
(mTECs). As cTECs and mTECs are apparently dedicated to negative and positive T cell selection, β5 
cleavage specificity could be linked to the immunological definition of self and non-self. Most likely, 
other subtypes of proteasomes are about to be discovered. An additional α-subunit, α8, which is 
expressed in testis, could replace α4 in the proteasome assembly to form a mammalian testis-specific 
proteasome. Another isoform of Rnp10 is specifically expressed in the embryonic brain in mice, implying 
the existence of a brain-specific proteasome. 
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Substrate recognition 
All in all, we can nowadays make a sketch of the proteasome and its main components and better 
understand how this highly elaborated machinery might be functioning but it is still rather unclear on 
which basis protein substrates are elected as eligible candidates which may enter the core of the CP 
chamber. The 26S proteasome degrades proteins which have been covalently modified with a 
polyubiquitin chain. Ubiquitin is a highly conserved 76 amino acid-protein which ends in a diglycine 
motif. It is attached onto the substrate by covalent bond formation between the carboxyl group of its 
terminal glycine (G76) and the ε-amino group of a lysine residue belonging to the substrate [41]. 
Polyubiquitin chain formation is achieved via isopeptide bond formation between G76 carboxyl group of 
the “n+1” ubiquitin to the ε-amino group of a lysine residue belonging to the preceding ubiquitin. 
Ubiquitin contains seven lysines: K6, K11, K27, K29, K33, K48 and K63; each of them can be used to form 
different polyubiquitin chains, which function like stamps for functionally distinct processes. Two kinds 
of chains have been extensively characterized: K48 and K63 chains. K48 chains are associated with 
proteasomal degradation; the 26S proteasome recognizes the motif formed by four ubiquitin molecules 
linked via their lysine 48 [38]. Substrate binding affinity for the proteasome depends on the total number 
of this motif present at its surface. In contrast, K63 chains provide a signaling function, they are involved 
in DNA repair, endocytosis and signal transduction pathways [42]. K48 and K63 chains adopt a radically 
different structural conformation, which was accounted for their dissimilar roles [43-45]. Recent studies 
have however led to a more complex picture. It seems that linkages other than K48 can occasionally 
target attached proteins to the proteasome e.g. K63, K29 and K11 [46]. Forked chains, in which one of 
the ubiquitin moiety is modified by more than one ubiquitin, can also be synthesized; they seem to be 
unfavorable substrates [47]. Finally, certain substrates can be degraded while being only 
monoubiquitinated [33, 48]. Ubiquitin chain length and linkage type, along with the affinity for 
proteasome receptors and ease of deubiquitination, seem to all contribute towards setting substrate 
hierarchy [49]. Noteworthy, some substrates can bypass the ubiquitin requirement to be processed by 
the proteasome. The best described ubiquitin-independent proteasome substrate is the Ornithine 
Decarboxylase (ODC) [50], which is recognized by a degradation signal located at its C terminus. This 
ubiquitin free route is presented in chapter 2.  
The truth of the matter is that we still do not completely understand how substrates make their way to 
the 26S proteasome. However selective depletion of intracellular proteins could be a powerful tool for 
protein function analysis and, in the long run, therapeutic applications. We aimed at developing 
strategies to lead a specific protein to the 26S proteasome. In this respect, we needed a versatile binding 
scaffold which could be easily expressed in the cytoplasm of cells and armed with different functional 
protein domains or sequences. For this purpose, we chose to work with DARPIns, an engineered protein 
scaffold based on the modular architecture of repeat proteins.   
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DARPIns, a new binding scaffold 
Ankyrin repeat 
Repeat proteins constitute, next to immunoglobulins, the most abundant natural binding proteins class 
[51]. Present in all phyla, their most common biological function is to bind to a protein ligand, which 
translates to different modes of action ranging from anchoring of proteins to each other to enzyme 
inhibition. Repeat proteins are involved in numerous biological processes such as cell cycle control, 
transcription regulation, innate immunity and apoptosis, among others. Their favorable binding 
properties most probably arise from their repetitive architecture [52]. Repeat proteins consist of 
consecutive homologous structural modules (repeats), which stack to form an elongated non-globular 
protein domain with a joined hydrophobic core. A repeat is characterized by conserved framework 
residues which mediate intra- and inter-repeat interactions and variable surface-exposed residues. The 
juxtaposition of all surface-exposed residues forms the target binding surface, whose size varies 
according to the number of repeats. The ankyrin repeat characterizes a prominent repeat protein family 
[53]. One module consists of 33 amino acids forming a well-defined architecture, consisting of a β-turn 
followed by a pair of anti-parallel α-helices and a loop which bridges to the next module. The overall 
structure of a fully assembled ankyrin repeat domain is elongated and slightly curved [54]. In most 
known complexes involving ankyrin repeat proteins, the concave surface formed by the β-turn and the 
first α-helix is involved in binding the ligand protein.  A strategy harnessing the modular architecture of 
ankyrin repeat proteins was developed for the creation of novel binding molecules [52]. 
DARPin design and biophysical properties 
Information was extracted from natural ankyrin repeat proteins sequences (229 for initial design and 
2200 for subsequent refinement) to design an optimal self-compatible repeat module with 26 conserved 
framework positions and 7 randomized surface-exposed ones (Fig. 3a) [55]. The consensus sequence was 
finally refined using structural data. Assembling different numbers of the self-compatible repeat module 
provided a simple means of constructing and evolving new interaction surfaces. To shield the continuous 
hydrophobic core, special terminal repeats, called capping repeats, were added to yield a novel 
functional binding protein scaffold: Designed Ankyrin Repeat Proteins (DARPIns) (Fig. 3a) [55]. 
Combinatorial libraries of DARPins of varying size and randomized potential interaction surfaces were 
generated, the molecules were denoted as NxC, where x indicates the number of consensus designed 
ankyrin repeat module, typically ranging between two and four (Fig. 3b). Analysis of unselected 
members showed very favorable biophysical properties. Proteins were expressed in soluble form in the 
cytoplasm of E. coli; up to 200 mg/L purified protein could be obtained from simple shake flasks cultures 
in the E. coli strain XL1-blue [55]. The crystal structure of the unselected member E3_5 showed a vey 
regular and ordered ankyrin repeat domain fold with refined intrarepeat and extrarepeat interactions 
[56]. The design also yielded proteins of remarkable chemical and thermal stabilities; midpoints of  
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Fig. 3: Construction of DARPin protein libraries. (a) Sequences of the N-terminal capping ankyrin repeat 
(AR), the designed internal AR module and the C-terminal capping AR. The secondary structure elements 
are indicated above the sequences. The designed AR module consists of 26 defined framework residues, 
six randomized potential interaction residues (red x, any of the 20 natural amino acids except cysteine, 
glycine or proline) and one randomized  framework residue (z, any of the amino acids 
asparagine,histidine or tyrosine). (b) Schematic representation of the library generation of DARPins. This 
assembly is represented on the protein level, whereas the real library assembly is on the DNA level. By 
assembling an N-terminal capping AR (green), varying numbers of the designed AR module (blue) and a 
C-terminal capping AR (cyan), combinatorial libraries of DARPins of different repeat numbers were 
generated (side chains of the randomized potential interaction residues are shown in stick-mode in red). 
(c) Ribbon representation of the selected MBP binding DARPin protein off7 (colors as in b). This binder is 
derived from a N3C library, consisting of a N-terminal capping AR, three designed AR modules and a C-
terminal capping AR.  Adapted from Binz et al, 2004 [57]. 
  
17 
 
denaturation ranged between 2.9 and 5 M guanidine chloride or between 66°C and more than 95°C, 
respectively [55, 56]. Thermodynamic properties of full consensus DARPins were even more impressive 
with melting temperatures above 100°C for proteins with three or more repeat modules; their full 
denaturation required their heating in 5 M guanidine chloride [58].  
DARPin selection 
DARPin libraries were used as a source for generating new specific binders by directed evolution. 
Directed evolution mimics natural evolution but in a test tube format. The procedure relies on iterative 
cycles of selection and amplification of selected molecules, creating a new enriched pool as start for the 
next round. Using a diverse starting population and a suitable selection method which allows coupling of 
the genotype and phenotype, new molecules with desired properties can emerge from the procedure 
and be easily retrieved. Two selection systems were successfully applied for the selection of DARPins: 
ribosome display [59, 60] and phage display [61]. Ribosome display was the most frequently used one, it 
is a complete in vitro selection system (Fig. 4). It relies on in vitro translation and production of non-
covalent ternary complexes consisting of mRNA, ribosome and the nascent polypeptide chain. Such 
complexes are “locked” in this configuration by absence of a stop codon, thus preventing dissociation of 
the mRNA and the polypeptide chain. In addition, a C-terminal spacer at the end of the protein coding 
sequence allows the nascent polypeptide chain to fold in a functional protein. Complexes can be selected 
against an immobilized target protein, non-binding ones are washed away and the DNA is recovered by 
reverse transcription PCR after disassembly of the complexes by depletion of magnesium. New diversity 
can be directly generated during amplification of the genetic material of the selected molecules. Phage 
display is a semi-in vitro and semi-in vivo selection method. The protein (phenotype) is displayed on the 
surface of a bacteriophage particle while the respecting DNA (genotype) is encapsulated inside. The 
selection step against immobilized target is still performed in vitro but the DNA is replicated inside 
bacterial cells. The original method was adapted to DARPins, which were directed to the cotranslational 
signal recognition particle (SRP) translocation pathway instead of the conventional post-translational Sec 
translocation pathway [62]. SRP phage display is more efficient in displaying very stable and fast folding 
proteins. Both directed evolution techniques could, in a few selection rounds only, yield several DARPins 
with affinities ranging from pM to low nM [57, 63, 64]. Maltose Binding Protein (MBP) from E. coli was 
chosen as target for the first selection of DARPins. Using ribosome-display, low nanomolar binders were 
rapidly isolated. A selected DARPin named off7 was crystallized in complex with MBP, the X-ray structure 
showed that library modules with their randomized positions were responsible for the interaction (Fig. 
3c). After validation of the strategy, numerous binders could be selected against various intracellular 
proteins.  
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Figure 4: Schematic representation of a ribosome display selection cycle. An mRNA library encoding the 
proteins of interest without stop codon is translated in vitro [1]. After cooling, the translation yields 
stable ternary complexes of mRNA, ribosomes and nascent polypeptides. These complexes are used for 
the binding selection on the immobilized target [2]. After binding of the polypeptides to the target 
protein, unbound complexes are washed away [3]. The mRNA of the bound complex is eluted by 
dissociating the ribosomal complex with EDTA [4]. A reverse transcription reaction followed by PCR 
yields the genetic information of the selected clones [5]. The amplified genes can then be used as input 
for the next selection round starting with in vitro transcription [6] or cloned into plasmids for analysis. 
Adapted from Daniel Steiner dissertation, 2007. 
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DARPin applications 
In combination with in vivo activity screening, DARPIns revealed to be valuable tools which could fulfill 
various functions. Several inhibitors could be identified against diverse enzymes. A very potent 
intracellular kinase inhibitor, named 3a, was able to trap the bacterial kinase aminoglycoside 
phosphotransferase IIIa (APH) in an inactive conformation [65, 66]. An intracellular inhibitor was selected 
against the NIapro, the main proteinase responsible for tobacco etch virus maturation, a major plant 
pathogen [67]. Finally, the first specific caspase-2 inhibitor could be produced; its binding caused 
allosteric inhibition [68]. DARPins could also be successfully selected against various cell-surface 
receptors, e.g. members of the ErbB receptor family [63, 69] (Jost & Tamaskovic, in preparation). EGFR 
(ErbB1) specific DARPins exhibited a cytostatic effect on EGFR-overexpressing A431 cells (Boersma, in 
preparation). Her2 (ErbB2) specific bivalent DARPIns were constructed and depending on their format 
(homo-/hetero-specificity and flexible/rigid linker), they could have cytotoxic or proliferative effects on 
Her2-overexpressing BT474 cells (Jost & Tamaskovic, in preparation). CD4-specific DARPins could 
compete with the HIV envelope protein gp120 and potently block HIV entry in both cell line and primary 
cell-based infection systems [70]. Recently, immunoglobulin E receptor was blocked by a bispecific 
DARPin preventing the release of proinflammatory mediators and potentially allergic reaction [71]. 
Alternatively DARPins binding activity could also be exploited to facilitate crystallization of arduous 
proteins [72]. A better resolution could be obtained for the structure of the bacterial multidrug exporter 
AcrB and allowed a better understanding of its mechanism [73]. The first structure of wild-type apo Plk-
1, a well-validated drug target in cancer therapy, could be determined by co-crystallization with a DARPin 
[74]. Owing to their robust biophysical properties and highly specific binding capacity, DARPins 
constitute very promising protein based drugs.  
PhD project 
We propose to expand the formerly described portfolio of applications and use DARPIns as tools to 
engineer effector proteins able to lead a specific target to the 26S proteasome for degradation. Several 
strategies were employed and will be described in the following chapters. First, DARPins were exploited 
to alter the recognition function of an ubiquitin ligase, the enzymes responsible for the ubiquitin-
proteasome pathway specificity (chapter 1). We aimed to better understand how ubiquitin ligases were 
mediating ubiquitination and degradation of a substrate and then apply this knowledge to design 
“tailored” ubiquitin ligases. Next, DARPins were armed with different sequences enabling a direct 
interaction with the 26S proteasome, the proteasomal degradation of a complex was investigated 
(chapter 2). Finally, techniques which have been described so far to achieve targeted protein 
degradation were reviewed and both DARPin-strategies were, after being developed in a yeast system, 
evaluated in mammalian cells (chapter 3).  
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Figure 1: A. Sequence of events in the degradation of a protein via the ubiquitin-proteasome pathway. 
Activation of ubiquitin by the ubiquitin-activating enzyme, E1. Transfer of the activated ubiquitin from E1 to a 
ubiquitin-conjugating enzyme, E2. Conjugation of ubiquitin mediated by RING-finger ubiquitin ligases (E3R). 
Formation of a ternary complex between ubiquitin-charged E2, E3R, and the target substrate (S1), and 
initiation of synthesis of substrate-bound polyubiquitin chain by direct transfer of the activated ubiquitin 
moiety from E2 to the substrate. Conjugation of ubiquitin mediated by HECT domain ubiquitin ligases, E3H. 
Generation of binary complex between the ubiquitin-charged E2 and the E3H, and transfer of activated 
ubiquitin to the ligase. Transfer of the first ubiquitin moiety from E3H to the substrate (S2). Formation of 
substrate-bound polyubiquitin chain by the successive conjugation of additional ubiquitin moieties to one 
another. Binding of the polyubiquitinated substrate to the 26S proteasome and degradation of the 
ubiquitinated substrate to peptides. Adapted from Schwartz & Ciechanover [1]. B. Biochemistry of the 
ubiquitin-activation reaction. (a) adenylation of the carboxyl terminus of a ubiquitin molecule by E1; (b) rapid 
cis transfer of the E1-bound ubiquitin molecule from AMP to the active-site cysteine in E1, with subsequent 
release of free AMP; (c) adenylation of another free ubiquitin residue by the same Cys~Ub-loaded E1 molecule; 
and (d) recruitment of E2 followed by transfer of the activated ubiquitin from the active cysteine of E1 to the 
catalytic cysteine of E2. Adapted from Nalepa et al, 2006 [2].  
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Introduction 
 
The selective degradation of specific cellular proteins is essential for the cellular metabolism. 
In eukaryotes, most proteins are degraded via the ubiquitin-proteasome pathway [3]. This 
mechanism ensures the quality of intracellular proteins by destroying denatured/misfolded or 
damaged polypeptides [4]. Ubiquitin-mediated proteolysis plays also an important role in the control 
of numerous cellular processes by regulating the break-down of key regulatory proteins such as cell 
cycle proteins (e.g. cyclins), transcriptional factors (e.g. IκB) or proto-oncogenes/tumor suppressors 
(e.g. Jun, p53) [5]. Finally, the ubiquitin-proteasome system is also involved in the immune response, 
both innate and adaptative [6]. A well known example is the proteasome-dependent processing of 
many antigenic proteins, whose peptide epitopes are presented by major histocompatibility complex 
(MHC) class I molecules [7]. 
Protein degradation via the ubiquitin-proteasome pathway involves two successive steps:  the 
labeling of the substrate by ubiquitin and degradation by the 26S proteasome [8]. Ubiquitin is a 
highly conserved 76 amino acid-protein; its conjugation to the substrate is mediated by the 
sequential activities of 3 different enzymes (Fig. 1) [9]. The E1 enzyme (ubiquitin activating enzyme) 
activates the ubiquitin molecule and transfers it to E2 (ubiquitin conjugating enzyme). E3 (ubiquitin 
protein ligase) binds to the substrate and recruits Ub-loaded E2 to mediate bond formation between 
ubiquitin and an internal lysine residue on the substrate. Multiple cycles of conjugation of new 
ubiquitin moieties to the previous one result in the formation of a polyubiquitin chain. A chain of four 
or more molecules, formed via lysine 48 of ubiquitin, is recognized by the 26S proteasome [10, 11], 
which unfolds the substrate and channels the unfolded polypeptide into its catalytic lumen, where a 
host of protease sites digest the protein into short peptides [12]. The ubiquitin conjugation 
machinery has a hierarchical structure [13]. In a simplified view, a single E1 activates ubiquitin and 
interacts with all E2s; each E2 interacts with several E3s and finally each E3 targets several 
substrates. However, some overlapping interactions may remodel this “pyramid” structure. For 
instance, specific E3s can interact with more than one E2 and some substrates can be targeted by 
more than one E3. 
The specificity of ubiquitination reaction relies on the many hundreds of E3 enzymes which recognize 
particular substrates motifs, often referred to as degrons [14]. E3s can be divided into two main 
groups, based on one of two characteristic protein motifs: the “Homologous E6-associated protein 
Carboxyl Terminus” (HECT) domain and the “Really Interesting New Gene” (RING) domain [15]. HECT-
type E3s transiently accept ubiquitin from E2 via their HECT domain before transferring it onto the 
substrate (Fig. 1). In contrast RING-type E3s do not catalyze the reaction but assist it by recruiting the 
ubiquitin loaded-E2 via its RING domain and activating it to discharge its ubiquitin cargo to the 
substrate [16].  
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Figure 2: A: Schematic representation of SCF-E2 complex. Cul1, Rbx1, skp1, F-box protein, substrate 
and E2 are colored in green, purple, dark blue, pink, light blue and orange, respectively. B: Models for 
the SCFFbw7-CyclinE-E2 complex, SCFCdc4-CPD-E2 complex, SCFβTrcP1 -β catenin-E2 complex and SCFskp2-
p27/cks1-E2 complex. Every model was built by superimposing the Skp1-F box portion of the 
respective Skp1-F box complex structure [17-20] on the corresponding region of the SCFSkp2 structure, 
which had been experimentally determined separately [21]. The UbcH7 E2 (active site cysteine in 
cyan) was docked on the Rbx1 subunit of the SCF based on the c-Cbl-UbcH7 structure [17, 21]. 
Proteins were colored as in A. In all SCF-E2 complexes models, the substrate-binding domain points 
in the general direction of the E2 active site. Adapted from Hao et al., 2007 [20]. 
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SCF (Skp1 - Cullin - F-Box protein) ubiquitin ligases are the archetype for the RING-type E3 enzymes, 
they are built in a modular format that is conserved from yeast to humans [22] (Fig. 2A). The 
invariant core complex consists of Cullin, a scaffold subunit with a curved yet rigid and extended 
structure, at its C-terminus binds the RING-containing protein Rbx1, the E2 docking site, and at its N-
terminus binds Skp1, the adaptor subunit. Skp1 connects this core catalytic complex to one of a suite 
of F-Box proteins, the substrate recognition subunit which recruits a specific pool of substrates [23]. 
The different SCF complexes are designated according to the variable F-box component (e.g. SCFMet30 
contains the Met30 F-box protein); 13 F-box proteins were identified in yeast and 68 were found in 
the human genome [24, 25]. Available structural data show that the SCF complex subunits fit 
together into a C-shaped conformation and revealed a 50-60 Å gap between the substrate binding 
domain platform and the location of predicted ubiquitin-thioester bond on docked E2~Ub [17-21] 
(Fig. 2B). A hypothetical working mechanism of E2 was proposed to bridge this cleft. The ubiquitin-
charged Cdc34 (cdc34~Ub) had been observed in dynamic binding equilibrium with SCF [26].  It was 
then proposed that E2~Ub could bind to the RING domain, dissociate and diffuse across the gap until 
it finds one of the substrate Lys residues. This “Hit and Run” model is, however, controversial [27]. 
Other experimental data tend to indicate that the 50-60 Å space is a kind of “hot zone” with a 
maximal ubiquitination for the substrate lysine residues lying next to the E2 catalytic site [17]. In 
addition, precise positioning by the F-box protein seemed crucial for certain substrates [18].  
Despite the accumulation of biochemical and structural data, little is known about how the SCF-E2 
complex mediates the ubiquitination reaction and delivers ubiquitinated substrates to the 26S 
proteasome. To further unravel the mechanism of ubiquitination by SCF ligases, we used a chimeric 
F-box protein. F-box proteins contain two essential domains; an N-terminal F-box domain responsible 
for the interaction with Skp1 and a C-terminal substrate binding domain mostly composed of WD40 
repeats or Leucine Rich Repeats [28]. The budding yeast S. cerevisiae F-box protein Cdc4 was chosen 
as scaffold for the design of the chimeric F-box protein. Cdc4 triggers the G1-S phase transition by 
mediating the degradation of the B-type (Clb)-Cdc28 cyclin-dependent kinase inhibitor Sic1 in a 
phosphorylation-dependent manner [29]. Sic1 phosphorylation generates several Cdc4 phospho-
degrons (CPD) which can be recognized by the WD40 domain of Cdc4 [30]. The crystal structure of a 
Skp1-Cdc4 complex bound to a high affinity CPD phosphopeptide shed light on phosphodependent 
substrate selection and enabled modeling of the E2-SCFCdc4 complex to provide visualization of 
substrate orientation (Fig. 2B) [18]. DARPins, a new binding scaffold based on repeat proteins 
modular architecture [31], was used to replace the original substrate binding domain of Cdc4. This 
new artificial substrate binding domain was designed to recognize a model substrate.  
In S. cerevisiae, the chimeric F-box protein could specifically destabilize a target protein in a SCF- and 
proteasome-dependent manner. It was then used as tool and the target protein degradation assay as 
read-out, to investigate how F-box proteins mediate protein degradation. Parameters affecting 
essential properties of the chimeric F-box protein could be monitored without inducing any toxicity. 
Information was mostly collected on substrate presentation and delivery to the proteasome.  We 
also propose a model for the F-box protein level regulation mechanism. This new strategy gave 
further insights into the working mechanism of SCF ubiquitin protein ligases.   
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Materials & methods 
 
Yeast strains and genetic experiments 
Yeast strains are described in Table 1. The genotypes of the yeast strains are:  
W303: ade2-1, trp1-1, can1-100, leu2-3,112, his3-11,15, ura3-1, GAL+, psi+, ssd1-d2  
S288C: ade2-101, ura3-52, lys2-801, trp1- 1, his3 200, leu2-  
Unless noted otherwise strain K699 was used.  
Table 1: Yeast strains 
Strain Relevant genotype Background Source 
K699 Mat a  W303 M. Peter 
Cdc53_1 Cdc53_1 W303 M. Peter 
Cdc34_2 Cdc34_2 W303 M. Peter 
Erg6  Erg6::KAN S288C M. Peter & G. Rabut 
MGa ura3-1::URA3-PADH-MBPGFP K699 This study 
AGa ura3-1::URA3-PADH-APHGFP K699 This study 
F75Gg [p415/Gal/cdc4_5GS_off7] K699 This study 
F35Gg [p415/Gal/cdc4_5GS_3a] K699 This study 
MGaF75Gg ura3-1::URA3-PADH-MBPGFP  
[p415/Gal/cdc4_5GS_off7] 
K699 This study 
AGaF35Gg ura3-1::URA3-PADH-APHGFP 
[p415/Gal/cdc4_5GS_3a] 
K699 This study 
Mg ura3-1::URA3-PGal1-MBP K699 This study 
MGg ura3-1::URA3-PGal1-MBPGFP K699 This study 
MgFB5Ga ura3-1::URA3-PGal1-MBP 
[p415/ADH/cdc4_5GS_B] 
K699 This study 
MgF75Ga ura3-1::URA3-PGal1-MBP 
[p415/ADH/cdc4_5GS_off7] 
K699 This study 
eMGgF75Ga [p415/Gal/MBP-GFP] 
[p413/ADH/cdc4_5GS_off7] 
Erg6 This study 
WtMGgF75Ga [p415/Gal/MBP-GFP] 
[p413/ADH/cdc4_5GS_off7] 
W303 This study 
53MGgF75Ga [p415/Gal/MBP-GFP] 
[p413/ADH/cdc4_5GS_off7] 
Cdc53_1 This study 
34MGgF75Ga [p415/Gal/MBP-GFP] 
[p413/ADH/cdc4_5GS_off7] 
Cdc34_2 This study 
MGgF75Ga ura3-1::URA3-PGal1-MBPGFP 
[p415/ADH/cdc4_5GS_off7] 
K699 This study 
MgF710Ga ura3-1::URA3-PGal1-MBP 
[p415/ADH/cdc4_10GS_off7] 
K699 This study 
MgF715Ga ura3-1::URA3-PGal1-MBP 
[p415/ADH/cdc4_15GS_off7] 
K699 This study 
MgF73Aa ura3-1::URA3-PGal1-MBP 
[p415/ ADH /cdc4_3ala_off7] 
K699 This study 
MgF710Aa ura3-1::URA3-PGal1-MBP 
[p415/ ADH /cdc4_10ala_off7] 
K699 This study 
MgF717Aa ura3-1::URA3-PGal1-MBP 
[p415/ ADH /cdc4_17ala_off7] 
K699 This study 
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MGgF7’5Ga ura3-1::URA3-PGal1-MBPGFP 
[p415/ADH /cdc4_5GS_off7_Y56A] 
K699 This study 
MGgF7’’5Ga ura3-1::URA3-PGal1-MBPGFP 
[p415/ADH /cdc4_5GS_off7_Y56AY81A] 
K699 This study 
MGgF7’’’5Ga ura3-1::URA3-PGal1-MBPGFP 
[p415/ADH /cdc4_5GS_off7_Y56AY81AY125A] 
K699 This study 
F75Ga [p415/ADH/cdc4_5GS_off7] K699 This study 
MGgF75Gaa ura3-1::URA3-PGal1-MBPGFP 
[p425/ ADH /cdc4_5GS_off7] 
K699 This study 
MGgF75Gt ura3-1::URA3-PGal1-MBPGFP 
[p415/TEF/cdc4_5GS_off7] 
K699 This study 
MGgF75Gtt ura3-1::URA3-PGal1-MBPGFP 
[p425/TEF/cdc4_5GS_off7] 
K699 This study 
MgF7∆5Ga ura3-1::URA3-PGal1-MBP 
[p415/ ADH /cdc4_5GS_off7_deltaN] 
K699 This study 
MgF7Lys5Ga ura3-1::URA3-PGal1-MBP 
[p415/ ADH /cdc4_5GS_off7_5Lys] 
K699 This study 
MLysgF75Ga ura3-1::URA3-PGal1-MBP_5Lys 
[p415/ADH/cdc4_5GS_off7] 
K699 This study 
 
Standard yeast growth conditions and genetic manipulations were used as described [32]. Yeast cells 
were cultured in YPD (1% yeast extract, 2% bacto peptone, 2% glucose) or in synthetic media (S) (1.7 
g/L yeast nitrogen base, 5 g/L ammonium sulfate) supplemented with a standard amino acid  and 
nucleobases solution (30 mg/L isoleucine, 150 mg/L valine, 40 mg/L adenine, 20 mg/L arginine, 20 
mg/L histidine, 100 mg/L leucine,  30 mg/L lysine, 20 mg/L methionine, 50 mg/L phenylalanine, 200 
mg/L threonine, 40 mg/L tryptophane, 30 mg/L tyrosine, 20 mg/L uracil, 100 mg/L glutamic acid, 100 
mg/L aspartic acid) and 2 % carbon source (glucose (D), raffinose (Raff) or galactose (Gal)). According 
to the strain and the experiment, a synthetic media prepared without amino acids or nucleobases 
supplemented with auxotrophic requirements: uracil (-Ura), leucine (-Leu), histidine (-His) and the 
appropriate carbon source (SD, SRaff or SGal) was used. 
Yeast transformations were performed by the lithium acetate procedure [33]. Strains expressing the 
target protein were created by homologous recombination using StuI linearized plasmid 
pRS306/ADH/X or pRS306/Gal/X (see below).  
DNA manipulations and plasmids 
Standard molecular biology procedures were used for recombinant DNA manipulation [34]. Enzymes 
were from NEB (Ipswich, MA, USA) or Fermentas (Vilnius, Lithuania). PCR reactions were performed 
with the Phusion TM High-Fidelity DNA polymerase as recommended by the manufacturer (NEB). 
Plasmids used as PCR DNA templates and all oligonucleotides are listed in tables 2 and 5.  
Chimeric F-box proteins coding sequences cdc4_5GS_off7 (see sequence in annex) and cdc4_5GS_3a 
were constructed by assembly PCR.  The cdc4 (ΔNLS) DNA sequence, encoding residues 1 to 358, and 
DARPin DNA sequences were amplified by PCR in two separate reactions, and a second PCR step was 
used to fuse the two sequences. Primers used at the C-terminus of cdc4 part and the N-terminus of 
DARPins encoded a GSGSG linker. Finally, a third PCR amplified the whole length product with the HA 
tag at the C terminus, which was then SpeI/XhoI digested and cloned in p415Gal1 [35]. 
cdc4_5GS_off7 and cdc4_5GS_3a coding sequences were subcloned in p415ADH [35]. The chimeric 
F-box protein coding sequence cdc4_3ala_off7 (see sequence in annex) was constructed by assembly 
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PCR, similarly to cdc4_5GS_off7, except that the primers used at the C-terminus of the cdc4 part and 
the N-terminus of DARPins encoded a AAA linker and that the final product was cloned in p415ADH. 
p415/ADH/cdc4_10GS_off7 was generated by integrating the annealed double-stranded Gly-Ser 
encoding oligonucleotides into BamHI/AvaI digested cdc4_5GS_off7 coding sequence and ligating the 
final product into p415/ADH (see sequence in annex). p415/ADH/cdc4_15GS_off7 was generated by 
integrating the annealed double-stranded Gly-Ser encoding oligonucleotide into BamHI/AvaI 
digested cdc4_10GS_off7 and ligating the final product into p415/ADH (see sequence in annex). 
p415/ADH/cdc4_10ala_off7 and p415/ADH /cdc4_17ala_off7 were produced by adding the double-
stranded 10ala or 17ala encoding oligonucleotides into PstI digested p415/ADH/cdc4_3ala_off7 (see 
sequence in annex). Site-directed mutagenesis was performed by assembly-PCR. Oligos containing 
the point mutation of choice were used to produce the mutated off7 DNA sequence, which was then 
used to replace the original off7 sequence in p415/ADH/cdc4_5GS_off7. off7Y56AY81A and 
off7Y56AY81A DNA sequences were made by using p415/ADH/cdc4_5GS_off7_Y56A and 
p415/ADH/cdc4_5GS_off7_Y56AY81A as templates, respectively. The chimeric F-box protein genes 
were cloned between SpeI and Xho I sites of p415Gal, p415ADH or p413 ADH [35]. pQE30/off7_Y56A, 
pQE30/off7_Y56AY81A and pQE30/off7_Y56AY81AY125A were constructed by amplifying the off7 
mutant sequence from p415/ADH/off7_Y56A, p415/ADH/cdc4_5GS_off7_Y56AY81A and 
p415/ADH/cdc4_5GS_off7_Y56AY81AY125A respectively with primers EWT3 and WTC4 and inserting 
the digested PCR product at the BamHI and HindIII sites of pQE30 (Qiagen, Chatsworth, CA).  
The target protein genes were cloned with a N-terminal RGS(His)6 tag, between SpeI and HindIII or 
XhoI sites of pRS306/ADH, pRS306/Gal or p415Gal. GFP fused target protein genes were constructed 
by assembly PCR. The target protein and GFP genes were amplified by PCR in two separate reactions 
and a final PCR step was used to fuse the two sequences and amplify the whole length product (see 
sequences in annex). pRS306/ADH and pRS306/Gal were generated by  exchanging  the original SacI-
KpnI fragment of pRS306 [36]with the complete expression cassette (ADH or Gal1 promoter + 
multiple cloning site+ Cyc1-terminator) originating from p416ADH or p415Gal1, respectively [35]. 
Their maps are shown in annex. 
All constructs were confirmed by sequencing. Plasmids constructed for this study are listed in tables 
3 and 4, those marked with an asterisk have their plasmid map shown in annex.  
Table 2: Plasmids used as PCR DNA templates for cloning of target proteins and chimeric F-box proteins genes 
Plasmids Templates for  Source 
pQEMBP MBP Binz, 2004 [37] 
pAT223_APH APH Amstutz, 2005 [38] 
pET28GFP GFP Our laboratory, Andreas Ernst 
pBM165 cdc4 (K82A, R83A, K85A) Blondel, 2000 [39] 
pQE30_AR_3a 3a Amstutz, 2005 [38] 
pQE30_AR_B B Amstutz, 2005 [38] 
pQE30_mbpoff7 off7 Binz, 2004 [37] 
pQE30_mbp_3_16 mbp16 Binz, 2004 [37] 
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Table 3: Plasmids constructed for target protein expression 
Plasmids for target protein Relevant characteristics  
(promoter; gene; resistance; ori) 
Source 
pRS306/ADH* ADH; -; URA3 ; - This study 
pRS306/ADH/MBP-GFP* ADH; MBP-GFP; URA3 ; - This study 
pRS306/ADH/APH-GFP ADH; APH-GFP; URA3; - This study 
pRS306/Gal Gal1; -; URA3; - This study 
pRS306/Gal/MBP-GFP Gal1; MBP-GFP; URA3; - This study 
pRS306/Gal/MBP Gal1; MBP; URA3; - This study 
pRS306/Gal/APH Gal1; APH; URA3; - This study 
p415/Gal/MBP-GFP Gal1; MBP-GFP; LEU2; CEN6 This study 
pRS306/Gal/MBP_5Lys Gal1; MBP_5Lys; URA3; - This study 
 
Table 4: Plasmids constructed for chimeric F-box proteins expression 
Plasmids for chimeric F-box protein Relevant characteristics  
(promoter; gene; resistance; ori) 
Source 
p415/Gal/cdc4_5GS_off7* Gal1; cdc4_5GS_off7;  LEU2; CEN6 This study 
p415/Gal/cdc4_5GS_3a Gal1; cdc4_5GS_3a;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_off7* ADH; cdc4_5GS_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_mbp16 ADH; cdc4_5GS_mbp16;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_3a ADH; cdc4_5GS_3a;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_B ADH; cdc4_5GS_B;  LEU2; CEN6 This study 
p413/ADH/cdc4_5GS_off7 ADH; cdc4_5GS_off7;  HIS3; CEN6 This study 
p415/ADH/cdc4_10GS_off7 ADH; cdc4_10GS_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_15GS_off7 ADH; cdc4_15GS_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_3ala_off7 ADH; cdc4_3ala_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_10ala_off7 ADH; cdc4_10ala_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_17ala_off7 ADH; cdc4_17ala_off7;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_off7_Y56A ADH; cdc4_5GS_off7_Y56A;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_off7_Y56AY81A ADH; cdc4_5GS_off7_Y56AY81A;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_off7_Y56AY81AY125A ADH;cdc4_5GS_off7_Y56AY81AY125A;LEU2;CEN6 This study 
p425/ADH/cdc4_5GS_off7* ADH; cdc4_5GS_off7;  LEU2; 2µ This study 
p415/TEF/cdc4_5GS_off7* TEF1; cdc4_5GS_off7;  LEU2; CEN6 This study 
p425/TEF/cdc4_5GS_off7 TEF1; cdc4_5GS_off7;  LEU2; 2µ This study 
p415/ADH/cdc4_5GS_off7_deltaN ADH; cdc4_5GS_off7_deltaN;  LEU2; CEN6 This study 
p415/ADH/cdc4_5GS_off7_5Lys ADH; cdc4_5GS_off7_5Lys;  LEU2; CEN6 This study 
pQE30/ off7_Y56A T5; RGS(His)6 off7Y56A; Amp; ColE1 This study 
pQE30/ off7_Y56AY81A T5; RGS(His)6 off7Y56AY81A; Amp; ColE1 This study 
pQE30/ off7_Y56AY81AY125A T5; RGS(His)6 off7Y56AY81AY125A; Amp; ColE1 This study 
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Table 5: Oligonucleotides 
Oligonucleotides Sequence 5’-3’ direction Description  
(for=forward, rev=reverse) 
forSpeI GTGGTACTAGTATGAGAGGATCGCATCACCATCACCATCACGGA for target protein with 
RGS(His)6 tag + SpeI site 
revMBPXmaI  GGTGGTCCCGGGAGTCTGCGCGTCTTTCAGGG rev MBP linker with GFP 
revAPHXmaI GGTGGTCCCGGGAAACAATTCATCCAGTAAAATATAA rev APH linker with GFP   
linkerXmaIGFP GGTGGTCCCGGGTCCGCTGCTGGTTCTGGCG for linker GFP 
revGFPHindIII TGGTGGTAAGCTTTTATTTGTAGAGCTCATCCATGC rev GFP + HindIII site 
revAPHXho GTCTCGAGTTAAAACAATTCATCCAGTAAAATATA rev APH+ XhoI site 
revMBPHindIII GGTGGTAAGCTTTTAAGTCTGCGCGTCTTTCAGGG rev MBP + HindIII site 
revMBPlys TTTCTTTTTCTTAGTCTGCGCGTCTTTCAGGG rev MPB+5Lys (PCR1) 
revXhoLys GTCTCGAGTTACTTTTTCTTTTTCTTAGTCTGCGC rev MPB+5Lys (PCR2) + XhoI 
site 
forSpeIcdc4 GGT GGT ACT AGT ATG GGG TCG TTT CCC TTA GC for cdc4 with SpeI site 
revcdc45GS TACCCAGGTCGCCCGAGCCGGATCCATTCTCCAGAAAAGATAATCT rev 5GS linker  
for5GSDARPin TCTGGAGAATGGATCCGGCTCGGGCGACCTGGGTAAGAAACTGCT for 5GS linker 
revHADARPin CGTAATCTGGAACATCGTATGGGTATTGCAGGATTTCAGCCAGGT rev HA tag (25 first bases) + 
DARPin 
revXhoIHA  GTGGTCTCGAGTTAAGCGTAATCTGGAACATCGTATG rev XhoI site + HA tag (24 
last bases) 
revcdc43ala CTTACCCAGGTCGGCTGCAGCATTCTCCAGAAAAGATAATCTAAG rev 3ala linker 
for3alaDARPin CTTTTCTGGAGAATGCTGCAGCCGACCTGGGTAAGAAACTGCT For 3ala linker 
10alaupstrand GCGGCAGCTGCCGCAGCTGCA 10 ala linker 
10aladownstrand GCTGCGGCAGCTGCCGCTGCA 10 ala linker 
17alaupstrand GCGGCAGCTGCCGCAGCTGCGGCAGCTGCCGCAGCTGCTGCA 17 ala linker 
17aladownstrand GCAGCTGCGGCAGCTGCCGCAGCTGCGGCAGCTGCCGCTGCA 17 ala linker 
Gly-Serupstrand GATCTGGTTCATCTGGATCCGGC 10 and 15 GS linker 
Gly-Ser 
downstrand 
CCGAGCCGGATCCAGATGAACCA 10 and 15 GS linker 
foroff7BamHI AATGGATCCGGCTCGGGCGA Off7 mutagenesis for 
primer 
Y56Arev AGATGCAGCAGCCAGGTGCAGCGGAGTAG Off7 mutant Y56A rev 
Y56Afor CACCTGGCTGCTGCATCTGGTCACCTG Off7 mutant Y56A for 
Y85Yrev AGTAGCACCAAAAACGTCAGAAGCGTC Off7 mutant Y81A rev 
Y85Afor TCTGACGTTTTTGGTGCTACTCCGCTG Off7 mutant Y81A for 
Y125Arev GATTTCCAGGGCACCCCACTTAGCAGC Off7 mutant Y125A rev 
Y125Afor AAGTGGGGTGCCCTGGAAATCGTTGAAG Off7 mutant Y125A for 
fordeltaNcdc4 GGTACTAGTATGTTAAAGAGGGACCTAATAACGTC for cdc4 position 808bpb + 
ATG+ SpeI site 
revshortXhoIHA GGTCTCGAGTTAAGCGTAATCTGG  
 
rev XhoI site + HA tag 
(15last bases) 
revHAlys TTTTTCTTTTTCTTAGCGTAATCTGGAACATCGTA rev 3 Lys +HA tag (21 last 
bases)  
revXhoIlys GTCTCGAGTTACTTTTTCTTTTTCTTAGCGTAATC rev 5 Lys + HA tag (9 last 
bases) + XhoI site 
EWT3 TTCCGCGGATCCGACCTGGG for DARPIn + BamHI site 
WTC4 TTTGGGAAGCTTTTGCAGGATTTCAGC rev DARPIn +HindIII site 
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Microscopy 
MGa and Aga yeast cells (see table 1) were grown to early exponential phase in SD-Ura, and GFP-
fused target proteins were visualized on a Zeiss axiophot fluorescence microscope using a Chroma 
GPII filter. For DAPI staining, cells were fixed 5 min in 70% ethanol and washed twice with water. 
Cells were then resuspended in a small volume of 50ng/ml DAPI in PBS and observed with a UV filter 
set.  
Degradation assays 
Experimental set-up 1: Yeast cells were grown in SD-UL or SGal-UL at 30°C. At OD600=0.6-0.8, 
cycloheximide was added to a final concentration of 75 µg/ml. At the indicated time points, 2 ml-
samples were withdrawn and OD600 was measured. Extracts for immunoblotting were immediately 
prepared as follows: cells were centrifuged for 3 min at 13,000 rpm in a tabletop centrifuge, the 
pellet was resuspended in 100 µl of 1.85 M NaOH/ 7.6 % v/v 2-mercaptoethanol and incubated for 10 
min on ice. After addition of 100 µl of 50 % trichloroacetic acid (TCA), additional 10 min incubation 
on ice was performed. Precipitated proteins were pelleted at 13,000 rpm for 2 min at 4°C; pellets 
were washed with acetone, air-dried and resuspended in 3 X Laemmli buffer (63 mM Tris-HCl pH 6.8, 
10 % glycerol, 2 % SDS, 50 mM 2-mercaptoethanol, bromophenolblue,). Normalized volumes 
according to the OD600 were loaded on 10 % or 15 % SDS-polyacrylamide gels followed by 
immunoblotting.  
Experimental set-up 2: Yeast cells were grown in SRaff-U or SRaff-UL at 30°C. At OD600=0.6-0.8, 2 % 
galactose was added. One hour  later, 2 % glucose was added, cells were collected by centrifugation 
for 5 min at 3000 g before being resuspended in SD-U or SD-UL. Cells were further incubated at 30°C 
and samples of decreasing size were taken at different time points in order to have a relatively 
constant amount of cells; e.g. : 8 ml at t=0 min, 6.1 ml at t=30 min, 5.3 ml at t=60 min, 4 ml at t=90 
min, 3.1 ml at t=120 min and 2 ml at t=180 min. OD600 was measured; cells were pelleted for 5 min at 
5000 g and immediately stored at -20°C. All samples were then extracted simultaneously as follows. 
Pellets were thawed and centrifuged for 1 min at maximum speed to remove possible medium 
traces; they were then resuspended in 200 µl SDS-urea loading buffer (60 mM Tris-HCl, 8 M urea, 5 % 
glycerol, 3 % SDS, 4 % 2-mercaptoethanol, 5 mM EDTA, bromophenolblue, pH6.8) and transferred in 
2 ml-tubes. After 20 min of water-bath sonication, 200 µl of acid-washed 425- to 600-μm glass beads 
(Sigma-Aldrich, St. Louis, MO) were added. Cells were lysed three times 2 min at 30 Hz in TissueLyser 
(Qiagen, Chatsworth, CA) and centrifuged at 1000 g. Samples were finally incubated for 5 min at 95°C 
and centrifuged at 4°C for 5 min at 20000 g. Normalized volumes according to the OD600 were loaded 
on 10 % or 15 % SDS-polyacrylamide gels followed by immunoblotting.  
Thermosensitive strains 
Yeast cells were grown in SRaff-LH at 25°C. At OD600=0.5, 2 % galactose was added. 2.5 h later, cells 
were collected by centrifugation for 5 min at 3000 g and resuspended in SD-LH. The t=0 h sample (5.5 
ml) was taken and the culture was divided in two halves which were further incubated at 25°C or 
37°C. Additional samples of 5 ml, 4.5 ml and 4 ml were taken after 1.5 h, 3 h and 4.5 h, respectively. 
OD600 was measured; cells were pelleted for 5 min at maximum speed in a tabletop centrifuge and 
immediately stored at -20°C. All samples were then extracted simultaneously according to the 
protocol described above in the degradation assay experimental set-up 2. 
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Immunoprecipitations 
Yeast cells were grown in the appropriate media (YPD, SRaff-U, SRaff-L or SRaff-UL) at 30°C. At 
OD600=0.6-0.8, 2 % galactose was added followed by 2 % glucose 1 h 30 min later. OD600 was 
measured. All subsequent steps were performed at 4°C.  Cells were collected by centrifugation for 5 
min at 3000 g and washed with wash buffer (50 mM Na2HPO4 pH 8, 300 mM NaCl, 10 mM N-
Ethylmaleimide (NEM)). Pellets were resuspended in ice-cold lysis buffer (50 mM Na2HPO4 pH 8, 300 
mM NaCl, 10 mM NEM, 50 µM MG132 (Sigma-Aldrich, St. Louis, MO), protease inhibitor cocktail 
(Sigma-Aldrich, St. Louis, MO)) and cells were mechanically lysed through 4 cycles of a French Press. 
Cell debris was removed by a 30 min centrifugation step at 18,000 g and cleared lysates were 
aliquoted in 2ml-tubes, snap-frozen in liquid nitrogen and stored at -80°C. Thawed lysates were 
centrifuged for 5 min at 20,000 g. Normalized volumes of supernatant (according to OD600) were 
incubated for 1 h 50 min with 7.5-10 µg anti-HA (product number H 9658) or anti-MBP antibody 
(product number M6295) (Sigma-Aldrich, St. Louis, MO) pre-captured on 100 ul Dynabeads® ProtG 
(Invitrogen, San Diego, CA). Beads were washed 4 times with 1 ml wash buffer and resuspended in 80 
µl 1 X SDS sample loading buffer (62.5 mM Tris-HCl pH 6.8, 7.5 % glycerol, 2 % SDS, 2.5 % 2-
mercaptoethanol, bromophenolblue). After 5 min at 95°C, eluted fractions were resolved by 10 % 
SDS-PAGE followed by immunoblotting.  
Pull-down under denaturing conditions 
Yeast cells were grown in the appropriate media (YPD, SRaff-U or SRaff-UL) at 30°C. At OD600=0.6-0.8, 
2% galactose was added followed by 2 % glucose 1 h 30 min later. OD600 was measured. Cells were 
collected by centrifugation for 5 min at 3000 g and washed with denaturing buffer (8 M urea, 0.1 M 
NaH2PO4 pH 8, 0.01 M Tric-HCl, 0.05 % Tween 20, 50 mM iodoacetamide). Pellets were resuspended 
in denaturing buffer and cells were mechanically lysed by 4 cycles of French Press. Cell debris was 
removed by a 30 min centrifugation step at 18000 g and cleared lysates were aliquoted in 2ml-tubes, 
snap-frozen in liquid nitrogen and stored at -80°C. Thawed lysates were centrifuged for 5 min at 
14000 rpm. Normalized volumes of supernatant (according to OD600) were incubated for 1 h 45 min 
with 200 µl Ni-NTA magnetic agarose beads (Qiagen, Chatsworth, CA, product number: 36111). 
Beads were washed 4 times with denaturing buffer and eluted with 80 µl 1X SDS sample loading 
buffer-EDTA (62.5 mM Tris-HCl pH 6.8, 100 mM EDTA, 7.5% glycerol, 2% SDS, 2.5% 2-
mercaptoethanol, bromophenolblue). After 5 min at 95°C, eluted fractions were resolved by 4-12 % 
SDS-PAGE followed by immunoblotting.  
Immunoblotting 
Samples were transferred to PVDF membranes and immunoblotted using standard methods. The 
RGS·His HRP conjugate was used at a 1:10,000 dilution (Qiagen, Chatsworth, CA, product number: 
34450). The anti-HA antibody (Sigma-Aldrich, St. Louis, MO, product number H9658) was used at a 
1:10,000 dilution, the anti-actin antibody (Millipore, Bedford, MA, product number: MAB1501R) at 
1:3000 dilution and they were both detected with anti-horseradish peroxidase (HRP)-coupled anti-
mouse antibody 1:10,000 diluted (Thermo Fisher Scientific, Rockford, IL, product number 31438). For 
immunoprecipitation samples, the RGS·His HRP Conjugate was used at a 1:8000 dilution (Qiagen, 
Chatsworth, CA, product number: 34450) and the anti-HA peroxydase conjugate at a 1:1000 dilution 
(Sigma-Aldrich, St. Louis, MO, product number H 6533). The anti-ubiquitin antibody (Abcam, 
Cambridge, UK, product number:  ab19247) was used at a 1:1000 dilution and detected with HRP-
coupled anti-rabbit antibody 1:10,000 diluted (Sigma-Aldrich, St. Louis, MO, product number A6154) 
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Modeling of the rigid linker 
PDF files of cdc4 (1NEX) and off7 in complex with MBP (1SVX) were superimposed using the graphics 
molecular modeling program Insight II. An artificial α-helix made of n alanine residues was aligned to 
the second helix of cdc4 linker (residues 348-358) and then off7 first helix (residues 12-17). The Skp1 
chain was removed from the PDF file in order to visualize only cdc4 and the phosphopeptide chain. 
Best fits were chosen according to their ability to place MBP on top of cdc4 WD40 domain. 
MALDI-MS  
Cell lysates were prepared identically as was described for immunoprecipitations.  Imidazole and 
Tween-20 were added to final concentrations of 10 mM and 0.05 %, respectively. All steps were 
performed at 4°C. 2ml-lysates were incubated for 1 h 45 min with 200 µl Ni-NTA magnetic agarose 
beads (Qiagen, Chatsworth, CA, product number: 36111). Beads were washed 3 times with 50 mM 
Na2HPO4 pH 8, 300 mM NaCl, 10 mM NEM, 0.05% Tween-20, 20 mM imidazole and eluted with 50 µl 
of 50 mM Na2HPO4 pH 8, 300 mM NaCl, 200 mM imidazole. 15 µl of eluted fraction was precipitated 
with 75 µl of cold 20% TCA. The precipitate was washed twice with cold acetone. The pellet was 
diluted in hexafluoroisopropanol/FA 1:3, co-crystallized with CHCA as matrix and measured by 
MALDI-MS.  
Surface Plasmon Resonance (SPR)  
Biotinylated MBP was produced in E. coli as described [37]. Off7 Y56A, Off7 Y56AY81A and Off7 
Y56AY81AY125A cloned in pQE30 were produced on a liter scale and purified as described [37]. SPR 
was measured using a BIAcore 3000 instrument (GE Healthcare, Waukesha, WI). The running buffer 
was 20 mM Hepes pH7.4, 150 mM NaCl, 0.005% Tween-20. A streptavidin SA chip was coated with 
450 or 900 RU biotinlyated MBP. The interactions were measured at 25°C and a flow of 60 µl/min 
with 5 min buffer flow, 2 min injection of different concentrations of off7 wt or mutant and an off-
rate measurement of 45 min with buffer flow. The signal of an uncoated reference cell was 
substracted from the measurements. The kinetic data of the interaction were evaluated with a global 
fit using Biaevaluation 3.0 (GE Healthcare, Waukesha, WI) and Scrubber 2.0 (BioLogic Software, 
Campbell, Australia). 
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Results 
 
Target proteins 
In order to avoid any interference with the yeast metabolism, heterologous proteins were chosen as 
target proteins.  Maltose Binding Protein (MBP) is a protein expressed in the periplasm of E. coli, it 
plays a key role in the transport of maltose. The aminoglycoside phosphotransferase IIIa (APH) is a 
bacterial kinase that transfers a phosphate group from ATP to aminoglycoside antibiotics (kanamycin, 
streptomycin) thereby conferring resistance to this class of antibiotics. APH shares structural 
homology with eukaryotic protein kinases (EPKs).  The coding sequence of MBP and APH was 
integrated in the genome of S. cerevisiae by homologous recombination at the ura locus using the 
integration vector pRS306/ADH (see material & methods). A RGS(His)6 tag was appended to their N-
terminus so that the target proteins could be detected by western blot using an anti-RGS(His)4 
antibody. A C-terminal fusion with Green Fluorescent Protein (GFP) showed that both APH and MBP 
were well expressed and distributed equally through the cytoplasm and nucleus of S. cerevisiae, 
being thus accessible (Fig. 3). The GFP-fused proteins were also used as target proteins, as they were 
usually easier to detect per western blot than the non-fused ones. 
 
 
Figure 3: Bright-field image and fluorescence microscopy of AGa (A,B) and MGa cells (C,D) (see material & methods). 
APH-GFP and MBP-GFP proteins emitted green color while the DNA was DAPI-stained in blue.  
 
Chimeric F-box protein 
The yeast F-box protein Cdc4 was chosen as scaffold for the engineering of chimeric F-box proteins. 
The original coding sequence underwent four major modifications (Fig. 4). First, Cdc4 is normally 
located in the nucleus, and thus the NLS-mutated variant, Cdc43A (K82A, R83A and K85A) was used so 
that it could be distributed everywhere in the cell [39]. Second, the sequence encoding the WD40 
domain responsible for substrate binding (residues 367-744), and the following C-terminal residues 
(residues 745-779), were deleted and replaced with a DARPin coding sequence.  Several DARPins, 
able to bind MBP or APH, were chosen as new substrate binding domains, they differed in their size 
and affinity (Table 6). Third, the linker between the F-box domain and the WD40 domain, constituted 
of two α-helices (α1 and α2), was modified. The last few amino-acids of α2, which were interacting 
with the original WD40 domain (residues 359-366), were deleted and a 5 amino-acid flexible linker 
(GSGSG) was inserted between the original linker (after residue 358) and the DARPin.  Finally, an HA-
tag was fused to the C-terminus of the chimeric F-box protein for detection purposes. The designed 
chimeric F-box proteins were expressed on a plasmid (p415Gal), under control of the Gal 1 promoter 
and detected by western blot. (Fig. 5) 
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Figure 4: Schematic representation of wt Cdc4 (A) and chimeric Cdc4 (B) domains.  
 
Target DARPin Size k on  (M
-1 s-1) k off  (s
-1) K D (M) 
APH 3a N3C (167 aa) 1.6 · 106 2.7 · 10-3 1.8 · 10-9 
B N2C (134 aa) 1.4 · 105 4.1 · 10-3 2.85 · 10-8 
MBP Off7 N3C (167 aa) 4.2 · 105 1.9 · 10-3 4.4 · 10-9 
mbp16 N2C (134 aa) 6.0 · 105 1 · 10-2 1.7 · 10-8 
 
Table 6: Characteristics of the different DARPins used as substrate binding domains for the engineering of diverse 
chimeric Cdc4 proteins. Data from Binz et al, 2004 [37] and Amstutz et al, 2005 [38]. 
 
 
Figure 5: Chimeric F-box proteins expression under the Gal1 promoter and detection.  F75Gg and F35Gg cells (see 
material & methods) were grown in the presence of glucose or galactose to repress or induce the expression of 
cdc4_5GS_3a or cdc4_5GS_off7. At OD600= 0.6-0.8, total proteins were extracted and samples normalized according to 
their OD600 before being subjected to SDS-PAGE.  The chimeric F-box proteins were detected using an anti-HA antibody. 
 
Target protein degradation assay 
Experimental set-up 1 
In order to test if a chimeric F-box protein could specifically lead a target protein to degradation, a 
first experimental set-up based on the constitutive expression of the target protein under the ADH 
promoter (integrated in the genome) and the inducible expression of the chimeric F-box protein 
under the Gal1 promoter (from plasmid p415Gal) was established. Cells were grown either in 
presence of glucose, repressing the expression of the F-box protein, or in presence of galactose, 
activating the expression of the F-box protein. After addition of cycloheximide, a protein translation 
inhibitor, the stability of the target protein was assessed by monitoring its amount after different 
time points. Both MBP-GFP and APH-GFP were unstable, but more so in presence of cdc4_5GS_off7 
or cdc4_5GS_3a, their respective cognate chimeric F-box proteins (Fig. 6). At time point 0, the 
amount of both MBP-GFP and APH-GFP was already lower in the presence of the chimeric F-box 
protein. If the target proteins were indeed constantly degraded, they could only accumulate to a 
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lower extent before the cycloheximide assay started. The chimeric F-box proteins seemed to be 
functional as they accelerated the target protein turnover, but they appeared to be also unstable 
themselves and disappeared quickly after addition of cycloheximide. After 2 to 4h, depending of their 
sequence, they were almost not present any more in the cells. The target protein degradation 
process was most likely not optimal under these conditions, since the degradation-adapter was itself 
degraded and thus removed from the system once its biosynthesis was stopped with cycloheximide. 
 
 
Figure 6: Stability of a target protein in absence or presence of a chimeric F-box protein using the experimental set-up 1.  
A: MGaF75Gg cells (see material & methods) expressing MBP-GFP were grown in the presence of glucose or galactose 
to repress or induce the expression of cdc4_5GS_off7. At OD600=0.6-0.8, cycloheximide was added, the t=0 sample was 
withdrawn followed by other ones at the indicated time points. B: AGaF35Gg cells (see material & methods) expressing 
APH-GFP were grown in the presence of glucose or galactose to repress or induce the expression of cdc4_5GS_3a. At 
OD600=0.6-0.8, cycloheximide was added and samples were withdrawn at the indicated time points. A, B: Total proteins 
were extracted and samples normalized according to their OD600 before being subjected to SDS-PAGE.  MBP-GFP and 
APH-GFP were detected with the anti-RGS(His)4 antibody and the chimeric F-box protein cdc4_5GS_off7 and 
cdc4_5GS_3a with the anti-HA antibody. The actin signal was used as an internal loading control. 
 
Experimental set-up 2 
A second experimental set-up was established to circumvent the significant instability of the chimeric 
F-box protein in the presence of cycloheximide. In this set-up, the target protein was placed under 
the control of the inducible Gal promoter (integrated in the genome) and the chimeric F-box protein 
was constitutively expressed under the ADH promoter (from plasmid p415ADH). The target protein 
was expressed during 1 h in presence of galactose and its stability was followed after promoter shut-
off by glucose, in absence or presence of a chimeric F-box protein. No cycloheximide was used. MBP 
was again more destabilized in presence of cdc4_5GS_off7 than in its absence (Fig. 7). This effect was 
specific as it was not destabilized in presence of a cdc4_5GS_B bearing an unspecific DARPin, not able 
to recognize MBP. Identical results were obtained for MBP-GFP (data not shown).  On average, the 
target protein half-life was shortened from around 180 min to 60-90 min in the presence of the 
chimeric F-box protein. The degradation was thus at least 2-fold accelerated. A similar destabilization 
was observed for the other target protein previously tested: APH, alone or fused to GFP (data not 
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shown). In conclusion, all tested chimeric F-box proteins were active and led to an accelerated 
protein break-down, cdc4_5GS_off7 and cdc4_5GS_mbp16 towards MBP and cdc4_5GS_3a and 
cdc4_5GS_B towards APH (data not shown). In the active constructs, the DARPin moiety was of 
different sizes and affinity. This second set-up allowed us to monitor target protein degradation 
within 3 h. All following degradation assays, unless stated, were then performed using the 
experimental set-up 2.  
 
Figure 7: Stability of MBP in the presence of an unspecific or specific chimeric F-box protein using the experimental set-
up 2. Cdc4_5GS_B was engineered with a DARPin which was selected against APH and does not recognize MBP. 
Cdc4_5GS_off7 was engineered with a specific DARPin which was selected against MBP. Mg, MgFB5Ga and MgF75Ga 
cells (see material & methods) were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. MBP expression 
was induced for 1 h with galactose and stopped with glucose. Samples were withdrawn at the indicated time points. 
Total protein was extracted and samples normalized according to their OD600 before being subjected to SDS-PAGE. The 
levels of MBP were detected by immunoblotting with the anti-RGS(His)4 antibody. The actin signal was used as an 
internal loading control. 
 
Stability of the target protein in presence of MG132, a proteasome inhibitor 
The target protein was destabilized when co-expressed with a specific chimeric F-box protein.  To 
investigate if this unstability was proteasome dependent, the effect of MG132 [40], a reversible 
proteasome inhibitor was tested. For this assay, a special strain mutated for erg6 [41], a sterol 
transmethylase involved in the final synthesis of the membrane ergosterol, was used to increase the 
membrane permeability and allow the compound to pass through the yeast cell wall. Under MG132 
treatment, the degradation was slower than in the presence of DMSO (the same amount as used for 
dissolving MG132) (Fig. 8). MG132, like most proteasome inhibitors, does not inhibit all proteolytic 
activities but it showed that the target protein was processed by the 26S proteasome, as its 
degradation was slowed down in the presence of MG132.   
 
 
Figure 8: Stability of MBP-GFP co-expressed with cdc4_5GS_off7 in presence of the proteasome inhibitor MG132. 
eMGgF75Ga cells (see material & methods) were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. 
Galactose and DMSO or MG132 were added to the cells. After 1 h, MBP-GFP expression was stopped with glucose. 
Samples were withdrawn at the indicated time points. Total protein was extracted and samples normalized according to 
their OD600 before being subjected to SDS-PAGE. The levels of MBP-GFP were detected by immunoblotting with an anti-
RGS(His)4 antibody. 
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Stability of the target protein in ubiquitylation mutant strains 
In order to make sure that the degradation process not only relied on proteasome activity but also 
on the SCF ubiquitin ligase (E3) complex which should contain the hybrid cdc4 protein, two plasmids, 
one containing the MBP-GFP gene and another containing the cdc4_5GS_off7 gene, were co-
transformed in two different thermosensitive strains, namely cdc53_1 and cdc34_2 and their wild-
type background strain, W303. Cdc53_1 contains a mutation in the cdc53 gene which encodes a 
deficient cullin 1, another subunit of the SCF ubiquitin ligase (Fig. 2). Cdc34_2 contains a point 
mutation in the cdc34 gene which encodes the ubiquitin conjugating enzyme (E2) interacting with 
the SCF complex. A degradation assay was performed for 4.5 h in parallel at 25 and 37°C. In W303, 
MBP-GFP was quickly degraded, while in cdc53_1, the degradation process was slowed down, but 
following the same pattern at the permissive and restrictive temperatures (Fig. 9).  In cdc34_2, MBP-
GFP was also more stable than in the wt strain, but the amount detected at 37°C was lower than at 
25°C. These results were not in agreement with the effect of the mutations, meant to be effective at 
the restrictive temperature only. However when carefully looking at the actin signal, one could see 
that despite the normalization of the samples, the amount of total protein (represented by actin) 
present in all samples was not equal. This discrepancy correlated with the differences observed for 
MBP-GFP signals, especially for the cdc34_2 strain samples.  The elongated shape of these mutant 
cells and the arrest in G1 might explain the difficulty to properly normalize samples while relying on 
the OD600nm [42]. Thermosensitive strains can partially display their mutant phenotype at the 
permissive temperature. Thus, despite the lack of reliable sample normalization between the 
permissive and restrictive temperatures, we could still observe that MBP-GFP was normally degraded 
in the background strain W303, while it accumulated more in both mutant strains, suggesting that its 
degradation required both the SCF ubiquitin ligase and the interacting ubiquitin conjugating enzyme.  
 
 
Figure 9: Stability of MBP-GFP co-expressed with cdc4_5GS_off7 in wt, cdc34_2 (deficient in E2) and cd53_1 (deficient in 
cullin 1) background strains. WtMGgF75Ga, 53MGgF75Ga and 34MGgF75Ga cells (see material & methods) were 
grown at 25°C in a synthetic raffinose based medium to an OD600 of 0.5. MBP-GFP expression was induced for 2.5 h with 
galactose and stopped with glucose. Halves of cultures were kept at 25°C (blue) and the other halves were switched to 
37°C (red). Samples were withdrawn at the indicated time points. Total protein was extracted and samples normalized 
according to their OD600 before being subjected to SDS-PAGE. MBP-GFP and cdc4_5GS_off7 were detected by 
immunoblotting with anti-RGS(His)4 and anti-HA antibodies, respectively. The actin signal was used as an internal loading 
control. 
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Target protein immunoprecipitations and Mass spectrometry analysis 
Immunoprecipitations were performed to see if ubiquitinated forms of the target protein could be 
detected. The MBP could be easily immunoprecipitated using an anti-MBP antibody as bait. An 
additional band to the one corresponding to the theoretical size of the MBP construct (43 kDa) 
appeared at 53 kDa, but both in the absence and presence of the chimeric F-box protein 
cdc4_5GS_off7, ruling out the possibility that it could be an ubiquitinated form of the target protein 
(Fig. 10A). The anti-ubiquitin antibody did not reveal any specific higher molecular weight species in 
the presence of the chimeric F-box protein either (Fig. 10B).  In order to counteract the general 
activity of deubiquitinases which can remove ubiquitin molecules and decrease the probability to 
retrieve ubiquitinated proteins, a pull-down was also performed under denaturing conditions. Ni-
NTA magnetic beads were used to pull down MBP via its terminal RGS(His)6 tag in 8 M urea (Fig. 
11A). Yet again, no specific higher molecular weight products could be detected (Fig. 11A,B). No 
ubiquitinated form of the target protein could be detected under the conditions used.  Nevertheless, 
the anti-HA antibody revealed that cdc4_5GS_off7 co-eluted with the target protein showing that 
they did interact in vivo. (Fig. 10C). cdc4_5GS_off7 was consistantly running at around 70 kDa, which 
was higher than its theoretical molecular weight of 56.8 kDa.  
 
 
Figure 10: MBP Immunoprecipitation. MBP was expressed alone in Mg cells or with the chimeric F-box protein 
cdc4_5GS_off7 in MgF75Ga cells (see material & methods). After cell lysis, MBP was immunoprecipitated with an anti-
MBP antibody. The eluted fractions were detected with an anti-RGS(His)4 antibody detecting MBP itself (A), an anti-
ubiquitin antibody (B) and an anti-HA antibody (C). A: The anti-RGS(His)4 antibody recognized MBP at 43 kDa and a non-
identified species at 53 kDa. B: The anti-ubiquitin antibody did not detect ubiquitinated forms of MBP in the presence of 
the chimeric F-box protein cdc4_5GS_off7. C: The anti-HA antibody detected the chimeric F-box protein cdc4_5GS_off7, 
running at 69 kDa, which co-immnunoprecipitated with MBP. The size marker is indicated in kDa.  
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Figure 11: MBP pull-down in denaturing conditions. MBP was expressed alone in Mg cells or with the chimeric F-box 
protein cdc4_5GS_off7 in MgF75Ga cells (see material & methods). After cell lysis in 8 M urea, MBP was pulled down by 
Ni-NTA magnetic beads. The eluted fractions were detected with an anti-RGS(His)4 antibody (A) and an anti-ubiquitin 
antibody (B). A: The anti-RGS(His)4 antibody recognized MBP at around 43 kDa. B: the anti-ubiquitin antibody did not 
detect ubiquitinated forms of MBP in the presence of the chimeric F-box protein cdc4_5GS_off7. The size marker is 
indicated in kDa. 
 
Mass spectroscopy was also used to see if any ubiquitinated target protein could be detected. After 
cells lysis, Ni-NTA magnetic beads were used to pull down MBP-GFP via its terminal RGS(His)6 tag. A 
sample of the eluted fraction was run on a SDS-PAGE and western-blotted with the anti-RGS(His)4 
antibody. The most prominent species in the sample was running at 83 kDa, two other additional 
proteins were also detected at 62 and 33 kDa while the theoretical size of MBP-GFP was 69964 kDa 
(Fig. 12A). The eluted sample was subjected to MALDI-MS. The largest species was identified with a 
molecular weight of 69935 kDa, which corresponded to non-modified MBP-GFP (Fig. 12B). No species 
of higher molecular weight were revealed in the spectrum but this one was ranging from 8 to 80000 
kDa. No species corresponding to the molecular weight of MBP-GFP plus 1,2, 3 or 4 molecules in a 
doubly charged or triply charged form could be detected, either. It should be noted that MBP-GFP 
was present in a rather large amount (approximately ≥ 70% of total protein) but did not give a strong 
signal; it did not fly well under the used conditions. The shift observed in the molecular weight of 
MBP-GFP per western blot was probably an artifact and did not seem to be due to ubiquitination. 
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Target protein ubiquitination could then not be demonstrated by immunoprecipitation or mass 
spectroscopy. However, as target protein degradation relied on the presence of a specific chimeric F-
box protein, a functional SCF complex, the activity of the E2 ubiquitin ligase and a proficient 26S 
proteasome, we assumed that the chimeric F-box protein was functional and was mediating target 
protein degradation by addressing it to the ubiquitin proteasome pathway. Further experiments 
were carried out, using the chimeric F-box protein cdc4_5GS_off7 and the target protein MBP to 
investigate the mechanism of natural F-box proteins.  
 
Linker engineering of the chimeric F-box protein 
The linker between the F-box domain and the substrate binding domain seems critical for cdc4 
function; it is a stiff helix which is thought to properly position the substrate for subsequent 
ubiquitination [18]. To probe the importance of orientation and rigidity in this linker domain, it was 
engineered so that the substrate can be either flexibly or rigidly positioned for an attack by E2 (see 
Fig. 2). In order to orient the target protein in a similar way to the original WD40 domain, structures 
of cdc4 and off7 in complex with MBP were superimposed (Fig. 13). An artificial α-helix made of 
alanine residues was used to extend the second helix of the cdc4 linker into the first helix of DARPin. 
Using 3, 10 or 17 Ala as a (more or less) rigid linker, MBP, while bound by off7, could be positioned at 
about the same place as the cdc4 WD40 binding surface, where the substrates are normally bound 
by the wt cdc4 protein.  In addition to the rigid linkers, two additional flexible ones of greater length 
were made: GSGSSGSGSG (10 GS) and (GSGSS)2GSGSG (15 GS). These linkers were meant to increase 
gradually the rotation possibility of the substrate binding domain. MBP (Fig. 14) and MBP-GFP (data 
not shown) could be both degraded with all kind of linkers. The shortest flexible one made of GSGSG 
residues (5 GS) was the most efficient one. In general, degradation efficiency was decreasing with 
linkers of increasing length, for both flexible and rigid ones. The linker rigidity seemed then not to be 
crucial for the substrate presentation, but rather its length.  
Figure 12: Maldi-MS analysis of MBP-GFP. MBP-GFP was expressed with the chimeric F-box protein cdc4_5GS_off7 in 
MGgF75Ga cells (see material & methods). After cell lysis, it was pulled down with Ni-NTA magnetic beads. A: A 
sample of the eluted fraction was subjected to SDS-PAGE and western blot which was performed with the anti-
RGS(His)4 antibody. B: Maldi-MS spectrum. The eluted fraction was precipitated with 20% TCA and washed with cold 
acetone. The pellet was diluted in hexafluoroisopropanol/FA 1:3, co-crystallized with CHCA as matrix and measured by 
MALDI-MS. 
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Figure 13: Engineering of a rigid linker in the chimeric F-box protein. A: Schematic representation of the strategy used to 
engineer a rigid linker between the F-box domain and the DARPins. Structures of cdc4 and off7 in complex with MBP 
were superimposed. An artificial α-helix made of alanine residues was used to extend the second helix of cdc4 linker into 
off7 first helix. B: Ribbon representation of cdc4. The F-box domain is colored in yellow, the WD40 domain in white and 
the linker in-between these domains in orange. The N-terminal domain was not crystallized. C: Ribbon representation of 
the MBP-Off7 complex. The DARPin Off7 is colored in red and the MBP in green. D: Ribbon representation of 
cdc4_3ala_off7 model. The F-box domain is colored in yellow, the original linker part in orange, the new linker part in 
blue and the DARPin Off7 in red. The side chains of residues involved in binding are displayed in purple. E: Superposition 
of cdc4 and the MBP-Off7 complex. The artificial alanine helix is colored in blue.  
 
 
Figure 14: Stability of MBP co-expressed with a chimeric F-box protein engineered with a rigid linker in MgF73Aa, 
MgF710Aa and MgF717Aa cells (A) or with a flexible linker in MgF75Ga, MgF710Ga and MgF715Ga cells (B). Cells 
were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. MBP expression was induced for 1 h with 
galactose and stopped with glucose. Samples were withdrawn at the indicated time points. Total protein was extracted 
and samples normalized according to their OD600 before being subjected to SDS-PAGE. The levels of MBP were detected 
by immunoblotting with the anti-RGS(His)4 antibody. The actin signal was used as an internal loading control. 
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Affinity engineering of the chimeric F-box protein 
The exact mechanism of ubiquitinated substrate delivery to the proteasome is not known. One 
hypothesis is that after ubiquitination, the substrate is released from the SCF complex and goes to 
the proteasome. The DARPins used for the engineering of the chimeric F-box proteins have a very 
strong affinity (low nM range), they could be preventing an efficient release of the processed 
substrate. In order to find the optimal affinity allowing an efficient recruitment and release of the 
substrate, a series of affinity mutants was generated by site-directed mutagenesis. Using the crystal 
structure of off7 in complex with MBP [37], three critical residues involved in H-bonds were mutated, 
leading three single mutants: Y56A; Y81A and Y125A, three double mutants: Y56AY81A;  Y56AY125A; 
Y81AY125A and one triple mutant: Y56AY81AY125A (Fig. 15A). Affinities were determined by SPR for 
several mutants, the obtained KD ranged from 11 nM to 2 μM (Fig. 15B). Biophysical properties were 
analysed by gel filtration, which showed that the mutants had the same running behavior than the 
wt off7.  Chimeric F-box proteins were engineered with the mutated off7, and their effect on target 
protein stability were compared with the wt one. Whereas MBP-GFP degradation was barely affected 
by a single mutation in the substrate binding domain, the double and triple mutants partially 
stabilized the target protein (Fig. 15B). Similar results were obtained with MBP (data not shown). The 
target protein degradation efficiency gradually decreased as the number of mutations increased. No 
affinity-engineered mutant improved the degradation rate over wt, which had a KD of 11nM, a very 
high affinity down to 2 μM, which is in the typical affinity range for intracellular interactions and had 
the smallest effect on degradation. With a KD of 11nM, the substrate was unlikely to be easily 
released from the F-box subunit. However, it was possible that it did not need to be discharged from 
the F-box subunit to be degraded, the F-box subunit and the substrate might go to the proteasome 
as a complex. 
 
 
Figure 15: Affinity engineering of the chimeric F-box protein cdc4_5GS_off7. A: Representation of the interaction 
between MBP (blue) and off7 (red). H bonds are shown in dark green and the mutated residues are boxed in light green. 
B: MBP-GFP stability in the presence of cdc4_5GS_off7 affinity mutants. MGgF75Ga, MGgF7’5Ga, MGgF7’’5Ga and 
MGgF7’’’5Ga cells (see material & methods) were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. 
MBP expression was induced for 1 h with galactose and stopped with glucose. Samples were withdrawn at the indicated 
time points. Total protein was extracted and samples normalized according to their OD600 before being subjected to SDS-
PAGE. The levels of MBP were detected by immunoblotting with the anti-RGS(His)4 antibody. 
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Chimeric F-box protein stability 
The chimeric F-box protein had already been observed during the first co-expression experiments to 
be unstable (Fig. 6).  To investigate if it was co-degraded with the target protein by the proteasome, 
its stability was assessed using a modified experimental set-up 1. cdc4_5GS_off7 was expressed on 
p415Gal for 1 h 30 min, alone or in a strain constitutively expressing MBP-GFP.  After Gal1 promoter 
shut-off, stability of the chimeric F-box protein was followed in the absence or presence of MBP-GFP. 
In both cases, the chimeric F-box protein was unstable and its half-life was even extended in the 
presence of the target protein: t ½ ≤ 60 min vs. 60< t ½ <120 min (Fig. 16A).  Similar results were 
obtained for cdc4_5GS_3a whose stability was monitored in the absence or presence of APH-GFP 
(Fig. 16B).   
 
 
 
Figure 16: Chimeric F-box protein stability in absence or presence of target protein. A: cdc4_5GS_off7 stability was 
monitored in F75Gg or MGaF75Gg cells (see material & methods) constitutively expressing MBP-GFP. B: cdc4_5GS_3a 
stability was monitored in F35Gg or AGaF35Gg cells (see material & methods) constitutively expressing APH-GFP. A, B: 
Cells were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. Chimeric F-box protein expression was 
induced for 1 h 30 min with galactose and stopped with glucose. Samples were withdrawn at the indicated time points. 
Total protein was extracted and samples normalized according to their OD600 before being subjected to SDS-PAGE. 
Chimeric F-box proteins were detected by immunoblotting with the anti-HA antibody and target proteins (MBP-GFP and 
APH-GFP) with the anti-RGS(His)4 antibody.  
 
The chimeric F-box protein was observed to be constantly degraded, in absence or presence of the 
target protein. Cdc4 was reported to be intrisincally unstable; its half-life was estimated according to 
the study to be 5 or 15 min [43, 44]. Like several other F-box proteins, it was reported to 
autoubiquitinate itself and be degraded by the proteasome. The chimeric F-box protein might have 
conserved this characteristic.  In order to see if any ubiquitinated form of the chimeric F-box protein 
could be detected, cdc4_5GS_off7 was immunoprecipitated using an anti-HA antibody. However, no 
higher molecular weight species were observed when probing the immunoprecipitated samples with 
the anti-HA or anti-ubiquitin antibodies (Fig. 17A,B). Only the interaction with the target protein in 
vivo was confirmed a second time, as MBP was co-immunoprecipitated, it ran at 46 kDa. (Fig. 17C). 
An additional species co-eluting with cdc4_5GS_off7 at 66 kDa also reacted with the anti-RGS(His)4 
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antibody. However, it did not correspond to any form of ubiquitylated MBP, as it was not detected by 
the anti-ubiquitin antibody. 
 
 
Figure 17: cdc4_5GS_off7 immunoprecipitation. cdc4_5GS_off7 was expressed in F75Ga cells or MgF75Ga cells with the 
target protein MBP (see material & methods). It was immunoprecipitated with an anti-HA antibody. The eluted fractions 
were detected with the anti-HA  antibody (A), the anti-ubiquitin antibody (B) and the anti-RGS(His)4 antibody (C). A: The 
anti-HA antibody recognized cdc4_5GS_off7 at 70.5 kDa B: the anti-ubiquitin antibody did not detect specific 
ubiquitinated forms of cdc4_5GS_off7. C: the anti-RGS(His)4 antibody detected the target protein MBP at 46 kDa and a 
non-identified species at 66 kDa. The size marker is indicated in kDa. 
 
Chimeric F-box protein overexpression 
Since the chimeric F-box protein seems to be constantly degraded, we wondered if it would be 
possible to improve the degradation of the target protein by increasing the overall amount of 
available chimeric F-box protein. Three additional increasing levels of expression were tested by 
placing the cdc4_5GS_off7 coding sequence under the ADH promoter or the stronger TEF promoter 
in a centromeric (415 plasmid, one copy per cell) or 2 micron (425 plasmid, 10-30 copies per cell) 
plasmid [35]. Contrary to what might be expected, MBP-GFP degradation efficiency decreased as 
more and more cdc4_5GS_off7 was expressed (Fig. 18). The chimeric protein, when overexpressed, 
slowed down the target protein degradation.  
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Figure 18: Stability of MBP-GFP co-expressed with increasing amounts of chimeric F-box protein. MGgF75Ga cells, 
MGgF75Gt cells, MGgF75Gaa cells and MGgF75Gtt cells were grown in a synthetic raffinose based medium to an 
OD600 of 0.6-0.8. MBP-GFP expression was induced for 1 h with galactose and stopped with glucose. Samples were 
withdrawn at the indicated time points. Total protein was extracted and samples normalized according to their OD600 
before being subjected to SDS-PAGE. The levels of MBP-GFP were detected by immunoblotting with an anti-RGS(His)4 
antibody. 
 
The N-terminal part of the chimeric F-box protein 
The N-terminal part of cdc4, upstream of the F-box domain, was left intact for the construction of the 
chimeric F-box protein, its role being unclear. Cdc4 had been reported to be able to form 
homomultimers through this region, which also possessed dominant-negative activity [45]. It was 
unclear, however, if this region was positively or negatively regulating F-box protein activity. In order 
to estimate the importance of the N terminal part of cdc4 for our chimeric F-box protein, a truncated 
mutant of cdc4_5GS_off7 was generated by deleting the sequence lying upstream of the F-box 
domain (∆N, deletion of aa 1-269). No difference was observed on MBP degradation with 
cdc4_5GS_off7 or cdc4_5GS_off7 ∆N (Fig. 19).  The chimeric F-box, consisting of only the F–box 
domain, a linker and the substrate binding domain was fully functional to degrade the target protein.  
 
 
Figure 19: Stability of MBP co-expressed with a N-terminally truncated chimeric F-box protein. MgF75Ga cells and 
MgF7∆5Ga cells (see material & methods) were grown in a synthetic raffinose based medium to an OD600 of 0.6-0.8. 
MBP expression was induced for 1 h with galactose and stopped with glucose. Samples were withdrawn at the indicated 
time points. Total protein was extracted and samples normalized according to their OD600 before being subjected to SDS-
PAGE. The levels of MBP were detected by immunoblotting with an anti-RGS(His)4 antibody. The actin signal was used as 
an internal loading control. 
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Chimeric F-box protein and substrate destabilization 
Ubiquitin moieties are attached onto Lys residues. The efficiency of ubiquitylation must then rely on 
the availability of lysine residues in the target protein sequence. In order to increase the 
ubiquitylation probability, a tail of 5 lysine residues was fused to the C-terminus of the target protein 
MBP. Independently, the same lysine tail was also appended to the C-terminus of the chimeric F-box 
protein, cdc4_5GS_off7. If the F-box protein was degraded in complex with the substrate, increasing 
its own turnover could potentially help degrading more target protein as well.  However, the addition 
of a lysine tail to the target protein did not improve its degradation, nor did the addition of the lysine 
tail to the chimeric F-box protein (Fig. 20).  
 
 
Figure 20: Addition of a lysine tail at the C-terminus of the target protein or the chimeric F-box protein. MgF75Ga  cells, 
MLysgF75Ga cells and MgF7Lys5Ga cells (see material & methods) were grown in a synthetic raffinose based medium 
to an OD600 of 0.6-0.8. MBP or MBP_lys expression was induced for 1 h with galactose and stopped with glucose. Samples 
were withdrawn at the indicated time points. Total protein was extracted and samples normalized according to their 
OD600 before being subjected to SDS-PAGE. The levels of MBP and MBP_lys were detected by immunoblotting with the 
anti-RGS(His)4 antibody. The actin signal was used as an internal loading control. 
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Discussion 
 
S. cerevisiae SCF cdc4 was used as framework for the engineering of an ubiquitin ligase with 
predefined specificity. A chimeric F-box protein was designed with new artificial substrate specificity 
using the cdc4 backbone and DARPin, a new binding scaffold, for replacing its original substrate 
binding domain. In order to investigate if it could function like a normal yeast F-box protein, it was 
co-expressed with a cognate target protein in S. cerevisiae. The target protein was significantly more 
unstable in the presence of the chimeric F-box protein. Its half-life was only 2- to 3-fold affected but 
this effect was specific.  The target protein was indeed not destabilized by the presence of a chimeric 
F-box protein engineered with a non-specific DARPin moiety. MG132, a proteasome inhibitor, could 
partially stabilize it and demonstrated that the target protein was degraded by the 26S proteasome. 
The degradation process also relied on the SCF activity.  The target protein was indeed less 
destabilized in the cdc53_1 and cdc34_2 thermosensitive strains than in the wt strain. No difference 
could be observed between the permissive and restrictive temperatures, but the lack of correct 
sample normalization because of the elongated shape of these mutant cells and the arrest in G1 
which might have affected the OD600nm measurements, prevented us to fairly compare the amount of 
target protein at both temperatures. Immunoprecipitations of the target protein were performed. 
The chimeric F-box protein was co-immunoprecipitated, proving that they interacted in vivo. 
However no ubiquitinated forms of the target protein could be revealed. It could be that once 
ubiquitinated, the target protein was quickly recognized by the proteasome and immediately 
deubiquitinated before being degraded. The ubiquitin moieties are indeed recycled by 
deubiquitinating enzymes residing close to or in the proteasome. In S. cerevisiae, the 
metalloprotease Rpn11 is a core structural component of the lid and has been seen to cleave 
substrate-linked chains at or near their base [46, 47]. This “en bloc“ chain removal resulted in the 
production of a prominent band of unmodified substrate. A fraction of target protein could also have 
been deubiquitinated before reaching the proteasome as deubiquitinating enzymes can also be 
found associated with E3 ligases, directly counteracting their activity [48].  However, even under 
denaturing conditions, when deubiquitinating enzymes should not have been active any more, no 
ubiquitinated target protein could be retrieved either. Despite the presence of several lysine residues 
at its surface, 10 whose surface availaibility was ≥ 40% and 10 whose surface availaibility was ≥ 30%, 
the exogenous target protein might also have been not very efficiently ubiquitylated (see discussion 
below). The use of overexpressed tagged ubiquitin instead of endogenous one might help detecting 
ubiquitinated species.  
To summarize, we could not state that our target protein was directly targeted for degradation by 
ubiquitination, as we could not demonstrate the presence of ubiquitinated target protein by 
immunoprecipitation or subsequent mass spectroscopy. Nonetheless its degradation relied on its 
specific recognition by the chimeric F-box protein, a functional SCF complex, the activity of the E2 
ubiquitin ligase and a proficient 26S proteasome.  Further experiments were carried out, using 
chimeric F-box proteins as a tool and the target protein degradation assay as a read-out, to 
investigate the mechanism of natural F-box proteins.  
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SCF protein subunits fit together into a fairly rigid C-shaped conformation which allows substrate 
positioning in a 50-60 Å space between the ubiquitin conjugating enzyme (E2) on one end and the F-
Box protein on the other end (Fig. 2) [17, 18, 21]. Structural and experimental data make it plausible 
that this large space is a kind of “hot zone” with a maximal ubiquitin transfer occurring for the 
substrate lysine residues lying next to the E2 active site. The linker between the F-box domain and 
the substrate binding domain seemed critical for the native cdc4 function; it is a stiff helix which is 
conserved throughout evolution as revealed by several F-box proteins structures [17, 18, 20, 21]. It 
forms a stalk-like structure which projects the WD40 domain away from skp1 and is thought to 
optimally place the substrate in the vicinity of the E2 active site. To probe the importance of 
orientation and rigidity in this domain, F-box proteins were designed with either a rigid linker (3, 10 
or 17 Alanine residues (ala)) which would position the substrate identically to the original one or a 
flexible one (5, 10 or 15 total Glycine and Serine residues (GS)). In all cases, the target protein could 
be degraded, however to a varying extent. In general, short linkers seemed to be more efficient than 
long ones, the 5GS one being slightly superior to the 3ala one. The longer ones might have positioned 
the target protein partially outside of the “hot zone”. No dramatic difference was observed between 
the rigid and flexible linker. It is possible that our model for the designed ala helix was not fully 
accurate and did not position the substrate correctly as it was meant to, or that the rigid linkers were 
by themselves not as rigid as presumed.  Nevertheless, it appeared that the substrate did not need to 
be presented in a rigid mode and specified orientation to the E2 to be degraded. Orlicky et al. had 
observed that cdc4 function was sensitive to the insertion of helix-detabilizing residues or additional 
alanine residues into the stalk [18]. These mutations disrupted the original linker structure, but 
positioned the substrate in a different orientation from the original one without enabling it to move. 
In our model, the substrate when bound to the chimeric F-box protein designed with a flexible linker 
was instead allowed to be in motion in the “hot zone” and probe the vicinity of the E2.  Nature might 
have evolved the chimeric F-box proteins to bind and hold their specific substrates in a defined way 
to increase the concentration of the substrate lysines at the E2 active site. The ubiquitination rate 
seems indeed to correlate with the spacing between the substrate Lys and the E2 catalytic site [17]. 
However for a non-optimally presented substrate, the E2 if functioning according to the “Hit and 
Run” model, could “sample” the substrate surface and collide with exposed lysines. The working 
mechanism of E2 is not well understood but the ubiquitin-charged Cdc34 (cdc34~Ub) has been 
observed in dynamic binding equilibrium with SCFcdc4 [26].  It was then proposed that cdc34~Ub 
could bind to the RING domain, be released in close proximity of the substrate and diffuse in the hot 
zone until it finds one of its Lys residues. This repetitive “Hit and Run” mechanism could ensure 
certain flexibility in selection of target lysines, as seen on natural SCF substrates which can be 
modified on multiple lysines [49], and accommodates the synthesis of multi-ubiquitin chains. 
Nevertheless, the ubiquitylation efficiency is most likely superior when performed onto optimally 
pre-positioned lysines, especially as the attachment of the first ubiquitin molecule was shown to be 
the rate limiting step in the multi-ubiquitin chain assembly [16]. In the case described here, the 
target protein ubiquitination was most likely not optimal as it did not yield detectable amounts of 
ubiquitinated products but seemed to be enough to trigger degradation. 
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After probing the importance of structural integrity of the chimeric F-box protein, we tried to 
determine its optimal binding strength to the target protein which would achieve a productive 
substrate recruitment within the SCF complex and a reasonable discharge to interact with the 
proteasome. Cdc4 has been described to interact with its specific substrate Sic1 with a KD of 250 nM 
[50]. A mammalian homolog, the F-box protein β-TrCP 1, binds to its substrates β-catenin and IκBα 
with similar KD, in the 500 nM range [17]. It is not known how the substrate, once ubiquitinated, 
leaves the SCF complex. DARPins have been evolved to high affinity (low nM range) and the target 
proteins release might be hindered by the binding strength of our artificial substrate binding domain. 
Site directed mutagenesis was used to gradually decrease the binding affinity of the chimeric F-box 
protein cdc4_5GS_off7. The degradation efficiency linearly decreased in parallel with the binding 
affinity. This confirmed the dependence of the degradation process on the specific interaction with 
the chimeric F-box protein and did not reveal any other binding affinity optimum between 11 nM 
and 2 μm. The target protein degradation seemed to depend only on the efficiency of the substrate 
recruitment and not on a fast dissociation rate which would also allow releasing the substrate from 
the chimeric F-box binding domain. These results led us to think that the substrate was most likely 
discharged as a complex with the F-box subunit, from the SCF machinery.  
Zhou & Howley had previously proposed that F box receptors and their bound substrates were 
degraded as a unit to ensure a continuous recycling of the SCF holocomplex and permit it to 
assemble with other F box receptor subunits [43]. The chimeric F-box protein had at the beginning of 
our study been observed to be unstable when co-expressed with the target protein. If it was co-
degraded with the target protein, stabilization might occur in absence of the target protein. However 
it was not observed. Instead, the chimeric F-box protein was also unstable when expressed alone. 
The original cdc4 protein, like other F-box protein, is degraded by the proteasome [24, 43, 44]. It gets 
ubiquitinated within its own SCF complex in an autocatalytic manner. This mechanism may allow 
rapid switching of F-box protein subunits and dynamically regulate the equilibrium between multiple 
SCF complexes. We looked for ubiquitinated forms of the chimeric F-box protein but could not detect 
any. It should be noted that ubiquitinated cdc4 could be readily observed by Galan et al. but Grr1p, 
another yeast F-box protein shown to autoubiquitinate, could only be accumulated in an 
ubiquitinated form using a dominant-negative ubiquitin which prevented its degradation [44]. The 
incapacity to retrieve ubiquitinated form and the longer half-life of our chimeric F-box protein 
compared to wt cdc4 might suggest a decreased autoubiquitination. Furthermore, some F-box 
proteins seemed to be more poorly ubiquitinated than others [24]. Noteworthy, the chimeric F-box 
protein was less unstable when co-expressed with the target protein. A similar observation has been 
made for HOS, the human homolog of the drosophila Slimb F-box protein, which was protected from 
autoubiquitination and degradation in presence of its substrate IκBα [51]. Deshaies suggested that a 
substrate would shield the F-box protein from the core components of the SCF, thus protecting it 
from autoubiquitination and stabilize it [52]. If a given F-box protein were synthesized in excess, its 
levels would be quickly pared down to match substrate demand. Our data do not fully agree with this 
model. In our experimental set-up, the target protein was present in excess amount and it slowed 
down the degradation process of the chimeric F-box protein but it did not prevent it. In parallel, 
when the chimeric F-box protein expression level was progressively elevated, it gradually decreased 
the degradation of the target protein. This effect would speak in favor of inhibition per competition, 
either at the SCF assembly or proteasomal degradation level. Indeed the F-box protein can assemble 
with the SCF machinery either alone or bound to the target protein. If the amount of chimeric F-box 
protein augments and exceeds the target protein one, the pool of free chimeric F-box protein will 
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increasingly compete for skp1 binding and subsequent SCF assembly and ubiquitination. Another 
possibility would be that the larger amount of free autoubiquitinated chimeric F-box protein would 
“jam” the 26S proteasome and reduce the degradation efficiency of other substrates, like the target 
protein. Either one or both of these models could apply to our experimental data, which show that 
increasing the amount of F-box protein might not be the solution to enhance substrate degradation. 
We thus propose a third model for the F-box protein level regulation mechanism. In presence of 
substrate, the F-box protein binds to it, assembles with the SCF holoenzyme. The substrate is 
ubiquitinated, the complex of F-box protein and ubiquitinated substrate is released from the SCF 
machinery and co-degraded. In the absence of substrate, the F-box protein assembles with the SCF 
holoenzyme. It gets autoubiquitinated, leaves the SCF machinery and is degraded alone. In this 
model, the F-box protein would be constantly degraded, alone or in complex with its substrate and in 
all cases travelling to the proteasome with the same rate. We therefore suggest that the stabilization 
effect of the substrate on the F-box protein half-life would result from the deceleration of the 26S 
proteasome activity when it processes the F-box protein and the substrate compared to the F-box 
protein alone. It is indeed plausible that preparation by the 19S and degradation of two polypeptidic 
chains by the 20S might require more time than for one substrate. 
The importance of the N-terminal domain of the F-box protein for its activity was also investigated. 
The impossibility to crystallize any of the F-box protein unless it was truncated for its N-terminal 
region prevented us to have insight into its function. Overproduction of polypeptides corresponding 
to the N-terminal region of cdc4 inhibited SCFcdc4 in vivo [45]. cdc4 was shown to homomultimerize 
through its amino terminus and the dominant negative activity of the N-terminal peptides correlated 
to their ability to associate with full-length cdc4. A similar observation was made for another F-box 
protein, Met30. It was thus uncertain if F-box protein multimerization was necessary for their 
function or could even have an inhibitory effect. The N-terminal region, lying upstream of the F-box 
protein, was deleted in our chimeric F-box protein. This deletion did not affect its function, as the 
target protein was degraded at the same rate by both the wt and mutant chimeric F-box proteins. 
The N-terminal part was thus not needed for the activity of the chimeric F-box protein. Meanwhile, 
Tang et al further characterized the dimerization domain (D domain) of cdc4 and determined its 
structure [50]. Their biochemical data suggested that dimerization of cdc4 was required in vivo. In 
vitro, a monomeric SCFcdc4 was deficient in ubiquitin chain initiation and especially elongation of its 
substrate sic1. SCFcdc4 dimerization was, however, not required when sic1 was modified to contain 
only one high-affinity phosphodegron, binding to the WD40 domain, and was thus bound in only one 
position. The target protein MBP would be a similar substrate, as it is bound by off7 in a unique 
configuration. A model of the dimeric holo-SCFcdc4 complex based on small-angle X-ray scatter 
measurements (Fig. 21) revealed that the D domain orients the substrate binding site and E2 binding 
site of each SCF protomer in a suprafacial configuration, in which cdc4 WD40 domain and E2 catalytic 
sites lie in the same plane with a separation of 64 Å within and 102 Å between each SCF monomer. 
The authors suggested that this spatial variability may facilitate lysine acceptor site utilization in both 
bound substrates and the elongating ubiquitin chain. Similar observations were made for Fbw7, the 
human homolog of cdc4, which was required to dimerize for the regulation of certain weak 
interacting substrates [53]. The dimerization ability of the chimeric F-box protein was not tested so it 
cannot be stated that it could support such a supra-complex but the new substrate binding domain 
could fit in the structural model of the dimeric holo-SCFcdc4 complex.  
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Figure 21: Model of the dimeric SCF cdc4 complex determined by SAXS in solution. A: Stereo ribbons representation of 
the SAXS solution-based model of the dimeric skp1-cdc4 222-744 subcomplex. B: Space-filling representation of the 
dimeric SCF cdc4 complex. Calculated distances between substrate-binding sites and catalytic sites are shown. Adapted 
from Tang et al, 2007 [50].  
 
The use of a chimeric F-box protein allowed us to have better insights into the mechanism of F-box 
proteins. The availability of a new substrate binding domain which could be stable in vivo enabled us 
to design chimeric F-box proteins capable of recognizing new substrates. The domains of a chimeric 
F-box protein could be dissected without interfering with the cell’s metabolism and without inducing 
toxicity. The collected data could, however, not be exploited to dramatically increase the target 
protein’s turnover. As the ubiquitination process seemed most likely to be the limiting step, we also 
tried to increase lysine availability in our target protein by fusing a lysine residues tail at its C-
terminus but this attempt stayed unsuccessful.  The presence of additional lysine residues scattered 
onto the target protein’s surface might have been more optimal. However, if the efficiency of the 
ubiquitination reaction relies on the dynamic interaction of SCF components, the substrate and E2, 
all assembled in a supra-complex, it is reasonable to think that not all target proteins will be 
ubiquitinated with the same efficacy. This fine-tuning of supra-complex subunits interplay could be 
an additional quality control mechanism meant to further regulate the degradation of appropriate 
substrates only.  
The use of tailored F-box proteins is appealing for creating protein knock-out. A similar strategy, 
based on the fusion of a peptide binding motif to the human F-box protein β-TrCP1 was already 
successful but has been applied so far to few proteins only [54-59]. This could undoubtedly be due to 
the lack of known peptide binding motifs or the requirement of other factors inherent to the target 
proteins. The use of a generalizable binding domain, like DARPins, would broaden the spectrum of 
targets and enable us to further analyze the characteristics of a proficient SCF substrate.  
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ApaLI (2905)
ApaLI (4257 )
ApaLI (9924)
p415/ADH/cdc4 5GS off7
927 6 bp
AmpR
LEU2
cdc4 5GS off7
HA tag
ADH promoter
f1 origin
ARS(H4)
CEN6
CYC1 terminator
STOP
BamHI (5381)
EcoRI (8157 )
SpeI (4301)
Xba I (4295)
Xho I (5888)
SacI (27 93)
ClaI (4485)
ClaI (7 67 2)
KpnI (4884)
KpnI (6150)
KpnI (7 7 7 1)
ApaLI (831)
ApaLI (207 7 )
ApaLI (3429)
ApaLI (9096)
p415/TEF/cdc4 5GS off7
8181 bp
AmpRLeu2
cdc4 5GS off7
tCYC1
HA tag
TEF1 promoter
f1 origin
ARS(H4)
CEN6
STOP
BamHI (4286)
EcoRI (7 062)
SpeI (3206)
Xba I (3200)
Xho I (47 93)
SacI (27 93)
ClaI (3390)
ClaI (657 7 )
ApaLI (831)
ApaLI (207 7 )
ApaLI (8001)
KpnI (37 89)
KpnI (5055)
KpnI (667 6)
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Construct DNA and amino-acid sequences 
 
RGS(His)6MBP-GFP construct DNA sequence 
 
 
actagtatgagaggatcgcatcaccatcaccatcacggatctggttccatgaaaactgaagaaggtaaactggtaatctggattaacggcgataa
aggctataacggtctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcatccggataaactggaagagaa
attcccacaggttgcggcaactggcgatggccctgacattatcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaa
atcaccccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttacaacggcaagctgattgcttacccgatcgctgtt
gaagcgttatcgctgatttataacaaagatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactgaaagcg
aaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccgctgattgctgctgacgggggttatgcgttcaagtatgaaaa
cggcaagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgattaaaaacaaacacatg
aatgcagacaccgattactccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcg
acaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgttggcgtgctgagcgcaggtattaac
gccgccagtccgaacaaagagctggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccg
ctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgccactatggaaaacgcccagaaaggtgaaatca
tgccgaacatcccgcagatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaagccctga
aagacgcgcagactcccgggtccgctgctggttctggcgaattcagcaaaggagaagaacttttcactggagttgtcccaattcttgttgaattag
atggtgatgttaatgggcacaaattttctgtcagtggagagggtgaaggtgatgctacatacggaaaactcacccttaaatttatttgcactactg
gaaaactacctgttccttggccaacacttgtcactactctgacctatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttt
tcaagagtgccatgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaa
ggtgatacccttgttaatcgtatcgagttaaagggtattgattttaaagaagatggaaacattctcggacacaaactcgagtacaactataactca
cacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagatggttccgttcaactag
cagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgccctttcgaaagatcc
caacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataaaagctt 
RGS(His)6MBP-GFP amino-acid sequence 
MRGSHHHHHHGSGSMKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDII
FWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKE
LKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE
AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGL
EAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQ
TPGSAAGSGEFSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGV
QCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNY
NSHNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLL
EFVTAAGITHGMDELYK 
 
RGSHis6-MBP-GFP
1899 bp
GFP
MBP
linkerRGS(His)6 STOP
EcoRI (1175)Spe I (2) XhoI (1598)
XmaI (1151) Sac I (1884)
HindIII (1895)
60 
 
RGS(His)6MBP construct DNA sequence 
 
 
Actagtatgagaggatcgcatcaccatcaccatcacggatctggttccatgaaaactgaagaaggtaaactggtaatctggattaacggcgata
aaggctataacggtctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcatccggataaactggaagaga
aattcccacaggttgcggcaactggcgatggccctgacattatcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctga
aatcaccccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttacaacggcaagctgattgcttacccgatcgctgt
tgaagcgttatcgctgatttataacaaagatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactgaaagcg
aaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccgctgattgctgctgacgggggttatgcgttcaagtatgaaaa
cggcaagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgattaaaaacaaacacatg
aatgcagacaccgattactccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcg
acaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgttggcgtgctgagcgcaggtattaac
gccgccagtccgaacaaagagctggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccg
ctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgccactatggaaaacgcccagaaaggtgaaatca
tgccgaacatcccgcagatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaagccctga
aagacgcgcagacttaaaagctt 
RGS(His)6MBP  amino-acid sequence 
MRGSHHHHHHGSGSMKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDII
FWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKE
LKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE
AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGL
EAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQ
T 
Cdc4_5GS_off7 construct DNA sequence 
 
 
actagtatggggtcgtttcccttagctgagtttccattacgtgatatccctgttccttatagctaccgtgtgtctggcggtatagcttcctcaggtagtg
ttactgcgcttgttactgccgctggcactcatcgaaactcgtccacggctaagacagttgagacagaggacggcgaagaagatatcgatgagtat
cagaggaaaagagcagctggtcctggcgaatccactcctgaacgcagtagtttcgccgcggtagcacatgataatcacaaaaccctccatccag
ttaacttacagaacaccggtgcagcgtctgtggataacgacggtctgcacaatttaacagatatatccaacgatgcagaaaaacttttgatgtctg
tggatgatggttctgccgcaccttctacattgagtgtaaacatgggagtggcatctcataatgttgctgctcccactaccgtcaatgcggcaacaat
aactggcagtgatgttagtaacaatgttaatagtgctactattaacaatcctatggaggaaggagcgctgccgttatcacccactgcttcctctcca
RGSHis6-MBP
1158  bp
MBP
RGS(His)6 STOP
H ind III (1154 )Sp e I (2)
Cdc4 5GS off7
1593 bp
off7cdc4
HA tag
5 GS linker
BamHI (1082)
Spe I (2) Xho I (1589)Ava I (1090)
Ava I (1589)
61 
 
ggtaccacaactcctttagctaaaactacgaaaactatcaacaacaataataatatcgccgatttgatagaatccaaagattctataatctcccct
gaatacctttctgatgagattttcagcgcaataaacaataatctccctcacgcatacttcaaaaatttattatttagattagttgccaacatggatag
gagtgaactatccgacttggggactttaatcaaggataatttaaagagggacctaataacgtctttgccttttgaaataagtttgaaaattttcaat
tatttgcaattcgaggatattataaattcccttggggtctcccaaaattggaacaaaataattagaaaatctacatcgttgtggaaaaaacttctga
tatcggaaaattttgtgagcccaaagggttttaattctctcaatctcaaactctcccaaaaatacccaaaactctcacaacaagatcgccttagatt
atcttttctggagaatggatccggctcgggcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgtatcctgat
ggctaacggtgctgacgttaatgctgctgacaatactggtactactccgctgcacctggctgcttattctggtcacctggaaatcgttgaagttctgc
tgaagcacggtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttctg
ctgaagaacggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagtt
ctgctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctga
aatcctgcaatacccatacgatgttccagattacgcttaactcgag 
cdc4_5GS_off7 amino-acid sequence (5 GS linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENGSGSGDLGKKLLEAARAGQDDEVRILMANGADVN
AADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTP
LHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
cdc4_10GS_off7 amino-acid sequence (10 GS linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENGSGSSGSGSGDLGKKLLEAARAGQDDEVRILMAN
GADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDS
DGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
cdc4_15GS_off7 amino-acid sequence (15 GS linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENGSGSSGSGSSGSGSGDLGKKLLEAARAGQDDEVRI
LMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGADVN
AMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
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Cdc4_3ala_off7 construct DNA sequence 
 
 
atggggtcgtttcccttagctgagtttccattacgtgatatccctgttccttatagctaccgtgtgtctggcggtatagcttcctcaggtagtgttactg
cgcttgttactgccgctggcactcatcgaaactcgtccacggctaagacagttgagacagaggacggcgaagaagatatcgatgagtatcagag
gaaaagagcagctggtcctggcgaatccactcctgaacgcagtagtttcgccgcggtagcacatgataatcacaaaaccctccatccagttaact
tacagaacaccggtgcagcgtctgtggataacgacggtctgcacaatttaacagatatatccaacgatgcagaaaaacttttgatgtctgtggat
gatggttctgccgcaccttctacattgagtgtaaacatgggagtggcatctcataatgttgctgctcccactaccgtcaatgcggcaacaataactg
gcagtgatgttagtaacaatgttaatagtgctactattaacaatcctatggaggaaggagcgctgccgttatcacccactgcttcctctccaggtac
cacaactcctttagctaaaactacgaaaactatcaacaacaataataatatcgccgatttgatagaatccaaagattctataatctcccctgaata
cctttctgatgagattttcagcgcaataaacaataatctccctcacgcatacttcaaaaatttattatttagattagttgccaacatggataggagtg
aactatccgacttggggactttaatcaaggataatttaaagagggacctaataacgtctttgccttttgaaataagtttgaaaattttcaattatttg
caattcgaggatattataaattcccttggggtctcccaaaattggaacaaaataattagaaaatctacatcgttgtggaaaaaacttctgatatcg
gaaaattttgtgagcccaaagggttttaattctctcaatctcaaactctcccaaaaatacccaaaactctcacaacaagatcgccttagattatctt
ttctggagaatgctgcagccgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgtatcctgatggctaacggt
gctgacgttaatgctgctgacaatactggtactactccgctgcacctggctgcttattctggtcacctggaaatcgttgaagttctgctgaagcacg
gtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttctgctgaagaac
ggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagttctgctgaagc
acggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcctgcaa
tacccatacgatgttccagattacgcttaa 
cdc4_3ala_off7 amino-acid sequence (3 ala linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENAAADLGKKLLEAARAGQDDEVRILMANGADVNA
ADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTPL
HLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
cdc4_10ala_off7 amino-acid sequence (10 ala linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENAAAAAAAAAADLGKKLLEAARAGQDDEVRILMAN
GADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDS
DGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
 
Cdc4 3Ala off7
1587 bp
cdc4 off7
HA tag
Ala linker
Ava I (1583)Pst I (1087)Spe I (2)
Xho I (1583)
63 
 
cdc4_17ala_off7 amino-acid sequence (17 ala linker underlined) 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGPGESTPER
SSFAAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPT
TVNAATITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSA
INNNLPHAYFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSL
WKKLLISENFVSPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENAAAAAAAAAAAAAAAAADLGKKLLEAARAGQDD
EVRILMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASDVFGYTPLHLAAYWGHLEIVEVLLKNGA
DVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
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Figure 1: Polyamines regulation. Polyamines increase the production of antizyme (AZ). The carboxy-
terminal half of antizyme interacts with ODC, generating AZ:ODC heterodimers at the expense of 
enzymatically active ODC homodimers. A carboxy-terminal domain of ODC that is occluded within the 
homodimer is exposed within the heterodimer, and is essential for subsequent degradation. A domain 
within the amino-terminal portion of antizyme provides a function needed for efficient degradation of 
ODC by the proteasome. The proteasome processes AZ:ODC, sequestering ODC and then degrading it to 
peptides but releasing antizyme, which participates in additional rounds of binding and degradation. 
Antizyme-mediated inhibition and destruction of ODC reduces synthesis of polyamines, the downstream 
products of the enzyme. Additionally, antizyme inhibits polyamine transport into the cell. Antizyme 
production is thus reduced, completing the regulatory circuit. Adapted from Coffino, 2001 [1]. 
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Introduction 
 
Selective protein degradation plays a pivotal role in cellular life and function. However, since 
intracellular proteolysis is a random event regarding which substrate molecule is degraded, cells have 
elaborated an effective tactic to destroy appropriate substrates and spare other proteins: 
compartmentalization. This strategy relies on confining proteolytic action to secluded sites that can only 
be accessed by proteins exhibiting some sort of degradation signals.  Such a compartment can be a 
membrane delimited organelle, such as the lysosome, or the proteolytic chamber of a self-
compartmentalizing protease, a structural design that has evolved in prokaryotic cells which are devoid 
of membrane-bound compartments [2].  The proteasome became the paradigm of this form of 
regulation [3]. In eukaryotes, the 26S proteasome is the major neutral protease.  It is a multicatalytic 
degradation machinery composed of a barrel-shaped catalytic chamber (20S core particle) flanked by 
one or two regulatory complexes (19S regulatory particle or PA700) [4].  The 19S regulatory particle 
interacts with the substrate, unfolds it and opens an axial portal into the 20S chamber to translocate the 
unfolded polypeptide in the  catalytic chamber [5].  
The 19S regulatory particle usually identifies its client proteins by the presence of a polyubiquitin tag [6]. 
A chain of four or more molecules formed via lysine 48 of ubiquitin is normally required [7, 8]. Two 
subunits were identified as integral ubiquitin receptors: Rpn10 and Rpn13 [9, 10]. They respectively trap 
their substrates via an Ubiquitin Interacting Motif (UIM) [11] or pleckstrin-like-receptor for ubiquitin 
(Pru) domain [12]. In addition, a small subset of proteins has been described to be degraded by the 
proteasome without prior ubiquitination [13, 14].  Some of these evaders seem to be recognized by the 
proteasome via the presence of a degradation signal, named degron in this study. 
The best described ubiquitin-independent proteasome substrate is Ornithine Decarboxylase (ODC) [15]. 
ODC is the first and rate-limiting enzyme in the biosynthesis of the polyamines spermine and spermidine 
[16]. Its level is regulated by a polyamine autoregulatory feedback loop maintaining optimal polyamine 
abundance in eukaryotic cells (Fig. 1). Polyamine accumulation leads to increased expression of Antizyme 
1 (AZ1) by promoting ribosomal translational frameshifting [17, 18]. AZ1 disrupts enzymatically active 
ODC homodimers to form an inactive ODC/AZ1 heterodimeric complex thereby inhibiting its activity [19]. 
Moreover, AZ1 binding triggers accelerated degradation of ODC by improving its affinity for the 26S 
proteasome about eightfold [20]. Upon binding AZ1 increases exposure of the C-terminus of ODC [21], a 
region formerly identified for being responsible for ODC turnover, the ODC degron [22]. Crystal-
structural analysis of this region (Fig. 2) had shown conformational disorder [19] but mutational analysis 
has unveiled the presence of two essential elements in these 37 C-terminal amino-acids [20, 23, 24].  The 
first one consisted of cysteine 441 which was shown to function as a proteasome association element 
[23]. In combination with alanine 442, these two adjacent residues must function together as a structural 
recognition element in which the cysteine thiol must be reduced and the side chain of the next residue 
must be no larger than a methyl group [24]. The second one was the C-terminus distal to residue 442  
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Figure 2: Ornithine Decarboxylase structure. Cartoon drawing of truncated mouse ODC (mODC’) (the last 
37 residues were omitted), the crystal structure was determined to 1.6 resolution. ODC monomer 
contains two domains: an α/βbarrel (yellow) which binds the pyridoxal-5’-phosphate (PLP) cofactor and a 
second domain consisting mostly of β structure which include two sheets, S1 and S2. Disordered 
segments were colored in cyan. Adapted from Kern & al, 1999 [19].  
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which engages entry into the proteasome [23, 25]. The C-terminal end had little or no sequence 
specificity but its span mattered as it was intolerant of long insertions or deletions [24]. The spacing 
between Cys441-Ala442 and the C-terminal end of the ODC degron seemed then to be crucial for their 
functional interaction. Despite the absence of similarity, experimental studies had shown that ODC 
harbor an AZ1-modulated recognition determinant which could be cross-competed by both substrate-
linked and free polyubiquitin chains for 26S proteasome association [20]. The authors suggested that the 
ODC-AZ1 complex and polyubiquitin chain recognition involved a common binding site of the 19S 
regulatory particle [20]. Yet more recent data were at variance with this model. ODC turnover rate was 
indeed accelerated in a rpn10Δ mutant strain in which the degradation of certain ubiquitinated 
substrates was impaired [26]. A very recent study also concluded that ODC degradation was not 
inhibited by ubiquitin chains, indicating that it bound to a different 19S subunit than ubiquitinated 
substrates [27]. The C-terminal 37 amino-acids of mouse ODC act as a portable ubiquitin-independent 
degradation signal [22, 28]. When fused to the C-terminus of GFP (Green Fluorescent Protein), the ODC-
degron destabilized the fusion protein in vivo in animal cells and in yeast [29, 30].  
Another degron was discovered in the cytoplasmic tail of NY-1V hantavirus G1 glycoprotein [31]. 
Hantaviruses belong to the Bunyaviridae family. While they do not produce disease in the rodent hosts, 
certain hantaviruses can cause two discrete diseases in humans: hemorrhagic fever with renal syndrome 
(HFRS) and hantavirus pulmonary syndrome (HPS) [32]. The NY-1 virus (NY-1V) is a pathogenic one which 
can elicit hantavirus pulmonary syndrome. Hantaviruses are enveloped negative-stranded RNA viruses 
which encode four proteins: a polymerase, a nucleocapsid protein and two surface glycoproteins G1 and 
G2. During infection, G1 and G2 form heterodimers that localize to the cis-Golgi compartment. 
Hantavirus virions are believed to assemble by association of nucleocapsids with glycoproteins 
embedded in the membranes of the Golgi apparatus, followed by budding into the lumen of the Golgi 
complex. Virions are then transported in secretory vesicles to the plasma membrane and released by 
exocytosis. Besides mediating maturation, the NY-1 V G1 glycoprotein has recently been shown to inhibit 
cellular interferon responses [33]. In addition, the G1 142-residue-long cytoplasmic tail of several 
pathogenic hantaviruses was observed to be degraded by the proteasome while it was stable in 
nonpathogenic hantaviruses [31]. A comparison of their sequences revealed a disparity in their C-
terminal 30 residues composing a hydrophobic region. Mutational analyses identified residues that 
selectively directed the proteasomal degradation of pathogenic hantavirus tails. Appending the last 42 
residues of the NY-1 V G1 glycoprotein to the C terminus of GFP or RFP (Red Fluorescent Protein) was 
sufficient to degrade the fusion proteins in mammalian cells [31]. This region seemed then to constitute 
a degron (NYV-degron) which could autonomously lead a protein to degradation. This cytoplasmic tail of 
the NY-1 V G1 glycoprotein had previously been observed to be polyubiquitylated [34]. Two lysine 
residues (K615 and K628) were identified as ubiquitylation sites and thought to be the primary signal 
responsible for NY-1 V G1 cytoplasmic tail degradation. The degron region contained these two lysine 
residues but a later study demonstrated that they were not required for the NYV-degron mediated 
degradation process [31]. Mutation of both lysine residues to alanine had namely no detectable effect 
on the proteasomal degradation of the fusion protein GAL4-NYV. The exact mechanism by which the NY-
1 V G1 cytoplasmic tail is degraded has remained unsolved.  It cannot be claimed that the NYV degron 
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was the only determinant responsible for its proteasomal degradation but it could act as a portable 
ubiquitin-independent degradation signal.  
The ODC-and NYV-degron were used as an ubiquitin free route to evaluate the proteasome processing 
capacity when fed with different kinds of substrates. It was often debated which minimal characteristics 
were required from a protein to become a proteasomal substrate and which role was playing a degron in 
the degradation process. The question of substrate protein intrinsic stability was addressed. We also 
tried to assess the proteasome ability to degrade a complex formed by a degron-construct and a binding 
partner. We investigated if a binding partner would affect degradation of the degron-construct. It had 
been proposed that increasing the local concentration of a substrate at the proteasome site was 
sufficient for degradation [35]. Finally, we focused our attention on the binding partner’s fate to see if it 
would be processed as collateral damage or else spared by the proteasome.  
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Materials & methods 
 
Yeast strains and genetic experiments 
Yeast strains are described in Table 1. The genotypes of the yeast strains are:  
W303: ade2-1, trp1-1, can1-100, leu2-3,112, his3-11,15, ura3-1, GAL+, psi+, ssd1-d2  
S288C: ade2-101, ura3-52, lys2-801, trp1- 1, his3 200, leu2-  
Unless noted otherwise strain K699 was used.  
Table 1: Yeast strains  
Strain Relevant genotype Background Source 
K699 Mat a W303 M. Peter 
Erg6  Erg6::KAN S288C M. Peter & G. Rabut 
K-M [p416/Gal/MBP] K699 This study 
K-MO [p416/Gal/MBP-ODC] K699 This study 
K-MN [p416/Gal/MBP-NYV] K699 This study 
K-G [p416/Gal/GFP] K699 This study 
K-GO [p416/Gal/GFP-ODC] K699 This study 
K-GN [p416/Gal/GFP-NYV] K699 This study 
K-5 [p416/Gal/E3_5] K699 This study 
K-5O [p416/Gal/ E3_5-ODC] K699 This study 
K-5N [p416/Gal/ E3_5-NYV] K699 This study 
K-19 [p416/Gal/E3_19] K699 This study 
K-19O [p416/Gal/ E3_19-ODC] K699 This study 
K-19N [p416/Gal/ E3_19-NYV] K699 This study 
E-GO [p416/Gal/GFP-ODC] Erg6 This study 
E-GN [p416/Gal/GFP-NYV] Erg6 This study 
E-19O [p416/Gal/ E3_19-ODC] Erg6 This study 
E-19N [p416/Gal/ E3_19-NYV] Erg6 This study 
KM-7Ot [p425/ TEF /off7-ODC] Mg (see chapter 1) This study 
KM-7Nt [p425/ TEF /off7-NYV] Mg (see chapter 1) This study 
KM-V [p425/ ADH] Mg (see chapter 1) This study 
KM-7Oa [p425/ ADH /off7-ODC] Mg (see chapter 1) This study 
KM-7Na [p425/ ADH /off7-NYV] Mg (see chapter 1) This study 
K-7 [p416/Gal/off7] K699 This study 
K-7O [p416/Gal/off7-ODC] K699 This study 
K-7O436 [p416/Gal/off7-ODCT436A] K699 This study 
K-7O438 [p416/Gal/off7-ODCP438A] K699 This study 
KM-7O436a [p425/ADH/off7-ODCT436A] Mg (see chapter 1) This study 
KM-7O438a [p425/ADH/off7-ODCP438A] Mg (see chapter 1) This study 
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Standard yeast growth conditions and genetic manipulations were used as described [36]. Yeast cells 
were cultured in synthetic media (S) (1.7 g/L yeast nitrogen base, 5 g/L ammonium sulfate) 
supplemented with a standard amino acid  and nucleobases solution (30 mg/L isoleucine, 150 mg/L 
valine, 40 mg/L adenine, 20 mg/L arginine, 20 mg/L histidine, 100 mg/L leucine,  30 mg/L lysine, 20 mg/L 
methionine, 50 mg/L phenylalanine, 200 mg/L threonine, 40 mg/L tryptophane, 30 mg/L tyrosine, 20 
mg/L uracil, 100 mg/L glutamic acid, 100 mg/L aspartic acid) and 2 % carbon source (glucose (D), 
raffinose (Raff) or galactose (Gal)). According to the strain and the experiment, a synthetic media 
prepared without amino acids or nucleobases supplemented with auxotrophic requirements: uracil (-
Ura), leucine (-Leu), and the appropriate carbon source (SD, SRaff or SGal) was used. 
 Yeast transformations were performed by the lithium acetate procedure [37]. The MBP expressing strain 
was created by homologous recombination using StuI linearized plasmid pRS306/Gal/MBP (see chapter 
1).  
DNA manipulations and plasmids 
Standard molecular biology procedures were used for recombinant DNA manipulation [38]. Enzymes 
were from NEB (Ipswich, MA, USA) or Fermentas (Vilnius, Lithuania). PCR reactions were performed with 
the Phusion TM High-Fidelity DNA polymerase as recommended by the manufacturer (NEB). Plasmids 
used as templates and all oligonucleotides are listed in Tables 2 and 4.  
ODC-, NYV- and stop-constructs ORFs (see schemes below) were constructed in several steps. First a 
plasmid containing the HA tag and required cloning sites (SpeI, EcoRI, BamHI and XhoI) was constructed 
by annealing updegron and lowdegron oligonucleotides, amplifying them by PCR using ext for degron 
and ext rev degron oligonucleotides as primers and introducing the digested PCR product at the SpeI and 
XhoI sites of p415ADH [39]. Second the low and up mODC/NY1V oligonucleotides were annealed, 
amplified by PCR using forBamHI and revXhoI ODC/NYV oligonucleotides as primers and the digested 
PCR product introduced at the BamHI and XhoI sites of the formerly constructed plasmid to yield 
p415ADH/ODC and p415ADH/NYV respectively. The stop sequence oligonucleotides were designed with 
BamHI and XhoI sticky ends and were inserted directly after annealing to construct p415/stop.  
 
 
ODC degron construct
174  bp
Target
HA tag ODC
Ba mH I (4 7)
EcoR I (4 1)
Sp e I (5) X h oI (16 7)
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Finally the target protein sequence was amplified by PCR using appropriate for EcoRI and revBamHI 
oligonucleotides as primers and the digested PCR product was introduced at the EcoRI and BamHI sites 
of p415/stop, p415ADH/ODC or p415ADH/NYV. The construct genes were subcloned as a SpeI/XhoI 
fragment in p416Gal, p425ADH or p425TEF [39]. The sequences of E3_5-stop, E3_5-ODC and E3_5-NYV 
constructs are shown in annex. Site-directed mutagenesis was performed with QuikChange kit 
(Stratagene, La Jolla, CA) according to the manufacturer’s instructions.  
pQE30/off7-ODC was constructed by amplifying the ODC degron sequence from p416/Gal/MBP-ODC 
with HindforODC and  HindrevODC oligonucleotides and inserting the digested PCR product at the HindIII 
site of pQE30_mbpoff7.  
All constructs were confirmed by sequencing. Plasmids constructed for this study are listed in Table 3, 
those marked with an asterisk have their plasmid map and the insert sequences shown in annex. 
Table 2: Plasmids used as PCR DNA templates for cloning 
Plasmids Templates for  Source 
pQEMBP MBP Binz, 2004 [40] 
pET28GFP GFP Our laboratory, Andreas Ernst 
pHKB26E3_5 E3_5 Binz, 2003 [41] 
pHKB26E3_19 E3_19 Binz, 2003 [41] 
pQE30_mbpoff7 off7 Binz, 2004 [40] 
 
  
NYV degron construct
189  bp
Target
HA tag NYV
Ba mH I (47)
Ec oR I (4 1)
Sp e I (5) X h oI (18 2)
stop degron construct
8 7 bp
Target
HA tag Stop sequenceBamH I (47)Ec oR I (4 1)Sp e I (5) X h oI (8 0)
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Table 3: Plasmids constructed for this study 
Plasmids Relevant characteristics  
(promoter; gene; resistance; ori) 
Source 
p416/Gal/MBP Gal1; MBP; URA3; CEN6 This study 
p416/Gal/GFP Gal1; GFP; URA3; CEN6 This study 
p416/Gal/E3_5* Gal1; E3_5; URA3; CEN6 This study 
p416/Gal/E3_19 Gal1; E3_19; URA3; CEN6 This study 
p416/Gal/MBP-ODC Gal1; MBP-ODC; URA3; CEN6 This study 
p416/Gal/GFP-ODC Gal1; GFP-ODC; URA3; CEN6 This study 
p416/Gal/E3_5-ODC* Gal1; E3_5-ODC; URA3; CEN6 This study 
p416/Gal/E3_19-ODC Gal1; E3_19-ODC; URA3; CEN6 This study 
p416/Gal/MBP-NYV Gal1; MBP-NYV; URA3; CEN6 This study 
p416/Gal/GFP-NYV Gal1; GFP-NYV; URA3; CEN6 This study 
p416/Gal/E3_5-NYV* Gal1; E3_5-NYV; URA3; CEN6 This study 
p416/Gal/E3_19-NYV Gal1; E3_19-NYV; URA3; CEN6 This study 
pRS306/Gal/MBP Gal1; MBP; URA3 Chapter1 
p425/ TEF /off7-ODC* TEF1; off7-ODC; LEU2; 2µ This study 
p425/ ADH /off7-ODC ADH; off7-ODC; LEU2; 2µ This study 
p425/ TEF /off7-NYV TEF1; off7-NYV; LEU2; 2µ This study 
p425/ ADH /off7-NYV* ADH; off7-NYV; LEU2; 2µ This study 
p416/Gal/off7 Gal1; off7; URA3; CEN6 This study 
p416/Gal/off7-ODC Gal1; off7-ODC; URA3; CEN6 This study 
p416/Gal/off7-ODCT436A Gal1; off7-ODCT436A; URA3; CEN6 This study 
p416/Gal/off7-ODCP438A Gal1; off7-ODCP438A; URA3; CEN6 This study 
p425/ADH/off7-ODCT436A ADH; off7-ODCT436A; LEU2; 2µ This study 
p425/ADH/off7-ODCP438A ADH; off7-ODCP438A; LEU2; 2µ This study 
pQE30/off7-ODC* T5; RGS(His)6 off7-ODC; Amp; ColE1 This study 
 
Table 4: Oligonucleotides 
Oligonucleotides Sequence 5’-3’ direction Description  
(for=forward, rev=reverse) 
Up degron  GGTACTAGTATGTACCCATACGATGTTCCAGATTACGCTGAATTCG
GATCCAAGC 
Upper HA tag + cloning sites 
Low degron ACCCTCGAGAGATCTTCCGCCCGAGCCAAGCTTGGATCCGAATTCA
GCGTAATC 
Lower HA tag + cloning sites 
ext for degron GGT GGT ACT AGT ATG TAC CCA TAC G For external primer 
ext rev degron ACC ACC CTC GAG AGA TCT TCC G Rev external primer 
Up mODC GGTAGATCTTTCCCGCCGGAGGTGGAGGAGCAGGATGATGGCAC
GCTGCCCATGTCTTGTGCCCAGGAGAGCGGGATGGAC 
Upper ODC degron 
Low mODC ACCCTCGAGCACATTGATCCTAGCAGAAGCACAGGCTGCAGGGTG
ACGGTCCATCCCGCTCTCCTGGGC 
Lower ODC degron 
Up NYV GGTAGATCTCGCCCTGAAGTTAAACAAGGATGCTATAGAACATTG
GGTGTTTTTAGATATAAGAGTAGGTGTTATGTTGGTCTTGTGTGG 
Upper NYV degron 
Low NYV ACCCTCGAGAGCACTAGCTGCCCAAACTATGAGTTCAGTTGTAAGA
AGGACCCCCCACACAAGACCAACATAACACCTAC 
Lower NYV degron 
forBamHI ODC GGT GGA TCC TTC CCG CCG GAG GTG GAG G For ODC + BamHI site 
revXhoI ODC ACC CTC GAG CTA CAC ATT GAT CCT AGC AGA AGC Rev ODC + XhoI site 
forBamHI NYV GGT GGA TCC CGC CCT GAA GTT AAA CAA GG For NYV + BamHI site 
revXhoI NYV ACC CTC GAG CTA AGC ACT AGC TGC CCA AAC TAT G Rev NYV + XhoI site 
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Up stop  GA TCC TAA TAG TGA AAG CTT TTA GCT GAC C Upper stop + BamHI/XhoI 
ends 
Low stop  TC GAG GTC AGC TAA AAG CTT TCA CTA TTA G Lower stop + BamHI/XhoI 
ends 
forEcoRI MBP GGT GAA TTC ATG AAA ACT GAA GAA GGT AAA CTG G 
 
For MBP + EcoRI site 
revBamHI MBP ACC GGA TCC AGT CTG CGC GTC TTT CAG G Rev MBP + BamHI site 
forEcoRI GFP GGT GAA TTC AGC AAA GGA GAA GAA CTT TTC AC For GFP + EcoRI site 
revBamHI GFP ACC GGA TCC TTT GTA GAG CTC ATC CAT GCC Rev GFP + BamHI site 
forEcoRI DARPin GGT GAA TTC GAC CTG GGT AAG AAA CTG CTG G For DARPin + EcoRI site 
revBamHI DARPin ACC GGA TCC TTG CAG GAT TTC AGC CAG G Rev DARPin + BamHI site 
for ODC T436A GCAGGATGATGGCGCGCTGCCCATGTCTTGTGC For ODC + mutation T436A 
Rev ODC T436A GCACAAGACATGGGCAGCGCGCCATCATCCTGC Rev ODC + mutation T436A 
For ODC P438A GGATGATGGCACGCTGGCCATGTCTTGTGCCC For ODC + mutation P438A 
Rev ODC P438A GGGCACAAGACATGGCCAGCGTGCCATCATCC Rev ODC + mutation P438A 
ForHindIII ODC GGT GGT AAG CTT TTC CCG CCG GAG GTG GAG G For ODC + HindIII site 
RevHindIII ODC CC ACC AAG CTT CTA CAC ATT GAT CCT AGC AGA AGC Rev ODC + HindIII site 
 
Determination of steady-state levels of target proteins 
Yeast cells were grown in SRaff-U at 30°C. At OD600=0.6-0.8, 2% galactose was added. After 1 h to 4 h, an 
aliquot was taken, OD600 was measured. Cells were collected by centrifugation for 5 min at 5000 g, the 
pellet was resuspended in 200 µl SDS-urea loading buffer (60 mM Tris-HCl pH 6.8, 8 M urea, 5% glycerol, 
3% SDS, 4% 2-mercaptoethanol, 5 mM EDTA, bromophenolblue), transferred in a 2 ml-tube and 
immediately stored at -20°C. The MG132 experiment was performed similarly; MG132 (Sigma-Aldrich, St. 
Louis, MO) was added at the same time as galactose to a final concentration of 50 µM (MG132 stock 
solution was prepared in DMSO with a concentration of 5 mM). An identical volume of DMSO was added 
to the negative control strains. Aliquots were taken after 1 h, 2 h or 16 h. 
Stability assays 
By promoter shut-off: Yeast cells were grown in SRaff-U or SRaff-UL at 30°C. At OD600=0.6-0.8, 2 % 
galactose was added. 1 h to 4 h later, 2 % glucose was added to shut off the Gal1 promoter; cells were 
collected by centrifugation for 5 min at 3000 g and resuspended in SD-U or SD-UL. Cells were further 
incubated at 30°C. Samples of decreasing volume were taken at different time points in order to have a 
relatively constant amount of cells. For each of them, OD600 was measured; cells were pelleted for 4 min 
at 5000 g, resuspended in 200 µl SDS-urea loading buffer and immediately stored at -20°C. For off7-ODC 
mutants comparison, cells were not resuspended in SD-U, the time-course experiment started 
immediately after addition of 2 % glucose. 
By cycloheximide treatment: Yeast cells were grown in SRaff-UL at 30°C. At OD600=0.6-0.8, 2 % galactose 
or glucose was added. 90 min later, a first aliquot was removed (t0 sample) before expression was 
turned off by addition of 75 µg/ml cycloheximide (Sigma-Aldrich, St. Louis, MO) (Cycloheximide stock 
solution was prepared in water with a concentration of 10 mg/ml).  Cells were further incubated at 30°C 
and samples of decreasing volume were taken at different time points.  For each of them, OD600 was 
measured; cells were pelleted for 4 min at 5000 g, resuspended in 200 µl SDS-urea loading buffer and 
immediately stored at -20°C.  
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Ni-NTA pull-down assay 
Yeast cells were grown in SGal-UL at 30°C. At OD600=0.7-0.8, cells were collected by centrifugation for 5 
min at 5000 g and stored at -20°C.  Pellets were resuspended in ice-cold lysis buffer (50 mM Na2HPO4 pH 
8, 300 mM NaCl, 0.05 % Tween-20, 20 mM imidazole) and cells were mechanically lysed through 4 cycles 
of French press lysis. Cell debris was removed by a 30 min centrifugation step at 18,000 g and cleared 
lysates were aliquoted in 2ml-tubes, snap-frozen in liquid nitrogen and stored at -80°C. Thawed lysates 
were incubated for 2 h with 200 µl Ni-NTA magnetic agarose beads (Qiagen, Chatsworth, CA, product 
number: 36111). Beads were washed 4 times with lysis buffer and eluted with 80 µl 1X SDS sample 
loading buffer-EDTA (62.5 mM Tris-HCl pH 6.8, 100 mM EDTA, 7.5 % glycerol, 2 % SDS, 2.5 % 2-
mercaptoethanol, bromophenolblue). After 5 min at 95°C, eluted fractions were resolved by 15 % SDS-
PAGE followed by immunoblotting.  
Proteins samples extraction 
Samples stored at -20°C were thawed and incubated in a sonicating water bath for 20 min. 200µl of acid-
washed 425- to 600-μm glass beads (Sigma-Aldrich, St. Louis, MO) were added and samples were lysed  
three times 2 min at 30 Hz in TissueLyser (Qiagen, Chatsworth, CA). After a 10 sec spin down at 1000 g, 
they were finally incubated for 5 min at 95°C and clarified at 10°C for 5 min at 20000 g. Normalized 
volumes according to the OD600 were loaded on 10 % or 15 % SDS-polyacrylamide gels followed by 
immunoblotting. For E3_5 and E3_19 stability assay samples, SDS-PAGE were run at 60°C. 
Immunoblotting 
Samples were transferred to PVDF membranes and immunoblotted using standard methods. The anti-HA 
peroxidase conjugate was used at a 1:1000 dilution (Sigma-Aldrich, St. Louis, MO, product number H 
6533) and the RGS·His HRP conjugate (Qiagen, Chatsworth, CA, product number: 34450) at a 1:7000 
dilution for detection of RGS(His)6 MBP or 1:8000 dilution for detection of RGS(His)6off7-ODC. The anti-
actin antibody (Millipore, Bedford, MA, product number: MAB1501R) was diluted 1:3000 and detected 
with anti-horseradish peroxidase (HRP)-coupled anti-mouse antibody diluted 1:10000 (Thermo Fisher 
Scientific, Rockford, IL, product number 31438).  
Expression, purification of MBP and off7-ODC and interaction analyses 
Biotinylated MBP was produced in E. coli as described (Binz, 2004). Off7-ODC was produced on a liter 
scale and purified as described (Binz, 2004). Interaction analyses were conducted at 25°C and measured 
on the Octet QK system (ForteBio, Inc., Menlo Park, CA). The running buffer was 50 mM Na2HPO4 pH 8, 
300 mM NaCl, 0.002 % Tween-20. Streptavidin biosensors were incubated for 5 min in running buffer 
and coated for 1 min with 100 nM biotinylated MBP. A new baseline was established for 5 min in running 
buffer. Different concentrations of off7-ODC were allowed to bind MBP-saturated biosensors for 20 min 
before dissociating for 30 min in running buffer. The kinetic data of the interaction were evaluated with 
a separate fit using the Octet data analysis software.  
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In vitro degradation assay 
Off7-ODC was first dialyzed against 50 mM Tris pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 10 % glycerol, 1 mM 
DTT overnight at 4°C. 20 nM Off7-ODC was added to the degradation mix which was kept on ice and 
contained 50 mM Tris-HCl pH 7.5, 2 mM DTT, 20 nM 26S Proteasome Fraction (Boston Biochem Inc., 
Cambridge, MA, product number: F-365) and 1X Energy Regeneration Solution (Boston Biochem Inc., 
Cambridge, MA, product number: B-10). All components were mixed and the t0 sample was immediately 
taken. The reaction was then incubated at 37°C, aliquots were withdrawn at different time points, mixed 
to 4 X SDS sample loading buffer (250 mM Tris-HCl pH 6.8, 30% glycerol, 8 % SDS, 10 % 2-
mercaptoethanol, bromophenolblue) and immediately stored at -20°C. When the reaction was 
performed with pre-denatured off7-ODC, a 10 times more concentrated off7-ODC solution was 
incubated for 5 min at 95°C and centrifuged for 10 sec at 1000 g before an aliquot of the “supernatant” 
was added to the degradation mix.  
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Results 
 
Degron constructs design and expression 
To test if a target protein could be directly degraded by the proteasome, three kinds of sequences were 
appended at its C-terminus:  the last 37 residues of mouse ornithine decarboxylase (ODC construct), the 
last 42 residues of the Hantavirus NYV1 G1 protein (NYV construct) or a stop codon only (- construct) as 
negative control (Fig. 3). Four different protein sequences were used as target proteins: GFP, MBP and 
the DARPIns E3_5 and E3_19.  The final constructs were cloned in p416 Gal with an N-terminal HA tag 
and transformed in yeast. All target proteins could be detected after a 1 to 4 h galactose induction (Fig. 
4, Fig. 5). The steady state amount of constructs not containing a degron-tag (negative control 
constructs), was always higher than for the ODC- and NYV-containing ones indicating that the degron 
sequence was destabilizing them.  Depending on the target protein, the ratios between the different 
kinds of constructs varied slightly. MBP seemed to be equally destabilized by the ODC- or NYV-degron, 
which lowered the steady state level to at least 50%. GFP and the DARPin E3_19 were much more 
destabilized by the NYV-degron than by the ODC-degron.  The DARPin E3_5 was destabilized by both 
degron sequences, however, their effect could not be compared as the samples were not properly 
normalized.  
 
 
Figure 3: Schematic diagrams of the negative control, ODC- and NYV-constructs. An HA tag was fused to the N-terminus of the 
target protein. The last 37 residues of mouse ornithine decarboxylase (ODC construct) or the last 42 residues of the 
Hantavirus NYV1 G1 protein (NYV construct) or a stop codon only (- construct) was appended at its C-terminus. 
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Figure 4: Steady-state levels of MBP and GFP constructs expressed from p416Gal. K-M, K-MO, K-MN, K-G, K-GO and K-GN 
cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.7.  After a 1 h- or 2 h-
galactose induction, Total protein was extracted and normalized before being subjected to SDS-PAGE. The levels of MBP and 
GFP constructs were detected by immunoblotting with the anti-HA antibody. The size marker is indicated in kDa. Theoretical 
molecular weights: MBP (43 kDa), MBP-ODC (46 kDa), MBP-NYV (47 kDa), GFP (27 kDa), GFP-ODC (32 kDa), GFP-NYV (33 kDa). 
 
Figure 5: Steady-state expression levels of E3_19 and E3_5 constructs expressed from p416Gal. K-19, K-19O, K-19N, K-5, K-
5O and K-5N cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.7.  A. 
After a 1 h- or 2 h-galactose induction, Total protein was extracted and normalized before being subjected to SDS-PAGE. The 
levels of E3_19 constructs were detected by immunoblotting with the anti-HA antibody. B. After a 1h-galactose induction, 
proteins were extracted and subjected to SDS-PAGE. The levels of E3_5 constructs were detected by immunoblotting with the 
anti-HA antibody. E3_5 negative control ran as several bands, this very stable protein was often difficult to denature 
properly. The completely denatured product is shown with an arrow. E3_5-ODC could not be detected. C. The experiment 
was repeated for E3_5-ODC with a longer galactose incubation of 3 h or 4 h. The size marker is indicated in kDa. Theoretical 
molecular weights: E3_5, E3_19 (18 kDa), E3_5-ODC , E3_19-ODC (22 kDa), E3_5-NYV, E3_19-NYV (23 kDa) 
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Expression of degron constructs under MG132 treatment 
In order to investigate if the lower amounts of ODC- and NYV-constructs were really due to proteasomal 
degradation, their expression was monitored in the presence of MG132, a reversible proteasome 
inhibitor. For this assay, a special strain mutated for erg6, a sterol transmethylase involved in the 
biosynthesis of the membrane ergosterol, was used to increase the membrane permeability. E3_19-ODC 
accumulated quickly under MG132 treatment while E3_19-NYV could do so only after an overnight 
incubation with the proteasome inhibitor (Fig. 6). Similar results were obtained for the GFP-constructs. 
The ODC- and NYV-degrons did lead the target proteins to the 26S proteasome. A longer MG132 
treatment was required to properly detect the NYV-constructs than the ODC-constructs. 
 
 
Figure 6: Steady-state expression levels of E3_19 (A) and GFP (B) degron constructs in presence of proteasome inhibitor 
MG132. A: E-19O and E-19N cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 
of 0.6-0.8. Galactose was then added to the cultures at the same time as DMSO or 50 μM MG132. After 1 h-, 2 h- or an 
overnight-incubation, total protein was extracted and normalized before being subjected to SDS-PAGE. B: E-GO and E-GN 
cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.8. Galactose was then 
added to the cultures at the same time as 50 μM MG132. After 1 h-, 2 h- or an overnight-incubation, total protein was 
extracted and normalized before being subjected to SDS-PAGE. The levels of E3_19 degron-constructs and GFP degron-
constructs were detected by immunoblotting with the anti-HA antibody. The size marker is indicated in kDa. 
 
Comparison of the stabilities of the degron constructs  
When fused to a C-terminal degron sequence, target proteins were degraded by the 26S proteasome as 
concluded from the sensitivity to MG132 treatment.  From the steady state and MG132 experiments, it 
seemed that the NYV-construct levels were lower than the ODC-construct ones. Their half-lives were 
then compared further.  After a 2 to 4 h gal induction, the promoter was shut off by addition of glucose, 
the cells were shortly centrifuged, resuspended in a glucose-based synthetic medium and the target 
protein stabilities followed. Among all target proteins, only GFP could be detected at the beginning of 
the assay, when fused to a degron sequence (Fig. 7, Fig. 8).  GFP-ODC had a half-life of less than an hour 
while GFP-NYV was already barely detectable at the time point 0. Even if their half-lives could not be 
properly compared as the initial amounts were not identical, this experiment did confirm that the NYV-
degron was more efficiently targeting to and/or processed by the 26S proteasome than the ODC-degron. 
All other target proteins were so quickly degraded that they had already vanished when the stability 
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assay started, preventing any degradation comparison. It is still unclear why GFP seemed to resist more 
than the other tested proteins, its higher expression level might help it to counteract its own 
degradation.  Another goal of this experiment was to assess if the substrate intrinsic stability could slow 
down the degradation process.  The DARPins E3_5 and E3_19 differ indeed in their stabilities [41, 42], 
however they were both extremely quickly degraded when fused to the ODC-or NYV-sequence. Thus, the 
higher stability of E3_5 was not an issue for the proteasomal degradation. Surprisingly, E3_19 was much 
better expressed than E3_5 (Fig. 8), whereas only a few residues vary in their amino-acid sequences and 
the number of rare residues did not significantly differ either. To summarize, all target proteins were of 
high stability, they could however all be efficiently processed by the 26S proteasome.  
 
Figure 7: Stabilities of GFP and MBP constructs with and without degron sequences. K-G, K-GO, K-GN, K-M, K-MO and K-
MN cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6. After a 2 h-
galactose induction, glucose was added; cells were shortly centrifuged and resuspended in a glucose-based medium. Samples 
were withdrawn every hour. Total protein was extracted and normalized according to their OD600 before being subjected to 
SDS-PAGE. The levels of MBP and GFP constructs were detected by immunoblotting with the anti-HA antibody. The size 
marker is indicated in kDa. 
 
Figure 8: Stabilities of E3_5 and E3_19 constructs with and without degron sequences. K-5, K-5O, K-5N, K-19, K-19O and K-
19N cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6. After a 4 h-
galactose induction, glucose was added; cells were shortly centrifuged and resuspended in a glucose-based medium. Samples 
were withdrawn at the indicated time points. Total protein was extracted and normalized according to their OD600 before 
being subjected to SDS-PAGE, ran at 60°C. The levels of E3_5 and E3_19 constructs were detected by immunoblotting with 
the anti-HA antibody. The size marker is indicated in kDa. 
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Stabilities of degron constructs in the presence of a binding partner 
Appending a degron sequence to the C terminus of a target protein led it to degradation. Would the 
presence of another protein interacting with the target protein prevent its proteasomal degradation?  
The influence of a binding partner on the degron construct’s stability was studied by performing a co-
expression experiment in a different set-up. The ODC- or NYV-degron sequence was fused to the DARPin 
off7, which recognizes MBP. The off7-degron constructs were designed identically to the E3_5 and E3_19 
ones, described above. They were expressed on a plasmid, under the constitutive ADH promoter in a 
strain for which a RGS(His)6 tagged MBP coding sequence had been integrated in the genome, under the 
control of a Gal1 promoter. The stabilities of off7-degron constructs were monitored after cycloheximide 
treatment in the absence or presence of RGS(His)6 MBP in the cells. They were equally unstable in the 
absence or presence of RGS(His)6 MBP (Fig. 9). off7-ODC could not be detected any more after 30 min. 
Remarkably, most of off7-NYV had also disappeared after 30 min, but then the degradation slowed down 
to reach a low level of off7-NYV which remained unchanged from 1 h until the end of the experiment. 
The starting amount of off7-degron constructs was lower in the presence of MBP but the co-expression 
of MBP protein might have temporarily decreased the expression level of off7-ODC and off7-NYV. In 
conclusion, the co-expression of a binding partner did not prevent or slow down off7-ODC or off7-NYV 
degradation. 
 
 
Figure 9: Stabilities of off7-degron constructs in the absence or presence of RGS(His)6MBP. KM-7Ot and KM-7Nt cells (see 
material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.8. The cultures were 
supplemented with galactose or glucose to induce or repress the expression of RGS(His)6MBP. After 1 h 30 min, 
cycloheximide was added (t0) and samples were withdrawn every half-hour. Total protein was extracted and normalized 
according to their OD600 before being subjected to SDS-PAGE. The levels of off7-degron constructs were detected by 
immunoblotting with the anti-HA antibody. 
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The presence of a binding partner did not influence the degron construct’s fate, but could the degron 
constructs lead the binding partner to the proteasome? To probe if the complex formed by the degron 
construct bound to its binding partner could be degraded, a second co-expression experiment was 
carried out. RGS(His)6 MBP was expressed under the galactose promoter and then repressed by addition 
of glucose. Its stability was monitored in the absence or presence of constitutively expressed off7-ODC or 
off7-NYV. RGS(His)6MBP remained stable, even when co-expressed with off7-ODC or off7-NYV (Fig. 10). 
The binding partner was not degraded.  
 
 
Figure 10: RGS(His)6MBP stability in absence or presence of off7-degron constructs. KM-V, KM-7Oa and KM-7Na cells (see 
material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.8. RGS(His)6MBP expression was 
induced for 1 h with galactose and stopped with glucose, cells were shortly centrifuged and resuspended in a glucose-based 
medium. Samples were withdrawn at the indicated time points. Total protein was extracted and normalized according to 
their OD600 before being subjected to SDS-PAGE.. The levels of RGS(His)6MBP were detected by immunoblotting with the anti-
RGS(His)4 antibody. The actin signal was used as loading control. 
 
To ensure that off7, when fused to a degron sequence, was able to interact with RGS(His)6MBP in vivo, a 
pull-down experiment was performed. Cells co-expressing RGS(His)6MBP and off7-ODC or off7-NYV were 
lysed and magnetic Ni-NTA beads were used to retrieve RGS(His)6MBP. off7-NYV co-eluted with 
RGS(His)6MBP, showing that they could interact in vivo, but off7-ODC did not (Fig. 11). However,  when 
off7-ODC was expressed and purified from E. coli, it could successfully bind RGS(His)6MBP in vitro, 
identically to off7 (Fig. 16). Both off7-NYV and off7-ODC conserved their excellent binding properties, 
and thus they should theoretically be able to complex with RGS(His)6MBP. Nevertheless, in vivo the 
interaction of a degron-construct with its binding partner might be weaker or considerably slower than 
the one with the 26S proteasome, leading to the degradation of the degron-constructs mostly in free 
form. The binding partner would in that case not be entering the proteasome if no complex was formed. 
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Figure 11: Pull-down of RGS(His)6MBP coexpressed with off7-degron constructs. KM-7Oa and KM-7Na cells (see material & 
methods) were grown in a synthetic galactose-based medium to an OD600 of 0.7-0.8. RGS(His)6MBP was pulled down from cell 
lysates by magnetic Ni-NTA beads. Eluted fractions were resolved by SDS-PAGE and probed with the anti-RGS(His)4 antibody 
(A) and the anti-HA antibody (B). The size marker is indicated in kDa. 
 
Off7-ODC degradation mutants 
off7-ODC could not be detected in complex with RGS(His)6MBP, it may possibly go too fast to the 
proteasome and thus not be able to interact with RGS(His)6MBP before being degraded. In order to see if 
a binding partner could be brought to the proteasome in complex with a degron-construct, one would 
first need to delay the degron-dependent degradation process. ODC mutants were previously generated 
by mutating key residues of the mouse ODC PEST sequence (MODC) appended to the C-terminus of eGFP 
[30]. FACS analysis revealed several mutants with a range of half-lives (Fig. 12, Table 1). The mutations 
T436A and P438A (residues 436 and 438 of mouse ODC sequence) were shown to gradually diminish 
eGFP-ODC degradation in CHO cells. These mutations (identically named) were tested with off7-ODC 
expressed in yeast under the Gal1 promoter. No difference could be observed between the wt off7-ODC 
and the mutant T436A stabilities, but the degradation was slightly slowed down with the mutant P438A, 
especially until 15 min after promoter shut-off (Fig. 13)  
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Figure 12: Schematic map of the PEST sequence of EGFP-MODC- 
(422-461) and the position of the mutations. 
Adapted from Li et al, 1998 [30]. 
 
 
 
 
 
 
These mutants were then assayed in co-expression with RGS(His)6MBP to see if they would allow the 
binding partner’s co-degradation. A regular decrease was observed for the RGS(His)6MBP signal when its 
stability was monitored in presence of the mutants, while it stayed rather constant when expressed 
alone or in presence of the wt off7-ODC (Fig.  14A). However, this degradation was observed to a smaller 
extent when the experiment was repeated and with P438A only (Fig. 14B). By looking at the 
RGS(His)6MBP and actin amounts, one can see that RGS(His)6MBP level was consistently lower with the 
off7-ODC P438A than with the wt off7-ODC. The binding partner, when co-expressed with a more slowly 
degraded ODC-construct, seemed to be degraded as well, though, with a significantly lower degradation 
efficiency than for the ODC-construct itself.  
 
 
Figure 13: Stabilities of off7-ODC mutant constructs. K-7, K-7O, K-7O436 and K-7O438 cells (see material & methods) 
were grown in a synthetic raffinose-based medium to an OD600 of 0.6-0.8. After a 3 h galactose induction, glucose was 
added and samples were withdrawn every 15 min. Total protein was extracted and normalized according to the sample’s 
OD600 before being subjected to SDS-PAGE. The levels of off7-ODC constructs were detected by immunoblotting with the 
anti-HA antibody. 
Adapted from Li et al, 1998. 
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Figure 14: RGS(His)6MBP stability in the absence or presence of off7-degron mutant constructs. KM-V, KM-7Oa, KM-
7O436a and KM-7O438a cells (see material & methods) were grown in a synthetic raffinose-based medium to an OD600 of 
0.6-0.8. RGS(His)6MBP expression was induced for 1 h with galactose and stopped with glucose, cells were shortly centrifuged 
and resuspended in a glucose-based medium. Samples were withdrawn at the indicated time points. Total protein was 
extracted and normalized according to the sample’s OD600 before being subjected to SDS-PAGE. The levels of RGS(His)6MBP 
were detected by immunoblotting with the anti-RGS(His)4 antibody. The actin signal was used as loading control. A and B 
were two independent experiments. 
 
In vitro degradation assay 
Retarding own degradation of off7-ODC seemed to somewhat allow co-degrading MBP, its binding 
partner. Nevertheless the degradation efficiencies of both proteins were not comparable, off7-ODC 
quickly vanished (Fig. 9 & 13) while MBP level only moderately declined over 3 h (Fig. 14). This difference 
could result from an insufficient complex formation, due to the fast degradation of off7-ODC or by the 
incomplete processing of a complex by the 26S proteasome. In order to further investigate these 
hypotheses, an in vitro system was set up using mammalian partially purified 26S proteasomes and an 
energy regenerating system. Both off7-ODC and MBP were expressed in E. coli and purified on IMAC.  
off7-ODC carried an N-terminal RGS(His)6 tag. MBP was expressed as a fusion protein with an N-terminal 
AviTag for in vivo biotinylation and a C-terminal (His)6 tag (Fig. 15).  
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Figure 15: Expression and purification of Off7-ODC (A) and MBP (B). Off7-ODC and MBP were expressed in E. coli and purified 
on a single-step IMAC. The proteins were visualized on a 15% SDS PAGE stained with Coomassie Brilliant Blue. The size 
marker is indicated in kDa. MBP molecular weight: 43 kDa, Off7-ODC: 22 kDa 
 
The affinity of off7-ODC for MBP was tested in vitro using the octet biosensor platform which enables 
the analysis of biomolecular interactions. The binding constants were very similar to the wild-type off7 
(KD= 10. 5 nM vs 9.8 nM), proving that the ODC tag did not interfere with off7 binding surface (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
A first experiment was performed to assess if off7-ODC alone could be degraded in our in vitro system. 
The reaction was performed at 37°C using a 1: 1 molar ratio between off7-ODC and the 26S proteasome. 
Despite the favorable conditions and an incubation of up to 4h, off7-ODC levels did not decrease, 
indicating that it was not degraded in vitro. After an overnight incubation, the level was only slightly 
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Figure 16: Figure 16: Octet biosensor analysis of Off7-ODC. A MBP-coated biosensor was incubated for 2 min with 
different concentrations of Off7-ODC (6.25; 12.5; 25; 50; 100 nM) and followed by 30 min with running buffer. Binding 
curves were separately fitted with a 1:1 model (black lines). 
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reduced. Another protein present in the degradation mixture was recognized as well by the anti-
RGS(His)4 Ab (below 70 KDa), it stayed at the same level (Fig. 17). In the in vitro conditions used, off7-
ODC degradation was extremely small and not comparable to what was observed in vivo.   
 
Figure 17: In vitro degradation assay for off7-ODC. The reaction was performed at 37°C. Samples were taken at the indicated 
time points after addition of off7-ODC to the degradation mix. They were subjected to SDS-PAGE and the levels of off7-ODC 
were detected by immunoblotting with an anti-RGS(His)4 antibody. The additional band running between 55 and 70 kDa 
corresponded to another protein present in the degradation mix which was recognized by the anti-RGS(His)4 antibody. The 
size marker is indicated in kDa. 
In order to use an even more accessible substrate, off7-ODC was first denatured 5’ at 95°C before being 
added to the in vitro assay. off7 had indeed been described to fully denature at 95°C (K.Binz, 
unpublished data). Under these conditions, the amount of off7-ODC did significantly decrease (Fig. 18). 
Nonetheless, the amount of total protein in the degradation mixture seemed to have also been altered. 
Indeed the amount of unspecific protein (below 70 KDa) present in the degradation mix and also 
recognized by the anti-RGS(His)4 Ab, was indeed much lower in samples, for which off7-ODC had been 
pre-incubated at 95°C than 4°C. 
 
Figure 18: In vitro degradation assay for off7-ODC after partial denaturation. Off7-ODC was first incubated for 5 min at 4°C or 
95°C before being shortly centrifuged and added to the degradation mix. The reaction was performed at 37°C. Samples were 
taken every hour and subjected to SDS-PAGE. The levels of off7-ODC were detected by immunoblotting with an anti-
RGS(His)4 antibody. The additional band running between 55 and 70 kDa corresponded to another protein present in the 
degradation mix which was recognized by the anti-RGS(His)4 antibody (see Fig. 15). The size marker is indicated in kDa. 
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To make sure that off7-ODC level decrease was due to a degradation process and not an unspecific 
aggregation, the experiment was repeated.  The off7-ODC level was monitored again after a heat 
denaturation step but this time in the absence or presence of the proteasome. In both cases, the amount 
of off7-ODC decreased. Therefore the decrease was not proteasome-dependent but rather due to an 
unspecific heat-induced process (Fig. 19). Curiously, off7-ODC level decreased even faster when the 
reaction was performed without proteasome. We concluded that off7-ODC alone could not be 
successfully degraded in our in vitro system. The degradation of a complex could then not be further 
studied.  
 
 
Figure 19: Second in vitro degradation assay for off7-ODC after partial denaturation. Off7-ODC was first incubated for 5 min 
at 95°C before being shortly centrifuged and added to the degradation mix. The reaction was performed at 37°C in absence or 
presence of the 26S proteasome. Samples were taken every hour and subjected to SDS-PAGE. The levels of off7-ODC were 
detected by immunoblotting with the anti-RGS(His)4 antibody. The additional band running between 55 and 70 kDa 
corresponded to another protein present in the proteasome preparation which was recognized by the anti-RGS(His)4 
antibody. The size marker is indicated in kDa. 
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Discussion 
 
Ornithine Decarboxylase was the first protein described to be degraded in an ubiquitin-independent 
manner. Its degron sequence has been considerably investigated and previous studies have already 
proven its efficacy when fused to several target proteins in both yeast and mammalian cells [22, 29, 30]. 
The NYV-degron which was recently identified in the cytoplasmic tail of the G1 glycoprotein of the NY-1 
hantavirus  has not been much examined yet [31]. It has been shown to destabilize GFP when expressed 
as a fusion protein in mammalian cells. In this study, we found that the NYV-degron was also recognized 
by the yeast proteasome and able to act as a destabilizing element when fused to several proteins. In 
fact, the NYV-degron seemed even more proficient than the ODC-degron when comparing their effect on 
the steady-state level of two target proteins, namely GFP and the DARPin E3_19. In contrast, the effects 
of ODC- and NYV-degrons on MBP steady-state level were similar. The NYV-constructs also required a 
longer proteasome inhibitor treatment than the ODC ones before accumulating in the cells, while the 
DARPin fusion E3_19-NYV accumulated only after 24h, the fusion E3_19-ODC was already slowly lost 
after this time. The degradation efficiencies of the ODC- and NYV-degrons were intended to be further 
analyzed while monitoring the half-life of the different constructs after promoter shut-off (Fig. 7 and 8). 
However, the rapidness of the degradation process prevented us to compare the stabilities of most 
target proteins in our experimental set-up. This assay could eventually only confirm that the GFP-NYV 
was being faster degraded than GFP-ODC.  A radioactive pulse-chase assay would probably be required 
to compare the relative destabilization induced by the ODC- or NYV-degron at the very low steady-state 
levels.  
It is possible that the ODC- and NYV-degrons differ in their affinity for the proteasome. This would justify 
their different destabilizing effects observed when they were appended to the same target protein, e.g. 
GFP. In a similar way, the ODC- and NYV-degrons could not follow the same pathway to the proteasome. 
Indeed, when their stability was studied after cycloheximide treatment, they did not behave similarly. 
off7-ODC immediately disappeared while the level of off7-NYV also quickly dropped, before reaching a 
constant low basal level. These results differed from the previous ones when the target protein stability 
was followed after promoter shut-off and where the NYV-constructs were completely and more rapidly 
degraded than the ODC-ones. It is likely that the cycloheximide treatment did also deplete the cell of one 
of the components involved in the NYV-constructs degradation but not in the ODC-constructs 
degradation. This could be a short-lived protein, directly or indirectly involved in the recognition of the 
NYV-degron sequence by the proteasome, e.g. a docking site at the proteasome, or a specific shuttle 
protein mediating the transport and/or recognition of NYV-substrates.    
Different target proteins were tested and the entire set of degron-constructs could be degraded without 
exception. All chosen target proteins were previously described as relatively stable and well expressed 
ones [41-45]. MBP is often used as carrier protein for the production of fusion proteins in E. coli to 
improve their yield and facilitate their purification [46]. It also often increases the stability and solubility 
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of the passenger protein [47]. Structurally, it consists of two strongly interacting globular domains. GFP is 
exceptional for its structural stability, high expression and fluorescent properties. It is widely used as a 
reporter to monitor gene expression and localization [48]. Its unique structural motif consists of an 11-
stranded β-barrel which forms a cylinder around the chromophore [44]. Finally, DARPins were designed 
to possess very favorable biophysical properties. They are soluble, very well expressed (up to 200 mg/L 
culture) in E. coli, show the typical ankyrin repeat domain fold and stable [42]. E3_5 was even described 
as extremely stable with a melting temperature higher than 85°C while E3_19 was melting at 66°C [41]. 
Nevertheless no distinction could be observed between the two DARPins, at least in our experimental 
set-up. In fact, among the different target proteins tested; GFP-ODC seemed to be the “most difficult” 
substrate. Its measured half-life of less than an hour was close to the previously reported one of 1 to 2 
hours when GFP-ODC was expressed in CHO cells [30]. When comparing the resistance of the different 
target proteins to chemical denaturation and their free energy of unfolding, E3_5 could be expected to 
be the most challenging substrate (Table 5). However GFP unfolding was described as a slow and 
stepwise process with a native-like intermediate state [49]. Its high kinetic barrier to unfolding could 
explain why it appeared to be less rapidly degraded than the other target proteins. It should be noted 
that GFP was quickly degraded when fused to the NYV degron sequence and a more precise comparison 
of all NYV-constructs half-lives would be needed to validate this hypothesis. The kinetic studies of several 
model proteasome substrates have demonstrated that unfolding is a rate-limiting step for their 
degradation. Methotrexate, a dihydrofolate reductase (DHFR) ligand, has been shown to stabilize the 
enzyme through binding. This ligand also impaired the proteasomal degradation of DHFR when the 
enzyme was fused to a Lys48 polyUb chain or the ODC degron [8, 20].  
 
Target protein  Dm, M Meas. Temp., C ΔG , kcal/mol Unfolding model 
MBP 1 1.1 25 12.9 Two-state 
GFP 2 1.7a and 4.3b 25 10.8 Three-state 
E3_5 3 5 23 14.8 Two-state 
E3_19 3 2.9 23 9.6 Two-state 
 
Table 5: Thermodynamic parameters for guanidinium chloride denaturation of target proteins.  
The data was gathered from : Fox, et al. (2001) [50] ; Xie and Zhou (2008) [49]; Kohl et al. (2003) [42]. Dm is the midpoint 
denaturation concentration of guanidinium chloride at the measurement temperature indicated. ΔG is the free energy of 
unfolding extrapolated to zero denaturant concentration assuming the indicated unfolding model. 
midpoint concentration between the native and intermediate state 
a
 
midpoint concentration between the intermediate and unfoldingstate 
b 
 
The co-expression of a binding partner had no effect on the degron-constructs stabilities and vice-versa. 
The degron construct was still degraded at the same rate while no destabilization was observed for the 
binding partner. The presence of the degron sequence did not alter the binding properties of off7 for 
MBP but it might have prevented an efficient complex formation between the two proteins. Indeed, the 
degradation process of off7 degron-constructs was remarkably fast. It is then possible that complex 
formation did not occur for this reason alone. In mammalian cells and yeast, pulse-chase experiments 
demonstrated that ornithine decarboxylase was mostly degraded before it completed folding [51, 52]. It 
was thus plausible that the degron-constructs were undergoing degradation immediately after 
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translation and that they could not completely fold and /or interact with the binding partner before 
going to the proteasome. To verify this hypothesis, mutations which had been previously identified to 
slow down the degradation process [30], were introduced in the ODC sequence fused to the DARPin 
off7. Their effect on off7 stability was less pronounced than what had been observed for GFP-ODC but 
our experimental data showed that the DARPins were anyhow faster degraded than GFP, so it might 
have been more problematic to monitor how the degradation kinetic was affected in this context as all 
of them remained to be degraded too fast to be accurately measured. These off7-ODC mutants were co-
expressed with a cognate binding partner, RGS(His)6MBP which seemed to be partially degraded, but 
only to a very low extent compared to the degradation of the cognate DARPin-degron fusion. Either the 
mutated off7-ODC constructs were still degraded too fast and only a small fraction of RGS(His)6MBP 
could bind to them and be brought to the proteasome, or the entire complex was going to the 
proteasome, but RGS(His)6MBP was not degraded along. It could be that the 19S subunit was interacting 
with the degron-construct solely and that RGS(His)6MBP could not penetrate the proteasome. 
Alternatively, the whole complex might enter the proteasome but upon unfolding of the degron-
construct in the 19S particle, the binding partner could dissociate and escape if not trapped by a specific 
recognition element. 
In yeast and mammals, when the ornithine decarboxylase is bound to the antizyme 1 (AZ1), it can be 
better recognized and processed by the proteasome, but AZ1 is apparently not degraded along with the 
ornithine decarboxylase [18]. In ornithine decarboxylase overproducing 653-1 mouse myeloma cells, 
ODC and AZ1 differed in their rate of degradation and AZ1 degradation relied on a functional ubiquitin 
system [53]. In yeast, ubiquitinated forms of AZ1 were also detected, suggesting that AZ1 degradation 
occurs mostly if not only independently of ornithine decarboxylase [18]. A protein might not solely need 
to interact with the proteasome to be processed as a substrate. The presence of a degradation signal 
might be required, and/or only a moderate structural stability might be tolerated to enable an efficient 
and rapid unfolding. Even if we have observed that MBP, when fused to the ODC- or NYV- degron could 
be well processed by the proteasome, it cannot be excluded that the degron sequence not only directed 
MBP to the proteasome but also promoted its unfolding in the 19S subunit. This unstructured peptide 
stretch at the C-terminus of the substrate could function as an initiation site, engaging the proteasome 
unfolding machinery [23, 54]. It was indeed observed that the proteasome initiated degradation of 
mouse ornithine decarboxylase at its C-terminus where its degron sequence is located [25]. Unfused 
MBP would, in that case, not constitute an identical substrate to MBP-ODC or MBP-NYV, and its 
unfolding might have been more problematic.  
In vitro degradation experiments would have been very beneficial to observe the potential degradation 
of a complex. It would have been more appropriate to monitor the stability of a degradation-prone 
protein and a non degradation-prone binding partner. We tried to set-up such an in vitro assay, but 
unfortunately, off7-ODC, which was very unstable in vivo, was not degraded in vitro. Similar results have 
been reported for other studies, e.g. GFP-ODC was not destabilized in an in vitro system either [20]. In 
the same way, when produced in E. coli, mouse ornithine decarboxylase could only be degraded to 10-
15% by purified yeast or rat 26S proteasomes [29], while up to 70% of in vitro translated protein could 
be deprived in a reticulocyte lysate fraction II [15]. Important co-factors, normally associated with the 
proteasome could have then been missing in our in vitro experimental set-up. Chaperone proteins 
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extrinsic to the proteasome might participate in unfolding the substrate. To test this hypothesis, off7-
ODC was first shortly heat-denatured before being added to the in vitro assay, but this substrate was not 
degraded, either. It is nevertheless possible that once denatured, the off7 structure was altered and its 
ODC degron sequence not exposed anymore, or that off7 aggregated to the bottom of the assay tube 
and was not available anymore for degradation. Its decreasing amount, even in the absence of 26S 
proteasomes in the assay, could favor this last explanation, but part of it was still in solution until the end 
of the experiment and should have been an appropriate substrate. Shuttle proteins which would help 
mediating off7-ODC interaction with the proteasome could have also been missing in the in vitro system. 
However, previous results have shown that even if GFP-ODC could not be processed in vitro, it was still 
able to interact with the proteasome by inhibiting the degradation of mouse ornithine decarboxylase 
[20]. This could be consistent with the observation that, when denatured off7-ODC was used as a 
substrate, its level decreased faster in absence of proteasome. off7-ODC was most likely interacting with 
the proteasome which could keep it longer in solution but not degrade it. 
Overall, our data showed that in vivo the yeast 26S proteasome could process all tested substrates in 
spite of their intrinsic stability or slow unfolding properties, as long as they were fused to the ODC- or 
NYV-degron sequence. It is reasonable to assume that this degradation did mostly take place shortly 
after the translation. The 26S proteasome might be able to efficiently process these proteins only before 
they reach their folded state. It has been demonstrated that ornithine decarboxylase was mostly 
degraded before it completed folding and that mature proteins could still turnover, but to a lower extent 
[51, 52]. This could explain why a purified degron-fusion could not be degraded in vitro. It is still unclear 
if a co-expressed binding partner could be led to the 26S proteasome and co-degraded as we found so 
far no clear evidence for this reaction. Another set-up allowing the exposure of the degron-sequence 
upon induction would allow controlling degradation in a time-manner and better comprehending how 
the degron-constructs and possibly binding partners are processed by the proteasome. If a complex 
could indeed be degraded, further investigating the prerequisites of the binding partner making it 
eligible for degradation would also help understanding how the proteasome selects its substrates and 
degrades them. 
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p416/Gal/E3 5
6060 bp
Amp R
URA3
E3 5
HA tag
Gal1 prom oter
ARS(H4)
CEN6
f1 origin
CYC1 terminator
stop
BamHI (37 65)
EcoRI (3297 )
Nco I (5435)
SpeI (3261)
Xba I (3255)
Xho I (37 95)
PstI (5666)
KpnI (4057 )
SacI (27 93)
ApaLI (831)
ApaLI (207 7 )
ApaLI (5880)
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p416/Gal/E3 5-ODC
6150 bp
Am p R
URA3
E3 5
ODC
HA tag Gal1 prom oter
ARS(H4)
CEN6
f1 origin
CYC1 term inator
STOP
BamHI (37 65)
EcoRI (3297 )
Nco I (5525)
SpeI (3261)
Xba I (3255)
Xho I (3885)
KpnI (4147 )
SacI (27 93)
PstI (3854)
PstI (57 56)
ApaLI (831)
ApaLI (207 7 )
ApaLI (597 0)
p416/Gal/E3 5-NYV
6165 bp
Amp R
URA3
E3 5
NYV
HA tag
Gal1 promoter
ARS(H4)
CEN6
f1 origin
CYC1 term inator
STOP
BamHI (37 65)
EcoRI (3297 )
Nco I (5540)
PstI (57 7 1)
SpeI (3261)
Xba I (3255)
Xho I (3900)
Kpn I (4162)
SacI (27 93)
ApaLI (831)
ApaLI (207 7 )
ApaLI (5985)
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p425/ADH/off7-NYV
9156 bp
Am pR
LEU2
NYV
off7
HA tag
ADH prom oter
f1 origin
2 MICRON
CYC1 term inator
STOP
BamHI (5633)
ClaI (7 552)
SpeI (5129)
Xho I (57 68)
SacI (3621)
EcoRI (5165)
EcoRI (8037 )
Xba I (429)
Xba I (5123)
Kpn I (6030)
Kpn I (7 651)
ApaLI (1659)
ApaLI (2905)
ApaLI (4257 )
ApaLI (897 6)
pQE30/off7-ODC
4008 bp
bla off7
ODC
RGS(His)6
T5 prom oter/ lac operator
ColE1
STOP
BamHI (146)
EcoRI (89)
Nco I (1407 )
Xba I (17 11)
Xho I (2)
Hin dIII (614)
Hin dIII (7 34)
ApaLI (1940)
ApaLI (2438)
ApaLI (3684)
p425/TEF/off7-ODC
8046 bp
AmpR
LEU2
ODC
off7
HA tag
TEF1 promoter
f1 origin
2 m icron
CYC1 terminator
STOP
BamHI (4538)
ClaI (6442)
PstI (4627 )
SpeI (4034)
Xho I (4658)
SacI (3621)
EcoRI (407 0)
EcoRI (6927 )
Xba I (429)
Xba I (4028)
KpnI (4920)
KpnI (6541)
ApaLI (1659)
ApaLI (2905)
ApaLI (7 866)
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Construct DNA and amino-acid sequences 
 
E3_5-stop construct DNA sequence 
 
actagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgt
atcctgatggctaacggtgctgacgttaacgctactgacaatgatggttatactccgctgcacctggctgcttctaatggtcacctggaaatcgttgaagt
tctgctgaagaacggtgctgacgttaacgcttctgaccttactggtattactccgctgcacctggctgctgctactggtcacctggaaatcgttgaagttct
gctgaagcacggtgctgacgttaacgcttatgacaatgatggtcatactccgctgcacctggctgctaagtatggtcacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatcctaatagtgaaagcttttagctgacctcgag 
E3_5-stop amino-acid sequence 
MYPYDVPDYAEFDLGKKLLEAARAGQDDEVRILMANGADVNATDNDGYTPLHLAASNGHLEIVEVLLKNGADVNASD
LTGITPLHLAAATGHLEIVEVLLKHGADVNAYDNDGHTPLHLAAKYGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNG
NEDLAEILQGS 
 
E3_5-ODC construct DNA sequence 
 
 
actagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgt
atcctgatggctaacggtgctgacgttaacgctactgacaatgatggttatactccgctgcacctggctgcttctaatggtcacctggaaatcgttgaagt
tctgctgaagaacggtgctgacgttaacgcttctgaccttactggtattactccgctgcacctggctgctgctactggtcacctggaaatcgttgaagttct
gctgaagcacggtgctgacgttaacgcttatgacaatgatggtcatactccgctgcacctggctgctaagtatggtcacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatccttcccgccggaggtggaggagcaggatgatggcacgctgcccatgtcttgtgcccaggagagcgggatggaccgtcaccctgcagcct
gtgcttctgctaggatcaatgtgtagctcgag 
E3 5-stop
54 0 bp
Stop sequence
E3 5
HA tag
BamH I (506 )
Ec oR I (38 ) H ind III (521)
Sp e I (2) X h oI (536 )
E3 5-ODC
630 bp
E3 5 ODC
HA tag STOPBamHI (506)
EcoRI (38)
Spe I (2) Xho I (626)
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E3_5-ODC amino-acid sequence 
MYPYDVPDYAEFDLGKKLLEAARAGQDDEVRILMANGADVNATDNDGYTPLHLAASNGHLEIVEVLLKNGADVNASD
LTGITPLHLAAATGHLEIVEVLLKHGADVNAYDNDGHTPLHLAAKYGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNG
NEDLAEILQGSFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV 
 
E3_5-NYV construct DNA sequence 
 
 
actagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgt
atcctgatggctaacggtgctgacgttaacgctactgacaatgatggttatactccgctgcacctggctgcttctaatggtcacctggaaatcgttgaagt
tctgctgaagaacggtgctgacgttaacgcttctgaccttactggtattactccgctgcacctggctgctgctactggtcacctggaaatcgttgaagttct
gctgaagcacggtgctgacgttaacgcttatgacaatgatggtcatactccgctgcacctggctgctaagtatggtcacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatcccgccctgaagttaaacaaggatgctatagaacattgggtgtttttagatataagagtaggtgttatgttggtcttgtgtggggggtccttc
ttacaactgaactcatagtttgggcagctagtgcttagctcgag 
 
E3_5-NYV amino-acid sequence 
MYPYDVPDYAEFDLGKKLLEAARAGQDDEVRILMANGADVNATDNDGYTPLHLAASNGHLEIVEVLLKNGADVNASD
LTGITPLHLAAATGHLEIVEVLLKHGADVNAYDNDGHTPLHLAAKYGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNG
NEDLAEILQGSRPEVKQGCYRTLGVFRYKSRCYVGLVWGVLLTTELIVWAASA 
 
Off7-ODC construct DNA sequence 
 
 
 
E3 5-NYV
645 bp
NYVE3 5
HA tag STOPBamHI (506)
EcoRI (38)
Spe I (2) Xho I (641)
0ff7-ODC
630 bp
off7 ODC
HA tag STOPBamHI (506)
EcoRI (38)
Spe I (2) Xho I (626)
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Actagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgt
atcctgatggctaacggtgctgacgttaatgctgctgacaatactggtactactccgctgcacctggctgcttattctggtcacctggaaatcgttgaagt
tctgctgaagcacggtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttct
gctgaagaacggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatccttcccgccggaggtggaggagcaggatgatggcacgctgcccatgtcttgtgcccaggagagcgggatggaccgtcaccctgcagcct
gtgcttctgctaggatcaatgtgtagctcgag 
Off7-ODC amino-acid sequence 
MYPYDVPDYAEFDLGKKLLEAARAGQDDEVRILMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASD
VFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISID
NGNEDLAEILQGSFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV 
 
Off7-NYV construct DNA sequence 
 
 
actagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgt
atcctgatggctaacggtgctgacgttaatgctgctgacaatactggtactactccgctgcacctggctgcttattctggtcacctggaaatcgttgaagt
tctgctgaagcacggtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttct
gctgaagaacggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatcccgccctgaagttaaacaaggatgctatagaacattgggtgtttttagatataagagtaggtgttatgttggtcttgtgtggggggtccttc
ttacaactgaactcatagtttgggcagctagtgcttagctcgag 
Off7-NYV amino-acid sequence 
MYPYDVPDYAEFDLGKKLLEAARAGQDDEVRILMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASD
VFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISID
NGNEDLAEILQGSRPEVKQGCYRTLGVFRYKSRCYVGLVWGVLLTTELIVWAASA 
  
off7-NYV
645 bp
NYVoff7
HA tag STOPBamHI (506)
EcoRI (38)
Spe I (2) Xho I (641)
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RGS(His)6off7-ODC construct DNA sequence 
 
 
Atgagaggatcgcatcaccatcaccatcacggatccgacctgggtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgtatcct
gatggctaacggtgctgacgttaatgctgctgacaatactggtactactccgctgcacctggctgcttattctggtcacctggaaatcgttgaagttctgc
tgaagcacggtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttctgctga
agaacggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagttctgctgaa
gcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcctgcaaa
agcttttcccgccggaggtggaggagcaggatgatggcacgctgcccatgtcttgtgcccaggagagcgggatggaccgtcaccctgcagcctgtgctt
ctgctaggatcaatgtgtagaagctt 
 
RGS(His)6off7-ODC amino-acid sequence 
MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDAS
DVFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISI
DNGNEDLAEILQKLFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV 
  
RGSHis6-off7-ODC
6 24  bp
off7 ODCRGS(His)6
STOPBa mH I (32) H ind III (500)
H ind III (6 20)
102 
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Introduction 
 
The selective depletion of intracellular proteins can be a powerful tool for protein function 
analysis and, in the long run, therapeutic applications. Reduction of a protein steady-state level often 
results in biochemical and/or phenotypic alterations; analysis of these physiological effects does usually 
give good leads on its function. Gene disruption at the DNA level has markedly advanced biological 
research. However, deletion of certain genes led to developmental arrest and/or lethality, and limitation 
in temporal and spatial specificities prevented a complete study of associated phenotypes. Moreover, 
developmental compensational effects could mask some loss-of-function-phenotypes.  Nowadays, siRNA 
(short interfering RNA) and antisense oligonucleotides are preferred over traditional genetics and elicit a 
great deal of interest; they can easily prevent the expression of a given protein by mRNA destruction 
and/or inhibition of mRNA translation by physical blockade of ribosomes. While being popular, this gene 
silencing technique may not be absolutely specific and can trigger “off targets” effects in addition to 
knockdown of the targeted gene [1, 2]. Furthermore, in some cases siRNAs can act as agonists of Toll-like 
receptors [3] and specific sequence motifs can induce cellular immune responses [4, 5]. Last but not 
least, functional assessment of knockdown or knockout phenotype depends also on the intrinsic stability 
of the targeted protein.  
Instead of maneuvering at the biosynthesis stage, other methods were developed to operate post-
translationally. Most of them relied on the exploitation of the ubiquitin proteasome pathway, the major 
path for regulated degradation of intracellular proteins in eukaryotes [6]. Protein degradation via the 
ubiquitin-proteasome pathway requires first the labeling of the substrate by ubiquitin and then 
degradation by the 26S proteasome. Several strategies tried to take advantage of the ubiquitination 
machinery or hijack it to degrade specific target proteins. The first described one aimed at mimicking the 
mode of action of the human papillomavirus (HPV) oncoprotein E6. Scheffner and colleagues had 
discovered that this protein could bind to the tumor suppressor p53 and stimulate in vitro its 
degradation via the “ubiquitin-dependent proteolysis system” [7]. Without having fully deciphered the 
mechanism of HPV E6 action yet (targeting p53 to the E6AP ubiquitin ligase), they investigated if it could 
induce degradation of other proteins brought into complex with itself. The domain of HPV E7, which 
contains the binding domain for the tumor suppressor retinoblastoma protein (pRB) was N-terminally 
fused to HPV E6; this chimeric fusion protein promoted pRB degradation in a rabbit reticulocyte lysate 
[8]. The authors envisioned that “E6 fusion proteins might therefore be useful tools in the study of 
protein-protein interactions in vitro and in vivo”. However, the in vivo efficacy has not been 
demonstrated due to the instability of E6-E7 fusion inside the cells [9]. Gosink and Viestra modified the 
C-terminus of ubiquitin conjugating enzymes (E2) with protein-binding domains, to induce ubiquitination 
of new target proteins [10]. Several natural or artificial ligands were fused to the C-terminus of two plant 
E2s: UBC1 from Aradopsis thaliana and UBC4 from wheat. A variety of ligand protein interactions, 
including protein A-antibody, epitope-antibody, peptide hormone-receptor and protein subdomains,  
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Figure 1: Overview of the PROTAC strategy meant to achieve chemical protein knock out. A PROTAC 
molecule is an adapter which, brings a target protein into contact with a multi-subunit E3 RING ubiquitin 
ligase (A: SCF β-TrCP ubiquitin ligase, B: VBC ubiquitin ligase, C: Mdm2 ubiquitin ligase) prompting transfer 
of ubiquitin (Ub) from an E2 ubiquitin conjugating enzyme, leading to polyubiquitination of the target 
protein and degradation by the 26S proteasome. A PROTAC molecule consists of a ligand or small 
molecule which is recognized by the E3 substrate binding domain (A: WD40 domain of β-TrCP, B: beta 
domain of VHL, C: p53 binding domain of Mdm2) and a ligand which binds the target protein. As it is 
added from the outside, the PROTAC molecule must be cell-permeable.  
A 
C 
B 
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were tested. In vitro modified E2s could in presence of E1 and ATP ubiquitinate the protein recognized 
by the fused ligand. One of the target proteins was also partially degraded in a reticulocyte lysate. This 
was the only attempt to engineer E2, the following strategies took advantage of ubiquitin ligases (E3) 
domains or activity; the last enzyme of the ubiquitination cascade, in charge of substrate recruitment. 
A new ubiquitin ligase was created by fusing the catalytic HECT domain of yeast ubiquitin ligase Rsp5 to 
the C-terminus of a peptide aptamer [11]. The HECT domain is a highly conserved domain, invariably 
located at the carboxyl-terminal region of HECT ubiquitin ligases; it accepts ubiquitin from bound E2 and 
subsequently transfers it to the substrate [12]. Peptide aptamers are engineered binding proteins, 
consisting of a variable peptide loop attached at both ends to a protein scaffold, in this case E. coli 
thioredoxin-A. Using a peptide aptamer selected against Cdk2 fused to the catalytic HECT domain, a 
LexA-Cdk2 fusion protein could be ubiquitinated in S. cerevisiae but was not degraded, even in presence 
of additional lysine residues and increased ubiquitination efficiency.   
While the three former strategies were not followed up, two other approaches could successfully and 
repeatedly harness multisubunit RING E3s ubiquitination machineries. They led to the development of 
“chemical knockout” and “protein knockout” techniques.  
Chemical knockout relies on the use of adapter molecules which have been termed PROteolysis 
Targeting Chimeric MoleculeS (PROTACS). PROTACS are bifunctional molecules comprising a ligand for 
the target protein, chemically linked to an ubiquitin ligase binding moiety (peptide). They were designed 
with the aim of bringing a target protein to the E3, in close enough proximity to allow multiubiquitin 
attachement and subsequent degradation. In a proof-of-principle experiment, methionine 
aminopeptidase 2 (MetAP-2), a stable protein which cleaves N-terminal methionine residues from 
nascent polypeptides, could when pre-bound to PROTAC-1, be degraded in Xenopus egg extracts [13]. 
PROTAC-1 consisted of a known covalent inhibitor of MetAP-2, ovalicin, joined to the 10-amino-acid 
phosphopeptide of IΚBα sequence which is normally recognized by the mammalian F-box protein β-TrCP, 
the substrate binding subunit of ubiquitin ligase SCF β-TrCP. By exchanging the substrate binding moiety 
with Estradiol or dihydroxytestosterone, PROTAC-2 and PROTAC-3 were generated to target two cancer-
promoting proteins: the estrogen receptor α (ER α) and androgen receptors (AR), respectively [14]. 
PROTAC-3 could, upon microinjection in HEK293 cells stably expressing AR-GFP (HEK293AR-GFP), activate 
the fusion protein turnover using the cellular degradation machinery. PROTAC-5 was designed to be cell 
permeable; IΚBα phosphopeptide was replaced with a 7-amino acid peptide, recognized by the von-
Hippel-Lindau tumor suppressor protein (VHL), the substrate recruiting unit of the VBC (VHL-elongin 
C/elongin B) ubiquitin ligase [15]. The VHL subunit, contrary to β-TrCP, does not recognize its substrate 
upon phosphorylation but upon hydroxylation [16]. Additionally, a polyarginine tag was fused to the C-
terminus of the PROTAC 5 to mimic HIV Tat protein translocation mechanism into cells. PROTAC-5 could 
upon addition to HEK293AR-GFP induce degradation of AR-GFP. Subsequently the 7-amino acid VHL 
recognition sequence was simplified to a pentapeptide [17]. Finally, an anti-ERα PROTAC designed in a 
fully genetic manipulation-free way (containing Estradiol, a linker and VHL pentapeptide), was able to 
potently inhibit endothelial cell differentiation in a three-dimensional angiogenic sprouting assay and 
inhibited proliferation of ERα-dependent breast cancer cells [18, 19]. Addition of a polyarginine tag 
allowed decreasing the effective concentration of PROTAC in the low μM range [18]. 
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Figure 2: Protein knock out strategy using chimeric F-box proteins. The target protein is recruited to the 
core SCF machinery by either fusing a targeting peptide (TP) to the C-terminus of the F-box protein (A), 
or directly replacing the F-box protein original substrate binding domain (in this case, WD40 domain) by 
a targeting peptide (TP). The target protein is ubiquitinated and subsequently degraded by the 26S 
proteasome.  
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A dihydroxytestosterone-based PROTAC inhibited proliferation of androgen-dependent prostate cancer 
cells [18, 20]. Later on, a new target, the Aryl Hydrocarbon Receptor (AHR) could also be degraded in 
epithelial cells; the AHR pathway, involved in tumor promotion was inhibited (Puppala, 2008). Recently, 
another example of PROTAC was developed where the E3-recognizing peptide was replaced with a small 
molecule [21]. An “all-small molecule PROTAC” was constructed with a non-steroidal androgen receptor 
ligand (SARM) and nutlin, a ligand of the ubiquitin ligase MDM2, connected by a PEG-based linker. 
MDM2 normally regulates the intracellular levels of p53 [22] and nutlin is an imidazoline derivative 
which has been shown to disrupt the binding of MDM2 to its target p53. This new PROTAC was capable 
of promoting degradation of AR transiently expressed in HeLa cells. Small molecule PROTAC libraries 
could be envisioned, leading to chemical proteomics and/or therapeutic applications. However, cell 
permeability issues have to be completely circumvented. The high concentrations needed to observe an 
effect (between 3.8 μM and 50 μM) might limit the application of PROTACS for therapeutic applications. 
The second strategy did not rely on bridging molecules but on the direct engineering of F-Box proteins, 
the substrate recruiting subunits of SCF ubiquitin ligases. Zhou and Howley constructed chimeric F-box 
proteins by fusing them to a targeting peptide (TP), capable of binding a target protein [23]. Their 
pioneering work consisted of selectively degrading pRb in yeast by co-expressing it with the F-box 
protein cdc4 to which they had C-terminally fused the N-terminal 35 residues of HPV E7, which contain a 
pRb binding motif. A similar engineering study was conducted on the mammalian F-box protein β-TrCP 
[23]. Transient expression of this chimeric F-box protein (βTrCP-E7N) in the human osteosarcoma SAOS-2 
cells decreased pRb levels and inhibited Rb-induced growth arrest. The properties of this protein 
knockout system were then further evaluated. It appeared that the formerly engineered βTrCP-E7N 
could also be used to degrade another member of the Rb proteins family; p107 levels could be reduced 
upon its expression in C33A cervical carcinoma cells [23]. Moreover, this proteolysis could be controlled 
by adjusting the amount of recombinant βTrCP-E7N adenoviruses used to infect C33A cells [24]. In 
addition to fine-tuning intracellular protein levels, the degradation could be confined to a post-
translationally modified subpopulation. HPV E7 was found to selectively bind to the hypophosphorylated 
form of pRB. When present in U2OS osteosarcoma cells, expressing both hypo- and 
hyperphosphorylated forms of pRB, βTrCP-E7N was only eliminating hypophosphorylated pRB [24]. To 
reduce risk of unspecific interaction of the chimeric F-box protein, a minimal binding domain of HPV E7 
was used (9 instead of 35 residues) and interference with native βTrCP substrates was prevented by 
mutating βTrCP substrate binding sites [24]. Another chimeric F-box protein was designed by fusing β-
catenin binding domain of E-cadherin to βTrCP, it was successfully employed to degrade β-catenin in 
HEK293 cells [25]. It seemed to preferentially target soluble nuclear/cytosolic β-catenin (involved in Wnt 
signaling) for degradation, sparing the membrane-associated one. Its expression inhibited tumorigenicity 
of DLD1 colon cancer cells grown in vitro and in vivo, in mice. The design of chimeric F-box proteins was 
further refined; instead of hitchhiking for a ride with βTrCP, β-catenin was allowed to carjack it. The 
targeting peptide was not fused any more to the C-terminus of the full-length β-TrCP but used to replace 
its entire original substrate binding domain [26, 27]. Finally, a minimal chimeric F-box protein was 
constructed by deleting both the N-terminal domain upstream of the F-box motif and the WD40 
substrate binding domain, this truncated molecule was linked via a 10-amino acid serine-glycine peptide  
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Figure 3: Strategy of SIT assisted degradation of a target protein. IΚBα, a known substrate of the F-box 
protein βTrCP is fused to the intrabody (here depicted as a scFv), thereby creating a chimeric bifunctional 
protein. The intrabody domain carries out the target protein recruiting function while IΚBα serves as a 
bridging molecule with the ubiquitination complex and acts as a degradation domain. The faded 
ubiquitin chain appended to the target protein highlights the possible ubiquitination that the target 
undergoes before being degraded.  
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to four copies of a 15 residue-β-catenin binding motif found in the adenomatous polyposis coli (APC). 
This new molecule could induce colorectal cancer cell death in vitro and in vivo [26]. In addition to pRB 
proteins family and β-catenin, c-myc and cyclin A could be targeted for degradation. Cohen and 
colleagues fused c-myc interacting domain of the protein Max to the C-terminus of βTrCP [28]. Using in 
utero gene transfer, they revealed a role for c-myc in murine lung and intestine development. The 
therapeutic potential of the protein knockout strategy was further demonstrated with the degradation 
of Cyclin A/Cyclin-Dependent Kinase 2 (cdk2) complex [29]. An 8 residue peptide named LFG, originally 
found in the transcription factor E2F1, and able to bind Cyclin A, was C-terminally fused to βTrCP. 
Degradation of cyclin A in complex with cdk2 induced apoptosis for several tumor cell lines in vitro and 
also had antitumor effects in vivo, when tested in subcutaneous or intracranial tumor models.  
“Chemical knockout” and “protein knockout“ technologies open new possibilities for proteomics, 
drug target validation and therapeutic applications. Both technologies are nevertheless limited in the 
range of targets, as they rely on the availability of a tight-binding “adapter”, i.e. a ligand or a known 
naturally occurring binding motif. Recently, another strategy emerged which would allow not a case-by-
case but a more general applicability. Melchionna and Cattaeno developed the Suicide (or silencing) 
Intrabody Technology (SIT) [30]. SIT relies on the use of an intrabody C-terminally fused to IΚBα, a βTrCP 
substrate. IΚBα is only recognized by the ubiquitin ligase upon phosphorylation which results from NF-kB 
signaling pathway activation. This stimulus-induced degradation could be exploited to turn the fusion 
protein into a switchable suicide intrabody. Two constructs made with an anti-Tau and an anti-β-
galactosidase intrabody were transiently expressed in Hela cells. Upon addition of Tumor Necrosis Factor 
alpha (TNFα), both suicide antibodies were undergoing degradation. When co-expressed with the C-
terminal domain of Tau (τ) protein or whole length β-galactosidase, they could respectively induce their 
degradation. The steady-state level of endogenous τ was also highly decreased when the specific suicide 
antibody was expressed in TNFα-stimulated human neuroblastoma cells. The suicide intrabody seemed 
to act in a catalytic way as its steady-state level was always lower than the target protein’s one. It was 
suggested that the suicide antibody could escort the target protein to the proteasome but escape 
degradation and be recycled for a new round of action. The intrabody-based knock-out technology 
seems promising but does rely on the expression and degradation of an intrinsic player (IΚBα) via 
activation of a signaling cascade. The use of biologically inactive compounds for both interaction with the 
ubiquitin ligase and activation of the degradation cascade would lower the risk of side-effects. The 
precise mechanism by which suicide antibodies induce trans-degradation of their target protein remains 
to be investigated and the general applicability of the system to be further proven. If sufficient functional 
intracellular antibodies should be readily available to target a large spectrum of proteins, the in-trans 
mode of action may restrict it. The degradation of target protein necessitates namely two additional 
actors: IΚBα and the intrabody which might eventually be degraded too. In other words, the proteasome 
needs to process between two and three substrates at each round; this overloading approach may lower 
its overall processing efficiency and function properly for easy degradable target proteins only. It should 
be noted that the degradation efficiency differed greatly, from 70-90 % for the C-terminal domain of τ 
protein (30 kDa) to only 15-20% for β-galactosidase (120 kDa).  
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Figure 4: Strategy for AZ-assisted degradation of target proteins by ODC chimeric fusion proteins. A 
protein interaction domain (adapter= A) is expressed with ODC attached to its C-terminus with a flexible 
linker sequence. The ODC fusion protein binds the target protein and dimerizes. AZ dissociates the ODC 
fusion proteins dimer, induces a conformational change which enhances degradation of one ODC fusion 
protein with the target protein along by the 26S proteasome. In certain cases ODC fusion protein can be 
efficiently recognized by the proteasome and be degraded along with the target protein, without 
previous interaction with AZ.  
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To summarize, a strategy which could harness the ubiquitination machinery without interfering with the 
cell homeostasis and be readily adapted to a large range of target proteins would be optimal for 
achieving specific protein breakdown in the cell. Our chimeric F-box protein, described in chapter 1, does 
respond to these expectations. They are extremely specific and continuously degraded so they should 
not disturb the cell metabolism and DARPins, the solid scaffold used as substrate binding moiety can be 
selected against virtually any target.  
Selectively targeting a protein for ubiquitination and subsequent degradation opens another avenue for 
protein knock-out, but bypassing the target protein labeling step may be more powerful for “high-
throughput degradation”. Avoiding the use of an additional intracellular machinery may simplify and 
accelerate the degradation process. What’s more, it is very likely that some substrates are more prone to 
ubiquitination than others, based on their primary and tertiary structures. Matsuzawa and colleagues 
elaborated an alternative strategy for degrading selected proteins in an ubiquitin-independent way [31]. 
Their method was based on the use of ornithine decarboxylase (OZ), an enzyme which can naturally bind 
to the 26S proteasome thanks to its C-terminal sequence, called ODC-degron. Upon association with 
antizyme (AZ), ODC undergoes a conformational change which increases exposure of the ODC degron 
and accelerates its turnover rate 50- to 100-fold.  Matsuzawa & al. fused a binding moiety (whole 
protein, protein domain or peptide ligand) via a flexible linker to the N-terminus of ODC and co-
expressed these ODC fusion proteins with their respective binding partner in HEK293 cells, in absence or 
presence of overexpressed AZ [31]. 12 pairs of interacting proteins were tested, 5 of them resulted in 
specific reduction of the target protein. For two of them, degradation was strictly AZ-dependent while 
for another case, it was only enhanced by AZ and the last two ODC fusion proteins were functional 
independently of AZ. The system could increase target protein turn-over rate from at least two fold, 
reducing overexpressed TRAF-6 half-life from about 2 h to less than an hour. Endogenous TRAF-6 and 
pRB could also successfully be targeted, significantly affecting their intracellular activities. While having 
the advantage of being more straightforward, this method suffers from the same drawback than most of 
the previously described methods, namely the need of a known adapter. Furthermore, the use of active 
ODC and AZ molecules might alter cellular polyamines levels or other intracellular proteins, leading to 
several artifacts resulting in other phenotypes or toxicity. To prevent interference with the cellular 
metabolism, the authors proposed to use a mutant ODC which would be enzymatically non-active or 
unable to bind endogenous ODC, but have not demonstrated such molecules. 
With our DARPIn-degron strategy, described in chapter 2, we went two steps ahead. A general adaptable 
binding protein was used and side-effects were circumvented by using not the entire ODC molecule but 
only its degron sequence. Another degron sequence identified in the NYV G1 glycoprotein was also 
tested. When expressed in S. cerevisiae, all DARPIn-degrons were extremely rapidly degraded but failed 
to efficiently induce destruction of their binding partner. We envisioned that our molecules were 
disappearing too fast in the yeast system to function as carriers to the 26S proteasome. Inspired by the 
formerly described strategy elaborated in mammalian cells, we tested the DARPIn-degrons in a 
mammalian system. In parallel, we also examined the potential of our chimeric F-box protein (described 
in chapter 1) in mammalian cells. The F-box protein we used was designed on a yeast scaffold, but SCF 
ligases are well conserved throughout evolution as witnessed by their preserved structure [32-36]. 
Fbxw7, a homolog of cdc4 was identified in mammals, but its F-box domain does not display significant 
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similarity. However when a blast search was carried out against the human proteome database, cdc4 F-
box domain showed 42%, 38%, 36% and 34% identity with other F-box domain contained in human F-
box proteins named Fbxl5, Fbxl21, Fbxw8 and Fbxw2, respectively. 
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Materials & methods 
 
Plasmids and oligonucleotides 
Standard molecular biology procedures were used for recombinant DNA manipulation [37]. Enzymes 
were from NEB (Ipswich, MA, USA) or Fermentas (Vilnius, Lithuania). PCR reactions were performed with 
the Phusion TM High-Fidelity DNA polymerase as recommended by the manufacturer (NEB). All 
oligonucleotides are listed in Table 1.  
E3-5, Off7, Off7-ODC, Off7-NYV and cdc4-off7 constructs were described in chapter 2. The Off7 construct 
was subcloned in pcDNA3.1(+) (Invitrogen, San Diego, CA) at the SpeI and XhoI sites of the multiple 
cloning site. pcDNA3.1(+) also contained a SpeI site at the beginning of the CMV promoter. The ligation 
proceeded in two steps; SpeI/XhoI digested off7 construct was first ligated with the SpeI CMV promoter 
part before the rest of pcDNA3.1(+) backbone was added to the ligation mixture. The Off7 construct was 
subcloned as a HindIII fragment from pcDNA3+_Off7 in pcDNA5/FRT/TO (Invitrogen, San Diego, CA). For 
fluorescence microscopy, off7 was subcloned from pQE30_mbpoff7 (Binz, 2004, see chapter 1) in 
BamHI/HindIII sites of pTAG-RFP-DARPin (plasmid provided by Anja Mohr). For production of 
biotinylated off7, the off7 DNA sequence was amplified from pQE30_mbpoff7 (Binz, 2004, see chapter 1) 
by PCR using pQE_for and Avi_NcoI_G3_B oligonucleotides as primers and the digested PCR product was 
introduced at the BamHI and HindIII sites of pBD001 (plasmid provided by Brigit Dreier) to yield 
pBDoff7.E3-5, Off7-ODC and Off7-NYV constructs coding sequences were subcloned in EcorI and XhoI 
sites of pcDNA3+_Off7.  
pcDNA3+_cdc4-off7 was constructed by subcloning cdc4-off7 in pcDNA3.1(+) at the SpeI and XhoI sites 
of the multiple cloning site in a three-step process. The cdc4-off7 coding sequence was first ligated to 
SpeI/XhoI digested pcDNA3.1(+) lacking the SpeI CMV promoter part,  which was added in a second 
cloning step. Finally, the cdc4-off7 coding sequence was subcloned as a HindIII/XhoI fragment in a fresh 
pcDNA3.1(+) backbone. The cdc4-off7 coding sequence was subcloned from pcDNA3+_cdc4-off7 as a 
HindIII/XhoI fragment in pcDNA5/FRT/TO. The cdc4-E3_5 coding sequence was constructed by assembly 
PCR as described in chapter 1 with the exception that the oligonucleotide forHindcdc4 was used instead 
of forSpeIcdc4 (see chapter 1). The cdc4-E3_5 coding sequence was cloned at the HindIII/XhoI sites of 
pcDNA5/FRT/TO.  
The MBP DNA sequence was amplified from pQEMBP [38] by PCR using MBPforHind and MBPrevBamHI 
oligonucleotides as primers and the digested PCR product was introduced at the HindIII and BamHI sites 
of pcDNA3.1(+). For fluorescence microscopy, the MBP-GFP DNA sequence was amplified from 
pRS306/Gal/MBP-GFP (see chapter 1) by PCR using MBPforHind and revGFPHindIII oligonucleotides as 
primers and the digested PCR product was introduced at the HindIII site of pcDNA3.1(+). MBP-ODC and 
MBP-NYV constructs are similar to those described in chapter 2, except that they do not contain the N-
terminal HA tag. Their coding sequences were subcloned from p416/Gal/GFP-ODC and p416/Gal/GFP-
NYV as EcoRI/ XhoI fragments in pcDNA3.1(+) (see chapter 2). MBP coding sequence was subcloned from 
pcDNA3+_MBP as a HindIII/XhoI fragment in pcDNA5/FRT/TO.  
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All constructs were confirmed by sequencing. Plasmids constructed for this study are listed in Table 2, 
those marked with an asterisk have their plasmid map and the insert sequences shown in annex. 
 
Table 1: Oligonucleotides 
Oligonucleotides Sequence 5’-3’ direction Description  
(for=forward, rev=reverse) 
forHindcdc4 GGT GGT AAG CTT ATG GGG TCG TTT CCC TTA GC 
 
for cdc4 with HindIII site 
revcdc45GS TACCCAGGTCGCCCGAGCCGGATCCATTCTCCAGAAAAGATAATCT rev 5GS linker  
for5GSDARPin TCTGGAGAATGGATCCGGCTCGGGCGACCTGGGTAAGAAACTGCT for 5GS linker 
revHADARPin CGTAATCTGGAACATCGTATGGGTATTGCAGGATTTCAGCCAGGT rev HA tag (25 first bases) 
with DARPin 
revXhoIHA  GTGGTCTCGAGTTAAGCGTAATCTGGAACATCGTATG rev XhoI site with HA tag (24 
last bases) 
MBPforHind GT GGT AAG CTT ATG AAA ACT GAA GAA GGT AAA CTG for MBP with HindIII site 
MBPrevBamHI GT GGT GGA TCC CTA AGT CTG CGC GTC TTT CAG G rev MBP with BamHI site 
revGFPHindIII TGGTGGTAAGCTTTTATTTGTAGAGCTCATCCATGC rev GFP with HindIII site 
pQE_for CTTTCGTCTTCACCTCGAG for pQEMBP 
Avi_NcoI_G3_B GGCGAAGCTTGTTGCAGGATTTCAGCCAGGTCCTC rev off7 with HindIII site 
 
 
Table 2: Plasmids constructed for this study 
Plasmids Relevant characteristics  
(promoter; gene; ori) 
Source 
pcDNA3+_Off7* CMV; Off7; SV40 This study 
pcDNA3+_Off7-ODC* CMV; Off7-ODC; SV40 This study 
pcDNA3+_Off7-NYV* CMV; Off7-NYV; SV40 This study 
pcDNA3+_cdc4-off7 CMV; cdc4-off7; SV40 This study 
pcDNA5/FRT/TO_emptyV CMV/TetO2; -;  - This study 
pcDNA5/FRT/TO_MBP* CMV/TetO2; MBP;  - This study 
pcDNA3+_MBP-GFP CMV; MBP-GFP; SV40 This study 
pTAG-RFP-off7 CMV; off7-RFP; SV40 This study 
pBDoff7 T5; AviTag-off7; colE1 This study 
pcDNA3+_E3_5 CMV; E3_5; SV40 This study 
pcDNA3+_MBP CMV; MBP; SV40 This study 
pcDNA3+_MBP-ODC* CMV; MBP-ODC; SV40 This study 
pcDNA3+_MBP-NYV* CMV; MBP-NYV; SV40 This study 
pcDNA5/FRT/TO_Off7 CMV/TetO2; Off7; - This study 
pcDNA5/FRT/TO_cdc4-off7* CMV/TetO2; cdc4-off7; - This study 
pcDNA5/FRT/TO_cdc4-E3_5* CMV/TetO2; cdc4-E3_5; - This study 
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Cell culture 
HEK293T and Flp-In T-REx cells were grown in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 
10% (v/v) heat-inactivated Foetal Bovine Serum (PAA Laboratories GmbH, Pasching, Austria) and 1 % 
Penicillin-Streptomycin (Sigma-Aldrich, St. Louis, MO) at 37°C with 5 % CO2 in a humified incubator. For 
Flp-In T-REx cells, 15 µg/ml µg/ml Blasticidin (Invitrogen, San Diego, CA) was added to the medium in 
combination with 100 µg/ml Zeocin (Invitrogen, San Diego, CA) for wt cells or 150 µg/ml Hygromycin 
(PAA Laboratories GmbH, Pasching, Austria) for established stable Flp-In T-REx cell lines. When 
tetracycline induction was performed, tetracycline was first added at a final concentration of 1 µg/ml to 
fresh medium which was then added to the cells.  
Transfections  
Cells were transiently transfected at 90-95 % confluency with Lipofectamine 2000 (Invitrogen, San Diego, 
CA) or 70-80 % confluency with Fugene HD (Roche Applied Science, Penzberg, Germany) following the 
manufacturer’s instructions. The equivalent of 1.5 µg DNA and 3.75 µl Lipofectamine reagent or 1 µg 
DNA with 3 µl Fugene HD reagent were used to transfect cells grown in a well of a 12-well culture plate. 
Alternatively lipofectamine transfection experiments were also performed with cells in solution; the 
transfection mix was added to the well (untreated or pre-coated with 0.1 % fibronectin (Sigma-Aldrich, 
St. Louis, MO) for 2 h at 37°C) shortly before cells were seeded. For co-transfection experiments, the 
same amount of total DNA was used. Cells were also transiently transfected using DNA-calcium-
phosphate co-precipitates. At 60-70 % confluency, 1 to 2 µg DNA was diluted in 40 µl 250 mM CaCl2 and 
40 µl of HEPES solution (50 mM HEPES, pH 7.05, 1.5 mM Na2HPO4, 140 mM NaCl) was added, the final 
solution was quickly mixed and added onto the cells after 1 min standing time. The medium was changed 
6 h after transfection. 
Stable transfections of Flp-In T-REx cells were performed according to the manufacturer’s instructions.  
Cells grown to 90% confluency in a 6 cm dish were transfected with 20 µl Lipofectamine 2000 and 1 µg  
pcDNA5/FRT/TO/X plus 7 µg pOG44. 48 h later, cells were split to reach 25% confluency the next day at 
which stage 150 µg/ml Hygromycin was added to the medium. 15 µg/ml Blasticidin was added as well 
the following day. Two weeks after transfection, colonies were picked using cloning disks (Sigma-Aldrich, 
St. Louis, MO) and expanded. Positive clones were confirmed by sensitivity to 100 µg/ml Zeocin and 
expression of the protein of interest. 
Determination of steady-state levels and stability assays 
 One day before transfection, cells were counted with the CASY cell counter TT (Schärfe System GmbH, 
Reutlingen, Switzerland) and seeded at the same density in several 12-well plates. At the indicated time 
points after transfection, samples (cells contained in one well) were extracted for steady-state level 
determination or further treated with MG132 (Sigma-Aldrich, St. Louis, MO) or cycloheximide (Sigma-
Aldrich, St. Louis, MO). MG132 was added in each well at a final concentration of 30 µM (stock solution 
prepared in DMSO with a concentration of 10 mM). An identical volume of DMSO was added to the 
negative control strains. For stability assays, cycloheximide was added in each well at a final 
concentration of 20 µg/ml (stock solution was prepared in water with a concentration of 2 mg/ml). In 
both cases, cells were further incubated at 37°C and samples extracted at the indicated time points.  
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Proteins extracts 
The procedure is described for one sample, meaning cells contained in one well of a 12-well culture 
plate. Cells were washed with 500 µl PBS, 200 µl cold ProteoJET™ Mammalian Cell Lysis reagent 
(Fermentas, Vilnius, Lithuania) was added and the plate was agitated at 1200 rpm for 10 min at RT. The 
lysate was transferred in a 1.5 ml-tube and centrifuged for 15 min at 18,000 g at 10°C. 100 µl of the 
supernatant was stored at -20 °C. Total protein was quantified using the bicinchoninic acid (BCA) kit 
(Sigma-Aldrich, St. Louis, MO). The assay was performed in a 96-well plate format with 200 µl BCA 
working reagent and 10 µl of BSA standards (prepared in ProteoJET™ Mammalian Cell Lysis reagent) or 
5 µl sample complemented with 5 µl ProteoJET™ Mammalian Cell Lysis reagent. OD was measured at 
540 nm. Normalized volumes were loaded on 10 % or 15 % SDS-Polyacrylamide gels followed by 
immunoblotting. 
Pull-down experiments 
Lysate preparation: 20 h after induction with 1 µg/ml Tc, about 1.107 FlpIn Trex MBP cells were washed 
with PBS, trypsinized and resuspended in 6 ml PBS. Cells were pelleted 5 min at 3000 g and resuspended 
in 2.4 ml RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.25 % sodium-deoxycholate, 0.5 
mM EDTA, complete protease inhibitor cocktail EDTA-free (Roche Applied Science, Penzberg, Germany)), 
shortly vortexed and incubated 5 min on ice. Cell debris was removed by a 2 min centrifugation step at 
5000 g, 1 ml-aliquots of cleared lysates were snap-frozen in liquid nitrogen and stored at -80°C.  
Off7 pull-down: RGS(His)6off7 was produced in E. coli as described (Binz, 2004).  All subsequent steps 
were performed at 4°C.  50 µl Ni-NTA magnetic agarose beads (Qiagen, Chatsworth, CA, product 
number: 36111) were incubated for 90 min with 30 µg off7 protein diluted in PBST buffer (PBS, 0.05 % 
Tween 20) or only PBST buffer. Beads were washed 3 times with 0.5 ml PBST buffer and incubated for 1 
h 45 min with cell lysates which had been centrifuged for 10 min at 8000 g after thawing. Beads were 
washed 4 times with PBST buffer and eluted with 60 µl 1 x SDS sample loading buffer-EDTA (62.5 mM 
Tris-HCl pH 6.8, 100 mM EDTA, 7.5% glycerol, 2% SDS, 2.5% 2-mercaptoethanol, bromophenolblue). 
After 5 min at 95°C, eluted fractions were resolved by 15 % SDS-PAGE followed by immunoblotting.  
Biotinylated off7 pull-down: Biotinylated off7 was produced in E. coli using the plasmid pBDoff7. 
Expression and purification of the biotinylated protein were performed as described (Binz, 2004). The 
protocol was identical to the one used for Off7 pull-down, except that 30 µg biotinylated off7 was bound 
to 50 µl magnetic Dynabeads MyOne Streptavidin T1 beads (Invitrogen, San Diego, CA) and the elution 
was performed with SDS sample loading buffer (62.5 mM Tris-HCl pH 6.8, 7.5% glycerol, 2 % SDS, 2.5 % 
2-mercaptoethanol, bromophenolblue). 
Immunoprecipitations 
Lysate preparation: FlpIn Trex emptyV and FlpIn Trex cdc4-off7 cells were grown in three 6 cm-dishes for 
16 h in presence of 1 µg/ml Tc. Two dishes FlpIn Trex cdc4-off7 cells and one dish FlpIn Trex emptyV cells 
were transfected with pcDNA3+_MBP-NYV. 26 h after transfection, MG132 was added at a final 
concentration of 30 µM. 6 h later, cells were washed with PBS and lysed by addition of 1 ml cold 
ProteoJET™ Mammalian Cell Lysis reagent complemented with 10 mM NEM, 50 µM iodoacetamide and 
complete protease inhibitor cocktail EDTA-free (Roche Applied Science, Penzberg, Germany) per dish and 
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a 10 min agitation at 1200 rpm. Lysates were transferred in 1.5 ml-tubes and centrifuged for 15 min at 
18,000 g at 10°C. 900 µl aliquots of cleared lysates were snap-frozen in liquid nitrogen and stored at -
80°C. Total protein was quantified using the BCA assay as described above.  
Immunoprecipitations: All subsequent steps were performed at 4°C. Thawed lysates were centrifuged 
for 5 min at 8000 g. Normalized volumes of supernatant corresponding to approximately 1.9 mg and 1.6 
mg total protein were incubated for 2 h 30 min with 25 µg anti-HA (Sigma-Aldrich, St. Louis, MO, product 
number H 9658) or 10 µg anti-MBP antibody (NEB, Ipswich, MA, product number E8032) pre-captured on 
80 µl Dynabeads® ProtG (Invitrogen, San Diego, CA), respectively. Beads were washed 4 times with 1 ml 
wash buffer (PBS, 10 mM NEM, 50 µM iodoacetamide, complete protease inhibitor cocktail EDTA-free, 
0.05 % Tween 20) and resuspended in 100 µl 1 x SDS sample loading buffer (62.5 mM Tris-HCl pH 6.8, 7.5 
% glycerol, 2 % SDS, 2.5 % 2-mercaptoethanol, bromophenolblue). After 5 min at 95°C, eluted fractions 
were resolved by 10 % and 15 % SDS-PAGE followed by immunoblotting.  
Immunoblotting 
Samples were transferred to PVDF membranes and immunoblotted using standard methods. The anti-HA 
peroxydase conjugate was used at a 1:1000 dilution (Sigma-Aldrich, St. Louis, MO, product number H 
6533) and the anti-MBP HRP Conjugated (NEB, Ipswich, MA, product number E8038) at a 1:2000 dilution. 
The anti-β-actin peroxidase antibody (Sigma-Aldrich, St. Louis, MO, product number A3854) was diluted 
1:15000. The HRP conjugated anti-mono-and polyubiquitinylated conjugates antibody (Enzo Life Sciences 
Inc, Farmingdale, NY, product number: PW0150) was used at a 1:1000 dilution. The anti-skp1 antibody 
(Abcam, Cambridge, UK, product number: ab76502) was diluted 1:1000 and detected with anti-alkaline 
phosphatase-coupled anti-rabbit antibody diluted 1:10,000 (Sigma-Aldrich, St. Louis, MO, product 
number A3687) 
Fluorescence microscopy 
HEK293T cells were seeded on poly-L-lysine-coated glass coverslips (18*18 mm) contained in a 6-well 
culture plate. The next day, cells were transfected with pcDNA3_MBPGFP, pTAG-RFP-off7 or both 
plasmids.  The following day, cells were fixed with 4% (w/v) paraformaldehyde and DAPI stained. Cover 
slides were mounted using Fluoromont G (Brunschwig chemie, B.V., Amsterdam) and sealed after an 
overnight incubation at 4°C. Fluorescence images were acquired using a Lecia Leitz DMXRE microscope 
equipped with a DFC350FX camera. Colors, contrast and brightness were adjusted in Adobe Photoshop 
CS2 (Adobe systems, San Jose, CA). 
 
ELISA 
Lysate preparation: FlpIn Trex emptyV, FlpIn Trex off7 and FlpIn Trex cdc4-off7 cells were grown in a 10 
cm-dishes for 24 h in presence of 1 µg/ml Tc. MG132 was added at a final concentration of 10 µM. 14 h 
later, cells were washed with PBS, trypsinized and resuspended in PBS. Cells were transferred to 1.5 ml-
tubes and pelleted 5 min at 300 g and resuspended in 800 µl cold ProteoJET™ Mammalian Cell Lysis 
reagent complemented with 10 mM NEM, 50 µM iodoacetamide and complete protease inhibitor 
cocktail EDTA-free (Roche Applied Science, Penzberg, Germany). Tubes were agitated for 10 min and 
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centrifuged for 10 min at 20,000 g at 10°C. 750 µl of cleared lysates were snap-frozen in liquid nitrogen 
and stored at -80°C. Total protein was quantified using the BCA assay as described above. 
ELISA: Biotinylated MBP was produced in E. coli and immobilized on neutravidin-coated Maxisorp plates 
(Nunc, Rochester, NY) as described (Binz, 2004). 300 µg, 150 µg or 75 µg total proteins were applied to 
the wells and incubated for 1 h 30 min at 37°C in a final volume of 200 µl using ELISA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 0.2 % BSA, 0.05 % Tween 20). After extensive washing with ELISA buffer, 
binding was detected with the anti-HA antibody (Sigma-Aldrich, St. Louis, MO, product number H 9658) 
diluted 1:3000, followed by the anti-mouse IgG alkaline phosphatase conjugate (Sigma-Aldrich, St. Louis, 
MO, product number A3562) diluted 1:7500. 50 nM off7 protein, purified as described (Binz, 2004), was 
used as positive control. Its binding was detected with the RGS-His antibody (Qiagen, Chatsworth, CA, 
product number: 34610) diluted 1:5000 instead of the anti-HA antibody. Absorbance was read at 405 nm 
at different time points after addition of p-nitrophenylphosphate and incubation at room temperature. 
Each sample was assayed in duplicates. 
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Results 
Degradation of a target protein with different effector proteins 
 
Effector proteins expression and stability 
Three different effector proteins were designed using the DARPin off7 (Fig. 5). Two kinds of ubiquitin 
independent degradation degron sequences, the last 37 residues of mouse ornithine decarboxylase 
(Off7-ODC) or the last 42 residues of the Hantavirus NYV1 G1 protein (Off7-NYV) were appended at its C-
terminus.  Alternatively, the yeast F-box protein cdc4 was chosen as scaffold for the engineering of the 
third effector protein meant to exploit the ubiquitin proteasome pathway. off7 was used to replace its 
original substrate binding domain yielding a chimeric F-box protein, named cdc4-off7 which could 
function like a normal F-box protein in S. cerevisiae (see chapter 1). Finally, naked off7 was used as 
negative control (Off7). For detection purposes, an HA tag was added to the N-terminus of all effector 
proteins, except for cdc4-off7 where it was fused to its C-terminus. The effector proteins were cloned in 
pcDNA3(+) under the CMV promoter and their expression in mammalian cells was tested after transient 
transfection in HEK293T cells. All of them were expressed and could be detected 24 to 48h after 
transfection (Fig. 6). Significant differences could be observed in their steady-state levels.  To our 
surprise, naked off7 level was low while it was reported to be very well expressed in E. coli (Fig. 6A) [38]. 
Off7-ODC level decreased from 24 h to 72 h, suggesting that it was most likely unstable, while Off7-NYV 
level stayed rather constant. Finally, cdc4-off7 was present in small amounts and was the most difficult 
species to detect, an additional band running right below it was also revealed by the anti-HA antibody, 
indicating that cd4-off7 might be degraded (Fig. 6B).  
 
 
 
Figure 5: Schematic diagrams of the effector proteins. Off7-ODC was built by fusing the last 37 residues of mouse ornithine 
decarboxylase (red) to off7 (green) and Off7-NYV by fusing the last 42 residues of the Hantavirus NYV1 G1 protein (purple) to 
off7 (green), these constructs are explained in more detail in chapter 2. Cdc4-off7 was designed on the yeast cdc4 scaffold. Its 
NLS sequence present in the N-terminal part (light blue) was mutated. Its F-box domain was conserved (yellow). The linker 
made of two helices α1 and α2 (orange) was reengineered; part of α2 was replaced with a gly-ser linker (dark blue). Its 
substrate binding domain was deleted and replaced with off7 (green). An HA tag was fused to each effector protein (light 
brown). Cdc4-off7 construct is explained in more detail in chapter 1. 
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Figure 6: Expression of the effector proteins. HEK293T cells were transfected with pcDNA3+_Off7, pcDNA3+_Off7-ODC, 
pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 24, 48h or 72h later, total protein was extracted and samples were subjected to 
SDS-PAGE. Off7 (18 kDa), Off7-ODC (22 kDa), Off7-NYV (23 kDa) and cdc4-off7 (57 kDa) were detected by immunoblotting 
with the anti-HA antibody. The size marker is indicated in kDa. 
The stability of the various effector proteins was then compared under cycloheximide treatment.  All 
species were unstable, but to a different degree (Fig. 7A). Off7 and Off7-ODC disappeared rather quickly 
with a half-life roughly estimated between 30’ and 60’ while off7-NYV turnover was much slower with a 
half-life of 1 to 2 h. Again, cdc4-off7 levels were extremely difficult to monitor and its half-life was also 
evaluated between 30’ and 60’.  In presence of the proteasome inhibitor MG132, all effector proteins 
accumulated, demonstrating that they were processed by the 26S proteasome (Fig. 7A). Off7-ODC and 
Off7-NYV had been both observed to be rapidly degraded in S. cerevisiae, but Off7-NYV unexpectedly 
behaved differently in mammalian cells, it was much more stable.  Surprisingly as well, off7 was 
degraded by the proteasome, while it did not bear any specific known degradation signal. In order to 
confirm these results, a second cycloheximide experiment was performed to better compare the 
stabilities of Off7 and Off7-ODC. Off7-ODC appeared to be slightly more unstable than Off7 with 
respective half-lives estimated to 45’ and 60’ (Fig. 7B).  Off7 was then not further considered as a 
negative control, but rather as a fourth effector protein, potentially able to lead a target protein to the 
proteasome. Off7, Off7-ODC and Off7-NYV were all going to the proteasome with a different rate. cdc4-
off7 was unstable as well like in S. cerevisiae where it had a half-life close from 1 h and degraded via the 
proteasome. F-box proteins are normally unstable and degraded via autoubiquitination which occurs 
within the E3 ligase complex [39]. We hypothesized that the yeast based chimeric F-box protein was 
likely to be degraded via the same process. If it was indeed recognized by the human SCF machinery, it 
could potentially work as an endogenous F-box protein. 
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Figure 7: Stability of the effector proteins in presence of cycloheximide or MG132. A: HEK293T cells were transfected with 
pcDNA3+_Off7, pcDNA3+_Off7-ODC, pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 24 h later, 20 µg/ml cycloheximide was 
added to the cells and samples were withdrawn at the indicated time points. Independently, cells were treated with DMSO or 
30 uM MG132 for 4 h. Total protein was extracted and samples were subjected to SDS-PAGE. The effector proteins were 
detected by immunoblotting with the anti-HA antibody. B: HEK293T cells were transfected with pcDNA3+_Off7 or 
pcDNA3+_Off7-ODC. 24 h later, 20 µg/ml cycloheximide was added to the cells and samples were withdrawn at the indicated 
time points. Total protein was extracted and samples were subjected to SDS-PAGE. The effector proteins were detected by 
immunoblotting with the anti-HA antibody. The actin signal was used as an internal loading control. 
 
Establishment of MBP stable cell line: FLp-In T-Rex MBP 
In order to investigate the effect of different effector proteins on their target protein, a stable cell line 
expressing MBP under tetracycline control was generated using the Flp-In T-REx system (Invitrogen, San 
Diego, CA). A plasmid containing a FRT site and MBP coding sequence under the control of the 
tetracycline-regulated CMV/TetO2 promoter was integrated at a single FRT site in Flp-In T-Rex 293 cells 
via the action of Flp recombinase (Fig. 8). An identical plasmid missing the MBP coding sequence was 
also used to generate a negative control strain (emptyV). The Flp-In T-REx cell line also stably expressed 
the Tet repressor so that addition of tetracycline (Tc) to the medium would derepress the expression of 
the protein of interest. The recombination event should confer hygromycin resistance and zeocin 
sensitivity to the cells and lead to a loss of their β-galactosidase activity. Antibiotic resistance and 
sensitivity enabled screening of the correctly transfected clones (Fig. 9A) which were then further tested 
for expression of MBP in absence or presence of Tc (Fig. 9B). All tested hygromycin-resistant clones were 
also sensitive to zeocin and expressed under Tc only MBP, which could be detected slightly below 40 
kDa. Several additional bands running between 55 and 130 kDa were also recognized by the anti-MBP 
antibody. These species were not MBP-related as they were present in both the empty vector and MBP 
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strains, with and without Tc. As the clones expressed the protein of interest and showed the right 
antibiotic resistance, their β-galactosidase activity was not tested.  
 
 
 
Figure 8: Diagram of the Flp-In TREx system. Adapted from Invitrogen’s manual.  
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Figure 9: Selection of FLp-In T-Rex MBP cell lines. After recombination and growth in the presence of hygromycin, 5 positive 
clones (1,2,3,4 and 5) were tested for their zeocin sensitivity (A) and expression of MBP (B). A: Zeocin sensitivity was assessed 
by looking at the cell viability after 24, 48, 72 h or 1 week in presence of 100 µg/ml zeocin. Example of an isolated clone. B: 
Expression of MBP was induced with 1 µg/ml Tc. After 24 h, total protein was extracted and samples were subjected to SDS-
PAGE. MBP (43 kDa) was detected by immunoblotting with an anti-MBP antibody. The size marker is indicated in kDa. 
 
Off7 and MBP localization and interaction  
Off7 was described to bind MBP in vitro with a strong affinity (KD= 4.4 nM). To make sure that the 
constructs studied here would also be able to interact in vivo, their localization in HEK293T cells was 
monitored by fluorescence microscopy. Off7 was fused to RFP (Fig. 10A) and MBP was fused to GFP(Fig. 
10B). They were both distributed equally throughout the cell and were shown to colocalize (Fig. 10C). 
Off7, Off7-ODC and Off7-NYV only differed at their C terminus and the degron sequence was not 
expected to have any influence on localization. Cdc4, the scaffold F-box protein used for the engineering 
of cdc4-off7, contained a non-functional NLS sequence. This mutated NLS was previously shown to result 
in cdc4 expression in the nucleus and cytoplasm of S.cerevisiae [40], it was expected to behave similarly 
when expressed in mammalian cells. All effector proteins and MBP, the target protein, were predicted to 
be located in the cytoplasm. 
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To test if off7 was still able to recognize MBP expressed in mammalian cells, a pull-down assay was 
performed. RGS(His)6off7 was produced in E. coli and bound to Ni-NTA magnetic beads. In parallel, it was 
in vivo biotinylated and bound to magnetic streptavidin beads. Pre-loaded beads were incubated with 
FLp-In T-Rex MBP cell lysates; in both cases, part of MBP could be specifically pulled down (Fig. 10D,E). 
Two contaminating proteins migrating between 55 and 70 kDa interacted with the Ni-NTA beads but not 
the streptavidin beads. All effector proteins were desiged, so that off7 binding properties would not be 
affected by the presence of a degron or F-box motif, so the effector proteins were predicted to be able 
to interact with MBP as well. Off7-ODC was the only protein which could be easily expressed and purified 
in E. coli, it was observed to bind MBP with a similar affinity to the wt (see chapter 2). 
 
  
 
Figure 10: Off7 and MBP localization and interaction. A: Fluorescence microscopy of HEK293T cells expressing off7-RFP. B:  
Fluorescence microscopy of HEK293T cells expressing MBP-GFP. C: HEK293T cells expressing off7-RFP and MBP-GFP. D: Pull-
down experiment of MBP with off7 bound to Ni-NTA beads. E: Pull-down experiment of MBP with biotinylated off7 bound to 
streptavidin beads. D,E: FlpIn Trex emptyV or FlpIn Trex MBP cells were lysed 24 h after induction with 1 µg/ml Tc. Lysates 
were incubated with Ni-NTA beads preloaded with E. coli-produced off7 (D) or streptavidin beads preloaded with E. coli-
produced biotinylated off7 (E). Samples of FlpIn Trex MBP lysates, FlpIn Trex emptyV eluates and FlpIn Trex MBP eluates 
were subjected to SDS-PAGE and immunoblotted with an anti-MBP antibody. The size marker is indicated in kDa. 
 
Steady-state level of MBP in presence of effector proteins 
To test if one or several of the effector proteins could lead a target protein to degradation, identical 
amounts of FLp-In T-Rex cells stably expressing MBP, were transiently transfected with a plasmid 
encoding under the CMV promoter, Off7, Off7-ODC, Off7-NYV or cdc4-off7. MBP steady-state levels 
were compared by western blot. Several strategies were investigated to test different conditions 
regarding the timing of MBP induction and transient transfection. A first experiment was performed 
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where MBP expression was induced before or after the effector protein transfection. MBP was either 
induced 24 h before and stopped 6 h after transfection (30 h MBP expression) or induced 6 h after 
transfection (18 h MBP expression). 24 h after transfection, MBP steady-state levels were assessed. 
There was no significant difference between the non-transfected cells and the transfected ones but a 
small decrease could be observed when MBP was induced for 18 h only in presence of cdc4-off7 (Fig. 
11).   
 
Figure 11: Steady state level of MBP, expressed under Tet promoter and stably integrated into the chromosome, after 
transient transfection with the effector proteins. A: FLp-In T-Rex MBP cells were induced with 1 µg/ml Tc. 24 h later, they 
were transiently transfected with pcDNA3+_Off7, pcDNA3+_Off7-ODC, pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 6 h later 
after transfection, a medium without Tc was added to the cells to stop inducing MBP expression. Untransfected cells were 
used as negative control (-). B:  FLp-In T-Rex MBP cells were transfected with pcDNA3+_Off7, pcDNA3+_Off7-ODC, 
pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 6 h later, MBP expression was induced with 1 µg/ml Tc. Untransfected cells were 
used as negative control (-) A, B: 24 h after transfection, total protein was extracted and samples normalized before being 
subjected to SDS-PAGE. The levels of MBP were detected by immunoblotting with an anti-MBP antibody. The actin signal was 
used as an internal loading control. 
 
MBP was well expressed and seemed rather stable, and thus a second experiment was conducted on a 
longer time scale. MBP expression was first induced for 24 h, stopped and 6 h later, the cells were 
transfected. 24 h, 39 h and 48 h after transfection, MBP steady-state levels were compared. Despite the 
longer time range, no dramatic difference could be observed except a slight decrease 39 h after 
transfection with cdc4-off7 (Fig. 12).  
 
 
Figure 12: Steady state level of MBP after transient transfection with the effector proteins. FLp-In T-Rex MBP cells were 
treated with 1 µg/ml Tc for 24 h. 6 h later, they were transiently transfected with pcDNA3+_Off7, pcDNA3+_Off7-ODC, 
pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. Untransfected cells were used as negative control (-). 24 h, 39 h and 48 h after 
transfection, total protein was extracted and samples normalized before being subjected to SDS-PAGE. The levels of MBP 
were detected by immunoblotting with an anti-MBP antibody. The actin signal was used as an internal loading control. 
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Finally, the second experiment was repeated with a slightly modified protocol. MBP expression was 
induced for 19 h only and stopped; the transfection was performed 4.5 h later. The non-specific DARPin 
E3_5 (does not recognize MBP) was used as negative control in case the transient transfection would 
have an impact on MBP level.  Similarly to the previous results, MBP level was fainter 24 h after 
transfection with cdc4-off7, but not after 30 h (Fig. 13). To conclude, MBP steady-state level was not 
affected by the presence of Off7, Off7-ODC or Off7-NYV. Even if these effector proteins might efficiently 
go to the proteasome, they did not seem to induce MBP degradation. A faint effect was observed with 
cdc4-off7, but not on a regular basis.  
 
 
Figure 13: Steady state level of MBP after transient transfection with the effector proteins. FLp-In T-Rex MBP cells were 
treated with 1 µg/ml Tc for 19 h. 4 h 30 min later, they were transiently transfected with pcDNA3+_E3_5, pcDNA3+_Off7, 
pcDNA3+_Off7-ODC, pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 24 h and 30 h after transfection, total protein was extracted 
and samples normalized before being subjected to SDS-PAGE. The levels of MBP were detected by immunoblotting with an 
anti-MBP antibody. The actin signal was used as an internal loading control. 
 
MBP-ODC and MBP-NYV, potential alternative substrates to MBP 
In yeast, MBP had already been used as target protein and could be degraded by cdc4-off7 (see chapter 
1). In mammalian cells, its steady-state level was at most slightly affected, and only under certain 
experimental conditions. MBP was perhaps not an appropriate proteasomal substrate when expressed in 
mammalian cells. Its behavior was examined after cycloheximide treatment and it appeared indeed to be 
extremely stable with a half-life superior to 8 h (Fig. 14). It was not degraded by the proteasome, as the 
addition of MG132 did not increase its level. This highly stable molecule was probably reluctant to any 
degradation strategy.  
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Figure 14: MBP stability in the presence of cycloheximide or MG132. HEK293T cells were transfected with pcDNA3(+)_MBP. 
24 h after transfection, 20 µg/ml cycloheximide was added to the cells and samples were taken at the indicated time points. 
Independently, cells were treated with DMSO or 30 uM MG132 for 5 h. Total protein was extracted and normalized samples 
were subjected to SDS-PAGE. MBP levels were detected by immunoblotting with an anti-MBP antibody. The actin signal was 
used as an internal loading control. 
We therefore sought to use another target protein which could still be recognized by off7 but which 
could also be degraded by the proteasome. The ODC and NYV degrons which were previously used to 
construct Off7-ODC and Off7-NYV, were fused to the C-terminus of MBP, yielding MBP-ODC and MBP-
NYV (no HA tag at N-terminus). Their effect on MBP stability was inspected after addition of 
cycloheximide. MBP-ODC was also very stable, with a half-life higher than 8 h, while MBP-NYV had a half-
life close to 2 h and was the only one to accumulate in presence of MG132 (Fig. 15).  Similarly to their 
effect on off7, ODC and NYV degron sequences did not result in the same destabilization of MBP and 
remarkably, their effect seemed to be also dependent on the target protein. Indeed, Off7 was more 
destabilized by the ODC degron for which no effect could be observed on MBP. Instead, MBP was more 
destabilized by the NYV degron which had less an effect on Off7.  
 
 
Figure 15: MBP-ODC and MBP-NYV stability in the presence of cycloheximide or MG132. HEK293T cells were transfected with 
pcDNA3(+)_MBP-ODC or pcDNA3(+)_MBP-NYV. 24 h after transfection, 20 µg/ml cycloheximide was added to the cells and 
samples were taken at the indicated time points. Independently, cells were treated with DMSO or 30 uM MG132 for 5 h. 
Total protein was extracted and normalized samples were subjected to SDS-PAGE. MBP-ODC and MBP-NYV levels were 
detected by immunoblotting with an anti-MBP antibody.  
 
Co-transfection experiments with MBP-NYV 
MBP-NYV seemed to be an appropriate proteasomal substrate, and therefore was used as target protein 
instead of MBP. We aimed to look at its stability in the absence or presence of a specific effector protein. 
No stable cell line was generated with MBP-NYV, but a plasmid encoding MBP-NYV was co-transfected 
with a plasmid encoding E3_5, Off7, Off7-ODC, Off7-NYV or cdc4-off7 in HEK293T cells. 24 h after co-
transfection, cells were treated with cycloheximide and different behaviors were observed.  In the 
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presence of E3_5 (which does not recognize MBP), the negative control, MBP-NYV level rapidly dropped 
within 1 h before reaching a basal level (Fig. 16). This behavior differed somewhat from what had been 
witnessed previously when MBP-NYV was expressed alone and slowly and regularly degraded (Fig. 15).  
With Off7-ODC and Off7, a similar trend to what was described with E3_5, was observed but the reaction 
seemed to be slower and reached a constant level which was higher than the basal one observed wit 
E3_5 (Fig. 16). Both effects were more pronounced for Off7 than Off7-ODC. With Off7-NYV, MBP-NYV did 
not seem to be degraded or very slightly only (Fig. 16). Finally, when MBP-NYV was co-expressed with 
cdc4-off7, a slow regular decrease was observed reaching a final level lower than the basal one observed 
with E3_5 (Fig. 16). It seemed then that different processes were taking place, interfering with MBP-NYV 
own degradation pathway. The effector proteins Off7-ODC and Off7 especially were hampering MBP-
NYV degradation as they were slowing it down and Off7-NYV even inhibited it.  In parallel, the chimeric 
F-box did not inhibit the degradation of MBP-NYV, in fact when comparing with the effect of E3_5, cdc4-
off7 seemed to bring it to completion. After 4 h 30 min, MBP-NYV level in the presence of cdc4-off7 was 
indeed lower than in the presence of E3_5. MBP-NYV stability pattern was also different when it was co-
expressed with cdc4-off7. This slow regular decrease was very close to what could be observed in yeast 
when MBP was degraded by the action of cdc4-off7 and the ubiquitin proteasome pathway (see chapter 
1).  
 
 
Figure 16: Stability of MBP-NYV in the presence of all effector proteins. HEK293T cells were co-transfected with a 1:2 ratio of 
pcDNA3(+)_MBP-NYV and pcDNA3+_E3_5, pcDNA3+_Off7, pcDNA3+_Off7-ODC, pcDNA3+_Off7-NYV or pcDNA3+_cdc4-off7. 
24 h after transfection, 20 µg/ml cycloheximide was added to the cells and samples were taken at the indicated time points. 
Total protein was extracted and normalized samples were subjected to SDS-PAGE. MBP-NYV levels were detected by 
immunoblotting with an anti-MBP antibody. The actin signal was used as an internal loading control. 
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A second experiment was conducted but with E3_5, Off7 and cdc4-off7 only. MBP-NYV stability could 
not be nicely followed like in the first co-transfection experiment, but similar results were obtained (Fig. 
17). With E3_5, the negative control, MBP-NYV stayed at a constant low level. With off7, it was slowly 
decreasing and with cdc4-off7, it was so quickly disappearing that it was almost impossible to monitor.   
These co-transfection experiments results led us to think that cdc4-off7 was not inhibiting the degron-
dependent degradation pathway but more importantly, could be mediating MBP-NYV degradation via 
another mechanism, possibly the ubiquitin proteasome pathway.  
 
 
Figure 17: Stability of MBP-NYV in presence of E3_5, off7 or cdc4-off7. HEK293T cells were co-transfected with a 1:2 ratio of 
pcDNA3(+)_MBP-NYV and pcDNA3+_E3_5, pcDNA3+_Off7 or pcDNA3+_cdc4-off7. 24 h after transfection, 20 µg/ml 
cycloheximide was added to the cells and samples were taken at the indicated time points. Total protein was extracted and 
normalized samples were subjected to SDS-PAGE. MBP-NYV levels were detected by immunoblotting with an anti-MBP 
antibody. The actin signal was used as an internal loading control. 
 
Degradation of a target protein with a chimeric F-box protein 
 
Establishment of chimeric F-box proteins stable cell lines 
In order to better assess if chimeric F-box proteins could really degrade a target protein via the ubiquitin 
proteasome pathwayin mammalian cells, stable cell lines expressing the chimeric F-box protein cdc4-off7 
or cdc4-E3_5 were generated using the Flp-In T-REx system (Fig. 18). Cdc4-E3_5 was designed identically 
to cdc4-off7, the non-selected DARPin E3_5 was used instead of off7, to replace cdc4 original substrate 
binding domain. cdc4-off7 and cdc4-E3_5 coding sequences were integrated in the genome of the Flp-In 
T-Rex cells, yielding the FLp-In T-Rex cdc4-off7 and FLp-In T-Rex cdc4-E3_5 cells, respectively. In addition 
to the non-specific chimeric F–box protein cell line, two other ones were generated as negative controls. 
The first one contains off7, the naked DARPin, which cannot interact with the SCF machinery without any 
F-box domain (FLp-In T-Rex off7) (Fig. 18). The second one was constructed with the same plasmid as for 
the other ones but without any coding sequence (FLp-In T-Rex EmptyV). Selected clones which were 
hygromycin resistant, zeocin sensitive and lacking their β–galactosidase activity, were induced with Tc. 
All tested clones expressed the protein of interest (Fig. 19). Different expression levels were observed 
depending on the construct, cdc4-E3_5 was relatively well expressed, closely followed by cdc4-off7 while 
off7 was barely detectable.  The low level of off7 expression was consistently observed. Remarkably, FLp-
In T-Rex off7 grew also more slowly than the other stable cell lines. Phenotypically, FLp-In T-Rex cdc4-
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off7, FLp-In T-Rex cdc4-E3_5 and FLp-In T-Rex off7 were not spreading on the surface as homogeneously 
as the FLp-In T-Rex EmptyV cells and they tended to stack on the top of each other. This observation was 
made in the absence or presence of Tc.  
 
 
Figure 18: Schematic diagrams of the chimeric F-box proteins used to generate stable cell lines. cdc4-off7 and cdc4-E3_5 were 
designed on the cdc4 scaffold. Its NLS sequence present in the N-terminal part (light blue) was mutated. Its F-box domain was 
conserved (yellow). The linker made of two helices α1 and α2 (orange) was reengineered; part of α2 was replaced with a gly-
ser linker (dark blue). Its substrate binding domain was deleted and replaced with off7 or E3_5. An HA tag was fused to their 
C-terminus (brown). Off7 with an HA tag at its N-terminus was used to generate the control FLp-In T-Rex off7 cell line.  
 
 
Figure 19: Expression test for the stable cell lines FLp-In T-Rex off7, FLp-In T-Rex cdc4-E3_5 and FLp-In T-Rex cdc4-off7. 
Expression was induced with 1 µg/ml Tc. After 24 h, total protein was extracted and normalized samples were subjected to 
SDS-PAGE. Off7 (18.2 kDa), cdc4-E3_5 (56.6 kDa) and cdc4-off7 (56.8 kDa) were detected by immunoblotting with the anti-HA 
antibody. The size marker is indicated in kDa. 
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MBP steady-state level and stability in chimeric F-box proteins stable cell lines 
MBP was cloned, without any additional tag, in pcDNA3(+) under the CMV promoter and transiently 
transfected in FLp-In T-Rex cdc4-off7, FLp-In T-Rex cdc4-E3_5, FLp-In T-Rex off7 and FLp-In T-Rex emptyV 
cells. 15 to 22 h after transfection, Tc was added to the cells to induce the expression of cdc4-off7, cdc4-
E3_5 or off7. MBP steady state levels were monitored after 24 h and 32 h of Tc treatment. The relative 
amount of MBP varied from strain to strain, resulting from different transfection efficiencies (Fig. 20). All 
cell lines could not be transfected using the same conditions as they grew differently. FLp-In T-Rex cdc4-
E3_5 and FLp-In T-Rex cdc4-off7 cells were transfected with Lipofectamine and 1.5 µg DNA while FLp-In 
T-Rex off7 and FLp-In T-Rex emptyV cells were transfected 7 h later with Fugene and 1 µg DNA. For each 
assay, the optimal transfection method was chosen according to the cells confluency and was always 
constant within a group of samples: emptyV and Off7 cell lines formed one group and cdc4-E3_5 and 
cdc4-off7 the second one. A comparison of MBP steady-state levels in between different cell lines was 
then not possible but only within each cell line, in absence or presence of Tc. No distinction could be 
made in absence or presence of Tc in any of the cell lines. MBP steady-state level was not affected by the 
co-expression of the chimeric F-box protein cdc4-off7.  
 
 
Figure 20: Steady state level of MBP, expressed under CMV promoter on pcDNA 3(+), after transient transfection in FLp-In T-
Rex emptyV,  FLp-In T-Rex off7,  FLp-In T-Rex cdc4-E3_5 or FLp-In T-Rex cdc4-off7 stable cell lines. FLp-In T-Rex cdc4-E3_5 and 
FLp-In T-Rex cdc4-off7 cells were transfected with lipofectamine and 1.5 µg pcDNA3(+)_MBP. 7h later, FLp-In T-Rex emptyV 
and  FLp-In T-Rex off7 cells were transfected with Fugene and 1 µg pcDNA3(+)_MBP. 15 h later, Tc was added to all cells to 
induce expression of Off7, cdc4-E3_5 and cdc4-off7. After 24 h or 32 h of Tc treatment, total protein was extracted and 
samples normalized before being subjected to SDS-PAGE. The levels of MBP were detected by immunoblotting with an anti-
MBP antibody. The actin signal was used as an internal loading control.  N.B: Tc concentration in the medium was readjusted 
to a final concentration of 1 µg/ml after 24 h for samples which were withdrawn after 32 h.  
 
 MBP stability was then examined in in FLp-In T-Rex cdc4-off7, FLp-In T-Rex cdc4-E3_5, FLp-In T-Rex off7 
and FLp-In T-Rex emptyV cells. 16 h after transient transfection, Tc was added to the cells to induce the 
expression of cdc4-off7, cdc4-E3_5 or Off7. After a 24 h Tc treatment, cells were subjected to 
cycloheximide and MBP levels followed. In all cases, MBP level stayed constant during the whole 
experiment (Fig. 21). MBP half-life was higher than 8 h in every cell line. Similar to the previous 
experiment, relative amounts of MBP varied from strain to strain as different transfection methods were 
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used. Only cdc4-off7 cells were transfected with another method. They received 1.5 µg DNA while 1 µg 
was transfected in the other cell lines.  This might explain why the amount of MBP was higher in these 
cells. In this second experimental set-up, MBP was not destabilized by cdc4-off7, either. 
 
 
Figure 21: MBP stability in FLp-In T-Rex emptyV, FLp-In T-Rex off7, FLp-In T-Rex cdc4-E3_5 or FLp-In T-Rex cdc4-off7 cells. FLp-
In T-Rex cdc4-off7 cells were transfected with lipofectamine and 1.5 µg pcDNA3(+)_MBP. 6 h later, FLp-In T-Rex emptyV , FLp-
In T-Rex off7 and FLp-In T-Rex cdc4-E3_5 were transfected with Fugene and 1 µg pcDNA3(+)_MBP. 16 h later, 1 µg/ml Tc was 
added to all cells to induce expression of Off7, cdc4-E3_5 and cdc4-off7. After 24 h of Tc treatment, 20 µg/ml cycloheximide 
was added to the cells and samples were taken at the indicated time points. Total protein was extracted and normalized 
samples were subjected to SDS-PAGE. MBP levels were detected by immunoblotting with an anti-MBP antibody. The actin 
signal was used as an internal loading control. 
 
MBP-NYV steady-state level in stable cell lines expressing chimeric F-box 
proteins 
When MBP-NYV was co-transfected with cdc4-off7, it seemed to be degraded via another process (Fig. 
16). To double check this observation and compare with the observations made above with MBP, 
additional experiments were conducted in the established chimeric F-box proteins stable cell lines, using 
MBP-NYV as substrate. First, the MBP-NYV steady-state level was compared after transient transfection, 
under the same experimental conditions than for MBP. Within each strain, no difference was observed in 
the absence or presence of Tc. Surprisingly, MBP-NYV steady-state level did not seem to be affected by 
the co-expression of the chimeric F-box protein cdc4-off7 (Fig. 22).  
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Figure 22: Steady state level of MBP-NYV after transient transfection in FLp-In T-Rex emptyV, FLp-In T-Rex off7,  FLp-In T-Rex 
cdc4-E3_5 or FLp-In T-Rex cdc4-off7 cell lines. FLp-In T-Rex cdc4-E3_5 and FLp-In T-Rex cdc4-off7 were transfected with 
lipofectamine and 1.5 µg pcDNA3(+)_MBP-NYV. 7 h later, FLp-In T-Rex emptyV and FLp-In T-Rex off7 were transfected with 
Fugene and 1 µg pcDNA3(+)_MBP_NYV. 15 h later, Tc was added to all cells to induce expression of Off7, cdc4-E3_5 and cdc4-
off7. After 24 h and 32 h of Tc treatment, total protein was extracted and samples normalized before being subjected to SDS-
PAGE. The levels of MBP-NYV were detected by immunoblotting with an anti-MBP antibody. The actin signal was used as an 
internal loading control.  N.B: Tc concentration in the medium was readjusted to a final concentration of 1 µg/ml after 24 h 
for samples which were withdrawn after 32 h.  
 
Different transfection protocols were then tested to check if cdc4-off7 could have an effect on MBP-NYV 
steady-state levels under different conditions. First,  FLp-In T-Rex cdc4-off7 and FLp-In T-Rex cdc4-E3_5 
cells were calcium phosphate-transfected with a varying amount of pcDNA3(+)_MBP-NYV, 1, 1.5 or 2 µg 
DNA. 6 h after transfection, a fresh medium containing Tc was added to the cells. MBP-NYV steady-state 
levels were monitored after 24 h, 41 h or 48 h of Tc treatment. Despite lowering the amount of MBP-
NYV, no differences could be seen in the steady-state levels between the absence or presence of Tc (Fig. 
23). 
  
Figure 23: Steady state level of MBP-NYV after calcium phosphate transient transfection in FLp-In T-Rex cdc4-E3_5 or FLp-In T-
Rex cdc4-off7 cells with varying amount of DNA. Cells were transfected with 1, 1.5 or 2 µg pcDNA3(+)_MBP-NYV. 6 h after 
transfection, Tc was added to the cells to induce expression of cdc4-E3_5 and cdc4-off7. After 24 h, 41 h or 48 h of Tc 
treatment, total protein was extracted and samples normalized before being subjected to SDS-PAGE. The levels of MBP-NYV 
were detected by immunoblotting with an anti-MBP antibody. The actin signal was used as an internal loading control.  N.B: 
Tc concentration in the medium was readjusted to a final concentration of 1 µg/ml after 24 h for samples which were 
withdrawn after 41 h and 48 h.  
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Another protocol consisted of performing the transfection with cells in solution instead of immobilized 
on a cell culture plate. The different cell lines were not growing at the same speed and not spreading 
properly on the surface, and therefore it was difficult to carry out transfections under the same 
conditions and even sometimes within the same cell line. To limit variability, the same number of FLp-In 
T-Rex cdc4-off7 and FLp-In T-Rex cdc4-E3_5 cells were simultaneously transfected and seeded on a cell 
culture plate. 16 h later, Tc was added and 24 h after induction of chimeric F-box proteins expression, 
the MBP-NYV steady-state level was monitored (Fig. 24A). No difference was detected between the 
absence or presence of Tc for both cell lines. In spite of carrying out the transfection with the same 
number of cells, MBP level was still not identical in both FLp-In T-Rex cdc4-off7 and FLp-In T-Rex cdc4-
E3_5 cells. A better normalization of the cell number used for transfection was achieved with this 
protocol, but cells did not adhere very well, they were probably disturbed by the transfection process. A 
second transfection experiment was performed similarly but using 0.1 % Fibronectin pre-coated cell 
culture plates. Cells did easily adhere after seeding and were better distributed on the surface. Again, 
the MBP-NYV steady-state level was unaltered in the presence of Tc and despite all efforts; the level of 
MBP-NYV was still not identical between the two strains (Fig. 24B). 
 
 
Figure 24: Steady state level of MBP-NYV in FLp-In T-Rex cdc4-E3_5 or FLp-In T-Rex cdc4-off7 cells after transient transfection 
in solution. Cells were simultaneously seeded and transfected with lipofectamine and 1.5 µg pcDNA3(+)_MBP-NYV. 16 h later, 
Tc was added to the cells to induce expression of cdc4-E3_5 and cdc4-off7. After 24 h of Tc treatment, total protein was 
extracted and samples normalized before being subjected to SDS-PAGE. The levels of MBP-NYV were detected by 
immunoblotting with an anti-MBP antibody. The actin signal was used as an internal loading control. A: Cells were seeded on 
normal culture plates. B:  Culture plates were first pre-coated with 0.1 % fibronectin for 2 h at 37°C. 
 
MBP-NYV stability in stable cell lines expressing chimeric F-box proteins 
Several conditions were tested and MBP-NYV steady-state was definitely not affected by the presence of 
cdc4-off7, but could its turnover be altered? MBP-NYV stability was examined in FLp-In T-Rex cdc4-off7, 
FLp-In T-Rex cdc4-E3_5, FLp-In T-Rex off7 and FLp-In T-Rex emptyV cells in the absence or presence of Tc. 
12 h to 17 h after transient transfection with pcDNA3(+)_MBP-NYV, Tc was added to the cells. After 24 h 
Tc treatment, cells were treated with cycloheximide and MBP-NYV levels were followed. In FLp-In T-Rex 
emptyV and FLp-In T-Rex cdc4-E3_5 cells, no difference could be observed between the absence and the 
presence of Tc (Fig. 25). In FLp-In T-Rex off7 and FLp-In T-Rex cdc4-off7 cells, MBP-NYV degradation was 
slowed down and barely taking place in the presence of Tc. These results correlated with what had been 
previously seen for off7 in the co-transfection experiments but not with what had been observed for 
cdc4-off7 (Fig. 16 & 17). In the co-transfection experiments, MBP-NYV was still turned over in the 
presence of cdc4-off7, at a lower rate, but it was degraded within the same experimental time frame. In 
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the latter experiment, cdc4-off7 had the same effect than off7. The second experimental set-up proved 
that cdc4-off7 was interfering with MBP-NYV own degradation pathway but did not reveal how. 
 
 
Figure 25: MBP-NYV stability in FLp-In T-Rex emptyV, FLp-In T-Rex off7, FLp-In T-Rex cdc4-E3_5 or FLp-In T-Rex cdc4-off7 cells. 
FLp-In T-Rex emptyV and FLp-In T-Rex off7 cells were transfected with Fugene and 1 µg pcDNA3(+)_MBP_NYV. 5 h later, FLp-
In T-Rex cdc4-E3_5 and FLp-In T-Rex cdc4-off7 were transfected with calcium phosphate and 1.8 µg pcDNA3(+)_MBP_NYV. 12 
h later, 1 µg/ml Tc was added to all cells to induce expression of Off7, cdc4-E3_5 and cdc4-off7. After 24 h Tc treatment, 20 
µg/ml cycloheximide was added to the cells and samples were taken at the indicated time points. Total protein was extracted 
and normalized samples were subjected to SDS-PAGE. MBP-NYV levels were detected by immunoblotting with an anti-MBP 
antibody. The actin signal was used as an internal loading control. 
 
Immunoprecipitation of cdc4-off7 and MBP-NYV 
To investigate if cdc4-off7 was redirecting MBP-NYV to the ubiquitin proteasome pathway, we looked for 
ubiquitylated forms of it. MBP-NYV was transfected in FLp-In T-Rex cdc4-off7 and FLp-In T-Rex emptyV 
cells, it was immunoprecipitated using the anti-MBP antibody.  No additional species of higher molecular 
weight could be detected (Fig. 26A).  When the eluates were probed with the anti-ubiquitin antibody, a 
smear appeared but both in absence and presence of cdc4-off7, and therefore it did not correspond to 
ubiquityled forms of MBP-NYV, but probably to other ubiquitylated proteins, possibly interacting with 
MBP-NYV (Fig. 26C). The experiment was repeated with cell lysates containing MBP instead of MBP-NYV, 
but ubiquitylated species were not detected either and the smear observed with MBP-NYV was not 
present any more (data not shown). The chimeric F-box protein (56.8 kDa), running below 70 kDa, co-
eluted with MBP-NYV (47 kDa), proving that they were interacting in vivo (Fig. 26B). Strangely, when 
cdc4-off7 was immunoprecipitated with the anti-HA antibody, it did not co-precipitate MBP-NYV (Fig. 
26B). When the experiment was repeated with cell lysates containing MBP instead of MBP-NYV, identical 
results were obtained (data not shown). Cdc4-off7 was present in MBP immunoprecipitation eluate but 
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MBP was not detected in cdc4-off7 immunoprecipitation samples. F-box proteins are normally 
autoubiquitinated but no ubiquitylated forms of cdc4-off7 could be detected with the anti-HA or anti-
ubiquitin antibodies (Fig. 26B,C). 
 
 
Figure 5. Immunoprecipitations of MBP-NYV and cdc4-off7. MBP-NYV was transfected in FLp-In T-Rex emptyV and FLp-In T-
Rex cdc4-off7 cells which were cultured in the presence of 1 µg/ml Tc. 24 h after transfection, cells were treated with 30 uM 
MG132 for 6 h. After cell lysis, MBP-NYV (47 kDa) was immunoprecipitated with an anti-MBP antibody and cdc4-off7 (56 kDa) 
with an anti-HA antibody. The eluted fractions were detected with an anti-MBP antibody (A), the anti-HA antibody (B) and 
the anti-ubiquitin antibody (C). The size marker is indicated in kDa. 
 
Remarkably, the in vivo interaction of MBP-NYV and cdc4-off7 could be observed in only one direction by 
immunoprecipitation. Cdc4-off7 co-eluted with MBP-NYV, but when cdc4-off7 was pulled down, MBP-
NYV could not be detected. Identical results were obtained with MBP. To make sure that cdc4-off7 was 
not unspecifically pulled-down with MBP-NYV (or MBP) which was present in higher amount, its binding 
properties were checked by ELISA. MBP was produced in E. coli and immobilized.  Lysates from FLp-In T-
Rex off7, FLp-In T-Rex cdc4-off7 and FLp-In T-Rex emptyV cells were incubated for 1 h 30 min at 37°C. 
FLp-In T-Rex off7 lysate gave a huge signal, which was quickly saturated, confirming that off7 could 
readily bind to MBP (Fig. 27). FLp-In T-Rex cdc4-off7 lysate gave a more moderate but constantly 
increasing signal; after 90 min of development, it was 5-fold higher than the one obtained with FLp-In T-
Rex emptyV cells. cdc4-off7 could thus, when produced in  FLp-In T-Rex HEK293 cells, bind to E. coli 
produced MBP. Its binding strength seemed lower than off7’s one but it might have been more affected 
by the incubation at 37°C than off7 alone which is very stable in vitro. In addition, cdc4-off7 structural 
integrity and/or binding capacities were also altered by the buffer used for cell lysis as 100 µl lysate 
sample mixed with 100 µl ELISA buffer or 50 µl lysate sample mixed with 150 µl ELISA buffer gave a 
stronger signal than a 200 µl lysate sample. The effect was not so pronounced for off7. ELISA results 
confirmed that cdc4-off7 had the capacity to bind MBP and led us to think that an experimental artifact 
was preventing us to detect their in vivo interaction by cdc4-off7 immunoprecipitation. 
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Figure 27: ELISA with FLp-In T-Rex emptyV, FLp-In T-Rex off7 and FLp-In T-Rex cdc4-off7 crude cells lysates.  Biotinylated MBP 
was immobilized on neutravidin pre-coated plates. 300 µg (200 µl crude cell lysate), 150 µg (100 µl crude cell lysate) or 75 µg 
(50 µl crude cell lysate) total protein was incubated for 1 h 30 min at 37°C in a final volume of 200 µl using TBS + 0.2 % BSA + 
0.05 % Tween-20. The anti-HA antibody was used for detection followed by an alkaline phosphatase conjugated anti-mouse 
antibody. Each sample was assayed in duplicates. 50 nM purified off7 was used as positive control with the antiRGSHis4 Ab 
instead of the anti-HA one.  
 
In vivo interaction of cdc4-off7 and SCF E3 ligase  
According to the immunoprecipitations results, cdc4-off7 was interacting with the target protein but 
none of them could be detected in an ubiquitylated form. Its interaction with human skp1, the adaptor 
subunit of the SCF complex, was tested by a second immunoprecipitation assay. MBP was transfected in 
FLp-In T-Rex emptyV and FLp-In T-Rex cdc4-off7 cells. MBP and cdc4-off7 were pulled down using the 
anti-MBP and the anti-HA antibodies as respective baits and their eluates were probed with an anti-skp1 
antibody.  While skp1 (18 kDa) was easily detected in Flp-In T-Rex cdc4-off7 crude cells lysate, it was not 
present after immunoprecipitation of cdc4-off7 or MBP (Fig. 28). The only visible protein in the elution 
samples was the light chain of the antibody used for immunoprecipitation, which cross-reacted with the 
secondary Ab used for detection. No physical interaction could thus be observed in vivo between cdc4-
off7 and skp1. According to these results, the chimeric F-box protein, containing a yeast F-box motif, was 
not recognized by the mammalian SCF machinery.  However, co-immunoprecipitation seemed to be 
problematic under these conditions with cdc4-off7, e.g. it could not co-immunoprecipitate MBP, a highly 
expressed binding partner. Therefore the pull-down of endogenous skp1 could have been even more 
problematic. The ELISA also showed that the lysis buffer used for immunoprecipitation was probably not 
optimal for looking at cdc4-off7 interactions. Under these conditions, it was difficult to exclude the 
possibility that cdc4-off7 might still associate with the mammalian SCF complex. Nonetheless, we have 
found no direct evidence for it.  
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Figure 28: Skp1 interaction. MBP was transfected in FLp-In T-Rex emptyV and FLp-In T-Rex cdc4-off7 cells which were cultured 
in the presence of 1 µg/ml Tc. 24 h after transfection, cells were treated with 10 uM MG132 for 6 h. After cell lysis, MBP was 
immunoprecipitated with an anti-MBP antibody and cdc4-off7 with an anti-HA antibody.  FLp-In T-Rex cdc4-off7 crude lysate 
and all eluted fractions were detected with the anti-skp1 antibody. The size marker is indicated in kDa. Skp1 MW= 18 kDa. 
 
Chimeric F-box protein stability in presence of MBP or MBP-NYV 
F-box proteins were described as short-lived proteins which can catalyze their own degradation by 
autoubiquitylation [39]. cdc4-off7 was indeed very unstable in yeast and it behaved similarly in 
mammalian cells (Fig. 7). We considered the possibility that this chimeric F-box protein, engineered from 
a yeast F-box protein scaffold, might be functional as a F-box protein and interact with the host SCF 
ubiquitin ligase. We could not verify this hypothesis by detecting ubiquitylated forms of cdc4-off7, nor by 
verifying an interaction with skp1. We used a last approach to test if cdc4-off7 was protected from 
degradation by the presence of MBP or MBP-NYV. When cdc4-off7 was expressed in yeast as a functional 
F-box protein, the presence of the target protein MBP protected it from degradation and extended its 
half-life. cdc4-off7 was interacting with MBP-NYV and MBP in yeast and most likely in mammalian cells 
as well, even though the pull-down experiments worked only in one direction. Therefore we looked at 
the effect of MBP and MBP-NYV on cdc4-off7 stability. FLp-In T-Rex cdc4-off7 cells were grown in the 
presence of Tc and transiently transfected with pcDNA3+_MBP or pcDNA3+_MBPNYV. 24 h later, 
cycloheximide was added to the cultures and cdc4-off7 levels were monitored. In all cases, the chimeric 
F-box protein was very unstable with a half-life higher than 1 h (Fig. 29). The presence of MBP-NYV did 
not alter cdc4-off7 stability, nor did the more stable MBP. If cdc4-off7 had functionally recruited MBP or 
MBP-NYV as substrate, they would have interfered with its own degradation, but this was not the case. 
These results indicated that cdc4-off7 degradation process was not affected by the presence of a stable 
binding partner and was very likely independent of the SCF machinery.  
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Figure 29: Stability of cdc4-off7 in the absence or presence of MBP and MBP-NYV. FLp-In T-Rex cdc4-off7 cells were cultured 
in presence of 1 µg/ml Tc. 24 h after transefction with pcDNA3(+)_MBP_NYV or pcDNA3(+)_MBP, 20 µg/ml cycloheximide 
was added to the cells and samples were taken at the indicated time points. Total protein was extracted and normalized 
samples were subjected to SDS-PAGE. cdc4-off7 levels were detected by immunoblotting with the anti-HA antibody. The actin 
signal was used as an internal loading control. 
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Discussion 
 
Two different strategies were tested to lead a specific target protein for degradation by the 26S 
proteasome. One relied on the ubiquitin-free route which is employed by the mammalian ornithine 
decarboxylase and the G1 glycoprotein of the NY-1 hantavirus. The other one was chosen to exploit the 
ubiquitin proteasome pathway using a chimeric F-box protein. The DARPin off7 was used as scaffold for 
the engineering of all effector proteins meant to mediate the degradation of its binding partner: Maltose 
Binding Protein (MBP), in an ubiquitin-independent or -dependent way. 
Mouse ornithine decarboxylase and G1 glycoprotein of the NY-1 hantavirus harbor each a specific 
sequence, which is recognized by the 26S proteasome, that we, respectively, named the ODC- and NYV-
degron in our study [41, 42]. When any of these degrons was appended to the C-terminus of several 
proteins expressed in S. cerevisiae, they provoked their fast degradation by the yeast proteasome (see 
Chapter 2). These degron sequences had however variable effects when fused to proteins expressed in 
mammalian cells. Off7-ODC was unstable with a half-life of 45 min which was longer compared to the 15 
min observed in yeast. MBP-ODC was as stable as MBP, for at least 8 h while it was wholly degraded in 
yeast. Off7-NYV and MBP-NYV were both degraded with a similar half-life between 1 and 2 h. The ODC- 
and NYV-degron did not similarly affect proteins stabilities, depending on the protein sequence they 
were appended to and depending on the expression system. In general, both degrons were less 
proficient in mammalian cells. Degron-fused proteins were so rapidly degraded when expressed in yeast 
that their half-life could be barely determined. In HEK293T cells, the ODC degron could not even 
destabilize MBP anymore. It should be noted that an additional HA tag was present for both MBP-ODC 
and MBP-NYV expressed in yeast but it was fused at their N-terminus and it should not have promoted 
or enhanced degradation. It was indeed observed that the proteasome initiated degradation of mouse 
ornithine decarboxylase at its C-terminus, where its degron sequence is located, and it is likely that it did 
so for our ODC-degron constructs too [43]. It is difficult to speculate what could explain the differences 
observed between yeast and mammalian cells. It could be that the degron sequences were not handled 
identically in both systems; they could be differently recognized by the yeast and human proteasomes 
and/or associated factors. Additional checkpoints could exist in mammalian cells for these degron 
sequences which were identified in proteins normally expressed in mouse (mouse ornithine 
decarboxylase) or in all rodents and occasionally humans (NY-1 hantavirus hosts). Alternatively, degron 
recognition could take place at different time points after their synthesis, depending on the host system. 
It has indeed been demonstrated that ornithine decarboxylase is mostly degraded before it completes 
folding and that “mature proteins” could still turnover but to a lower extent [44, 45]. It is possible than in 
yeast, degron sequences were mostly recognized while or shortly after the proteins were synthesized 
and they could be efficiently degraded before they terminated folding and that in mammalian cells, the 
degron sequences were recognized at a later stage when proteins were more and more or completely 
folded and had become more strenuous substrates for the proteasome. Another striking difference was 
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Figure 30: Schematic representation of model 1. Model 1 assumes that the effector proteins Off7-ODC, Off7 and Off7-NYV 
have decreasing affinity for the proteasome, respectively and considers that there is only the rate by which the complex is 
going to the proteasome, which matters. If MBP-NYV was brought to the proteasome via the action of the co-expressed 
effector protein (left side), the degradation rate would decrease in this order 1, 2, 3 and 4. If the complex was brought to the 
proteasome at MBP-NYV normal own rate (right side), no difference would be seen and MBP-NYV degradation rate would be 
identical between all combinations. 
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observed between the yeast and mammalian systems. The DARPin off7 was described as a highly 
expressed and stable protein when produced in E. coli [38]. A similar behavior was observed when it was 
expressed in S. cerevisiae (see chapter 2) but in HEK293T cells, its steady-state level was low, as it 
appeared to be degraded by the proteasome. In spite of the absence of any degron sequence, it was only 
slightly more stable than off7-ODC (t1/2 ~ 1h). An incorrect folding of off7 in mammalian cells was unlikely 
and could be excluded, as its binding properties were conserved when an ELISA was performed with 
crude cell lysates. Upon multiple molecular dynamics simulation, the C-terminal cap of DARPins was 
observed to denature first [46]. Several mutations aiming at increasing the stability of the C-cap were 
predicted in silico and validated experimentally in vitro. The mutated C-cap also enhanced off7 steady-
state level in HEK293T cells and increased its stability (data not shown). In addition, the non-selected full 
consensus DARPin N3C, whose stability was far exceeding that of the most favorable selected DARPins 
[46], was highly expressed in HEK293T cells and stable (data not shown). It seemed thus that in 
mammalian cells, there was an active recognition of a detachable C-terminal sequence, independent of 
the overall high stability of a protein. It is possible that the sequence features recognized differ between 
mammalian cells and yeast. 
Off7, Off7-ODC and Off7-NYV were all proteasomally degraded but at different rates so we sought to 
investigate if these constructs could induce the degradation of a cognate target protein. When MBP was 
co-expressed with any of them, its steady-state level was not affected. However, MBP appeared to be 
extremely stable in HEK293T cells, with a half-life higher than 8 h, while a half-life of about 3 h was 
observed in S. cerevisiae (see Chapter 1). This difference correlated with the observation that MBP-ODC 
could be readily degraded in yeast but not in HEK293T cells. MBP could however be partially destabilized 
by the NYV-degron. As MBP-NYV was witnessed as a functional proteasome substrate and had a half-life 
higher than those of the effector proteins (Off7, Off7-ODC and Off7-NYV), it was used as an alternative 
target protein. Upon co-transfection experiments, MBP-NYV stability was monitored in the presence of 
each effector protein (Fig. 16). With Off7 and Off7-ODC turnover being faster than that of MBP-NYV, it 
was postulated that, if MBP-NYV was recruited to the proteasome, it would be degraded more rapidly 
than normally. However, none of them accelerated the degradation of MBP-NYV, instead they slowed it 
down. The effect was even more pronounced with Off7-NYV, which almost prevented MBP-NYV 
degradation.  
Off7, Off7-ODC and Off7-NYV were apparently interfering with the MBP-NYV degradation pathway. 
Several alternative models can be formulated, assuming that a complex could be formed between the 
effector protein and MBP-NYV, as none of them was extremely quickly degraded by the proteasome 
when expressed alone.  
Model 1 assumes that the different effector proteins (Off7, Off7-ODC and Off7-NYV) degradation rates 
are due to differences in their affinity for the proteasome, and considers that the only matter is the rate 
by which the complex is going to the proteasome (Fig. 30). If MBP-NYV was brought to the proteasome 
via the action of the co-expressed effector protein, it would be expected to turnover at a similar rate 
than the effector protein itself and thus faster than alone. It would be in agreement with the continuous 
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Figure 31: Schematic representation of model 2. Model 2 assumes that all effector proteins, Off7-ODC, Off7and Off7-NYV 
have the same affinity for the proteasome and that their degradation rates (Off7-ODC ≥ Off7 ≥ Off7-NYV) are due to 
differences in their unfolding efficiency by the proteasome. Model 2 considers that the proteasome degrades the complex, 
formed by the effector protein and the bound MBP-NYV, but that the unfolding of the effector protein slows down MBP-NYV 
processing. In this case, MBP-NYV degradation rate would decrease in presence of an effector protein, following the order 1, 
2, 3 and 4. 
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decreasing degradation rates of MBP-NYV, observed in presence of off7-ODC, off7 and off7-NYV, 
respectively. However MBP-NYV was degraded faster when it was co-expressed with the negative 
control: E3_5, the non-specific DARPin. In this case, the degradation was not accelerated by the presence 
of a specific effector protein. If the complex was brought to the proteasome at MBP-NYV normal own 
rate, no difference would be seen between all combinations and this was not the case either.  
Model 2 assumes that the different effector proteins (Off7, Off7-ODC and Off7-NYV) have the same 
affinity for the proteasome and that their degradation rates are due to differences in their unfolding 
efficiency by the proteasome (Fig. 31). Model 2 considers that the proteasome degrades the complex, 
formed by the effector protein and the bound partner (MBP-NYV), but that the unfolding and digestion 
of the effector proteins might hamper or disrupt MBP-NYV processing. Model 2 would be in agreement 
with the faster degradation of MBP-NYV in presence of E3_5, the non-specific DARPin and the 
continuous decreasing degradation rates observed in presence of off7-ODC, off7 and off7-NYV, 
respectively.  
Finally model 3 takes into account that the complex, formed by the effector protein (Off7, Off7-ODC and 
Off7-NYV) bound to MBP-NYV, might associate with the proteasome at different rates, and that the 
presence of the effector protein might impede MBP-NYV degradation (Fig. 32). The effector protein 
could simply compete with MBP-NYV for degradation, its unfolding and digestion could slow down the 
processing of MBP-NYV (like in model 2). Another possibility would be that MBP-NYV, when bound to the 
effector protein, could become structurally more stable and not be efficiently degraded any more by the 
proteasome. Methotrexate, a dihydrofolate reductase (DHFR) ligand, has been shown to stabilize the 
enzyme through binding and impaired the proteasomal degradation of DHFR when this one was fused 
the ODC degron [41]. If the complexe associated with the proteasome via MBP-NYV, MBP-NYV turn over 
would be gradually slowed down as the intrinsic stability of the effector protein increased. If the complex 
associated with the proteasome via the effector protein, it would be hard to predict if MBP-NYV would 
be faster degraded alone or in complex with off7-ODC or off7. In other words we cannot know if a faster 
association step could compensate a slower digestion step. Both models 2 and 3 could fit with the 
experimental data, but are questionable. off7-NYV for e.g. could have been rivaling MBP-NYV. As both 
proteins were bearing the same degradation signal, they could have been competing for interaction with 
key actors of the NYV degron degradation pathway. The non-specific DARPin E3-5 was used as negative 
control, but it was not optimal, as E3_5, like off7, was seen to be unstable and degraded by the 
proteasome, although at a lower rate. This did not seem to interfere too much with MBP-NYV 
degradation but it might explain why MBP-NYV degradation only reached a final basal level and did not 
fully complete (Fig. 16). A protein which could neither bind the target protein nor interact with the 
proteasome would be a better negative control. Finally a destabilized version of MBP, which could be 
degraded by the proteasome but could not associate with it, would be a better substrate than MBP-NYV 
to test the net effect of Off7, Off7-ODC and Off7-NYV on their binding partner stability.  
  
150 
 
 
 
 
 
Figure 32: Schematic representation of model 3. Model 3 takes into account the different association rate of the complex, 
formed by the effector protein (Off7-ODC, Off7 and Off7-NYV) bound to MBP-NYV, with the proteasome, and the presence of 
the effector protein, which might impede MBP-NYV degradation. The effector protein could slow down MBP-NYV 
degradation, simply by competing for proteasomal processing (like in model 2) or by increasing MBP-NYV stability and 
resistance to unfolding. If the complex associates with the proteasome via the effector protein (left side), MBP-NYV 
degradation rate would decrease following the order 1, 2 and 3. It cannot be predicted if MBP-NYV would be faster degraded 
alone or in complex with off7-ODC or off7, which might bring it faster to the proteasome but might also slow down its 
proteasomal processing. If all complexes associated with the proteasome via MBP-NYV, MBP-NYV turn over would be 
gradually slowed down, following the order 1, 2, 3 and 4, as the intrinsic stability of the effector protein increased.  
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Our experimental data seemed to indicate that a target protein, in spite of interacting with a protein 
prone for proteasomal destruction, was not necessarily co-degraded by the mammalian proteasome. 
When Matsuzawa et al. employed a similar set-up, by expressing protein-interaction domains as 
chimeric fusions with the whole ornithine decarboxylase and surveying the antizyme 1-dependent 
degradation of the interacting binding partners, only five out of twelve protein pairs could be degraded 
[31]. The authors hypothesized that for their negative cases, the affinity interaction was insufficient or 
that these proteins were recalcitrant to degradation. Interacting with the proteasome and achieving a 
high local concentration might not be enough for becoming an eligible substrate. In yeast and mammals, 
when the ornithine decarboxylase is bound to the antizyme 1 (AZ1), it can be better recognized and 
processed by the proteasome, but AZ1 is not degraded along [47]. AZ1 degradation occurs mostly, if not 
only, independently of ornithine decarboxylase, via the ubiquitin proteasome pathway [47]. The 26S 
proteasome has also been observed for selectively degrading single subunits of multimeric complexes. 
When ubiquitylated Sic1 was embedded within S phase cyclin-Cdk complexes, it could be specifically 
extracted by the 26S proteasome and degraded while bound partners were released untouched [48]. 
This subunit-selective degradation, often exploited as a regulatory switch for the cell’s metabolism, 
might tell us that in order to degrade a target protein, a clear degradation signal should be appended to 
it.  
Proteasomes usually require a polyubiquitin tag as the price of admission. The second tested 
degradation strategy was aiming to exploit the ubiquitin proteasome pathway. The E3 ligase SCF was 
chosen to label new target proteins. In order to harness this ubiquitination machinery, a chimeric F-box 
protein, cdc4-off7 was employed.  It was based on the yeast cdc4 F-box protein, but whose substrate 
binding domain has been replaced with off7. cdc4-off7 had been observed in yeast to specifically induce 
the degradation of the target protein MBP (see Chapter 1). Several SCF ligases, whose structural and 
functional details had been deciphered, showed that they had been well conserved [32-36]. cdc4 and 
Fbxw7, its human homolog, displayed very high similarities [34, 36], cdc4-off7 was thus tested in 
mammalian cells. Like in yeast, the chimeric F-box protein was unstable and degraded by the 
proteasome. We thus hypothesized that it was recognized by the mammalian SCF complex. Furthermore, 
upon transient transfection in a cell line stably expressing MBP, it seemed to slightly decrease MBP 
steady-state level. To investigate if cdc4-off7 could induce MBP degradation by the ubiquitin proteasome 
pathway, a second experimental set-up was established. A stable cell line expressing cdc4-off7 was 
created, but under these conditions, the chimeric F-box protein had no effect on transfected MBP 
steady-state levels. In spite of playing with the transfection methods and several parameters, the results 
observed in the first experimental set-up could not be reproduced. The main difference between the two 
experimental set-ups was the ratio between cdc4-off7 and MBP. The relative amount of chimeric F-box 
protein and target protein seems to be crucial for operating degradation [49]. cdc4-off7 was probably 
present in a higher amount in the first set-up, as it was expressed from transfected plasmid(s) while in 
the stable cell line, it was expressed from a single locus at a lower level than MBP, which was expressed 
from transfected plasmid(s). Considering that cdc4-off7 had, in addition, a short half-life, it is possible 
that under these conditions, it could not reach a sufficient amount to efficiently degrade MBP, which 
was furthermore well expressed and highly stable. In other studies, recombinant adenoviruses and 
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retroviruses were used for the high-level delivery and expression of chimeric F-box proteins, targeting 
more challenging substrates like endogenous proteins [24, 29].  
A destabilized version of MBP fused to the NYV degron, MBP-NYV was tested in co-transfection 
experiments with cdc4-off7. The chimeric F-box protein somehow shifted MBP-NYV normal degradation 
pattern towards a slower one very similar to what had been previously observed for MBP when it was 
co-expressed with cdc4-off7 in yeast. We first thought that cdc4-off7 could be using MBP-NYV as 
substrate too and redirect it towards the ubiquitin proteasome pathway, and potentially increase its 
degradation rate. However, MBP-NYV degradation was slowed down and barely taking place when it was 
monitored in Flp-In TRex cdc4-off7 cells. The second experimental set-up confirmed that cdc4-off7 was 
impeding MBP-NYV’s own degradation pathway. The lack of acceleration of degradation led us to test 
the authenticity of the working hypothesis: was cdc4-off7 really a functional F-box protein in mammalian 
cells? Immunoprecipitation experiments could not detect any interaction with skp1, indicating that cdc4-
off7 could most likely not associate with the mammalian SCF complex. This result was confirmed by 
cdc4-off7 stability, which stayed unaffected by the presence of a target protein previously observed to 
extend half-life in yeast. Most likely, cdc4-off7 was therefore, not a functional F-box protein and could in 
that case not induce MBP or MBP-NYV degradation. Human skp1 protein might not be able to recognize 
and/or bind to the cdc4 F-box motif with enough affinity even if its F-box binding domain was highly 
conserved (68% identity with yeast). skp1 binds to various F-box sequences, but the use of a homologous 
F-box domain might be decisive. Zhou and colleagues constructed their chimeric F-box proteins using β-
TrCP as scaffold, a mammalian F-box protein [23, 24, 26].  The effect of cdc4-off7 on MBP steady-state 
level, which was monitored several times in the first experimental set-up, was very likely not specific, 
these results could namely not be repeated. We cannot explain how cdc4-off7 was interfering with MBP-
NYV degradation. Since a similar effect was observed with Off7, it is possible that both Off7 and cdc4-
off7 were hampering MBP-NYV degradation simply upon binding and their “unstable” C-terminus might 
be directly interfering with NYV-degron interaction with the proteasome. cdc4-off7 was most likely not 
degraded by the SCF complex. The pathway leading it to the proteasome stays unknown, it could be 
upon direct binding with the proteasome, but we can only conclude that the presence of a stable binding 
partner did not affect it.   
Our chimeric F-box protein cdc4-off7 failed to induce the degradation of a cognate specific protein in 
mammalian cells. However, the strategy relying on the use of the ubiquitin proteasome pathway should 
not be condemned. The scaffold of a homologous F-box protein might be crucial for designing an 
effective chimeric F-box protein, as demonstrated by previous successful protein knock-out attempts 
[23, 24, 26-29]. These chimeric F-box proteins based on the in-frame fusion of a known “adapter” (ligand 
or a known naturally occurring binding motif), are nevertheless limited in the range of targets.  The use 
of a generalizable binding domain like DARPins would broaden the spectrum of targets. A second 
generation of chimeric F-box protein, based on a homologous F-box protein scaffold and DARPIns, might 
lead to a general strategy to engineer specific protein breakdown in the cell. 
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pcDNA3+ Off7
5912 bp
KanR
Am pR
off7
HA tag
SV40 polyA
BGH polyA
SV40 early prom oter and origin
CMV prom oter
P3
T7
bla prom oter
RBSam p
ColE1
f1 origin
STOP
BglII (13)
EcoRI (97 2)
SmaI (2562)
Xba I (147 6)
Xho I (147 0)
Xma I (2560)
BamHI (930)
BamHI (1440)
Hin dIII (912)
Hin dIII (1455)
SpeI (250)
SpeI (936)
ApaLI (33)
ApaLI (4414)
ApaLI (5657 )
Nco I (611)
Nco I (2446)
Nco I (3181)
pcDNA3+ Off7-ODC
6002 bp
KanR
AmpR
off7
ODC
HA tag
SV40 polyA
BGH polyA
SV40 early promoter and origin
CMV promoter
P3
T7
bla promoter
RBSam p
ColE1
f1 origin
STOP
BglII (13)
EcoRI (97 2)
Hin dIII (912)
SmaI (2652)
Xba I (1566)
Xho I (1560)
Xma I (2650)
BamHI (930)
BamHI (1440)
SpeI (250)
SpeI (936)
ApaLI (33)
ApaLI (4504)
ApaLI (57 47 )
Nco I (611)
Nco I (2536)
Nco I (327 1)
pcDNA3+ Off7-NYV
6017  bp
KanR
AmpR
off7
NYV
HA tag
SV40 polyA
BGH polyA
SV40 early promoter and origin
CMV promoter
P3
T7
bla promoter
RBSamp
ColE1
f1 origin
STOP
BglII (13)
EcoRI (97 2)
Hin dIII (912)
SmaI (2667 )
Xba I (1581)
Xho I (157 5)
Xma I (2665)
BamHI (930)
BamHI (1440)
SpeI (250)
SpeI (936)
ApaLI (33)
ApaLI (4519)
ApaLI (57 62)
Nco I (611)
Nco I (2551)
Nco I (3286)
pcDNA5/FRT/TO/MBP
6229 bp
Amp R
Hygro(R) (no ATG)
MBP
BGH polyA
SV40 polyA
CMV promoter
2X TetO2
bla promoter
FRT
STOP
BamHI (2089)
Hin dIII (97 9)
Xho I (2145)
EcoRI (2112)
EcoRI (2991)
Nco I (611)
Nco I (3100)
SpeI (250)
SpeI (2095)
Xba I (2151)
Xba I (27 23)
BglII (13)
BglII (837 )
BglII (1344)
ApaLI (33)
ApaLI (3028)
ApaLI (3330)
ApaLI (47 28)
ApaLI (597 4)
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pcDNA3+/MBP-ODC
6622 bp
Kan/Neo
AmpR
MBP
ODC
ODC
BGH PolyA
SV40 PolyA
CMV
SV40 early prom oter and origin
P3
T7
bla promoter
RBSamp
ColE1
f1 origin
STOP
EcoRI (953)
Hin dIII (912)
SmaI (327 2)
Xba I (2186)
Xho I (2180)
Xma I (327 0)
BamHI (930)
BamHI (2060)
BglII (13)
BglII (1318)
SpeI (250)
SpeI (936)
ApaLI (33)
ApaLI (5124)
ApaLI (6367 )
Nco I (611)
Nco I (3156)
Nco I (3891)
pcDNA3+/MBP-NYV
6637  bp
Kan/Neo
AmpR
MBP
ODC
NYV
BGH PolyA
SV40 PolyA
CMV
SV40 early promoter and origin
P3
T7
bla promoter
RBSamp
ColE1
f1 origin
STOP
EcoRI (953)
Hin dIII (912)
SmaI (3287 )
Xba I (2201)
Xho I (2195)
Xma I (3285)
BamHI (930)
BamHI (2060)
BglII (13)
BglII (1318)
SpeI (250)
SpeI (936)
ApaLI (33)
ApaLI (5139)
ApaLI (6382)
Nco I (611)
Nco I (317 1)
Nco I (3906)
pcDNA5/FRT/TO/cdc4-off7
667 4 bp
Amp R
Hygro(R) (no ATG)
cdc4 5GS off7
HA tag
BGH polyA
SV40 polyA
CMV promoter
2X TetO2
bla promoter
FRT
STOP
ClaI (1187 )
EcoRI (3436)
Hin dIII (97 9)
PstI (3530) Xho I (2590)
BamHI (997 )
BamHI (2083)
KpnI (989)
KpnI (1586)
Nco I (611)
Nco I (3545)
SpeI (250)
SpeI (1003)
Xba I (2596)
Xba I (3168)
SacI (819)
SacI (87 3)
SacI (995)
ApaLI (33)
ApaLI (347 3)
ApaLI (37 7 5)
ApaLI (517 3)
ApaLI (6419)
pcDNA5/FRT/TO/cdc4-E3-5
6650 bp
Amp R
Hygro(R) (no ATG)
cdc4-5GS-E3 5
HA tag
BGH polyA
SV40 polyA
CMV promoter
2X TetO2
bla prom oter
FRT
STOP
BamHI (2059)
ClaI (1163)
EcoRI (3412)
Hin dIII (97 9)
Kpn I (1562)
PstI (3506)
SpeI (250)
Xho I (2566)
Nco I (611)
Nco I (3521)
SacI (819)
SacI (87 3)
Xba I (257 2)
Xba I (3144)
ApaLI (33)
ApaLI (3449)
ApaLI (37 51)
ApaLI (5149)
ApaLI (6395)
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Construct DNA and amino-acid sequences 
 
Off7 construct DNA sequence 
 
 
Tctgctgaagcacggtgctgacgttgacgcttctgacgtttttggttatactccgctgcacctggctgcttattggggtcacctggaaatcgttgaagttct
gctgaagaacggtgctgacgttaacgctatggactctgatggtatgactccactgcacctggctgctaagtggggttacctggaaatcgttgaagttctg
ctgaagcacggtgctgacgttaacgctcaggacaaattcggtaagaccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcct
gcaaggatcctaatagtgaaagcttttagctgacctcgagactagtatgtacccatacgatgttccagattacgctgaattcgacctgggtaggaaact
gctggaagctgctcgtgctggtcaggacgacgaagttcgtatcctgatggctaacggtgctgacgttaatgctgctgacaatactggtactactccgctg
cacctggctgcttattctggtcacctggaaatcgttgaagt 
 
Of7 amino-acid sequence  
MYPYDVPDYAEFDLGRKLLEAARAGQDDEVRILMANGADVNAADNTGTTPLHLAAYSGHLEIVEVLLKHGADVDASD
VFGYTPLHLAAYWGHLEIVEVLLKNGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISID
NGNEDLAEILQGS 
 
Off7-ODC and Off7-NYV constructs:  
see in annex from chapter 2 
 
MBP construct DNA sequence 
 
 
 
Off7-stop
54 0 bp
Stop sequence
off7
HA tag
BamH I (506 )
Ec oR I (38 ) H ind III (521)
Sp e I (2) X h oI (536 )
MBP
1116  bp
MBP
STOP
BamH I (1112)H ind III (2)
156 
 
Aagcttatgaaaactgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggtctcgctgaagtcggtaagaaattcgagaaag
ataccggaattaaagtcaccgttgagcatccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacattatcttctggg
cacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatcaccccggacaaagcgttccaggacaagctgtatccgtttacctgggatgc
cgtacgttacaacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaagatctgctgccgaacccgccaaaaacctgg
gaagagatcccggcgctggataaagaactgaaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccgctgattg
ctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttc
ctggttgacctgattaaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaa
cggcccgtgggcatggtccaacatcgacaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgttg
gcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagc
ggttaataaagacaaaccgctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgccactatggaaaacgcc
cagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtc
gatgaagccctgaaagacgcgcagacttagggatcc 
MBP amino-acid sequence 
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAE
ITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDT
SKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIA
ATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQT 
 
MBP-ODC construct DNA sequence 
 
 
gaattcatgaaaactgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggtctcgctgaagtcggtaagaaattcgagaaag
ataccggaattaaagtcaccgttgagcatccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacattatcttctggg
cacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatcaccccggacaaagcgttccaggacaagctgtatccgtttacctgggatgc
cgtacgttacaacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaagatctgctgccgaacccgccaaaaacctgg
gaagagatcccggcgctggataaagaactgaaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccgctgattg
ctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttc
ctggttgacctgattaaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaa
cggcccgtgggcatggtccaacatcgacaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgttg
gcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagc
ggttaataaagacaaaccgctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgccactatggaaaacgcc
cagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtc
MBP-ODC
1236  bp
MBP
ODC
STOP
BamH I ( 110 9 )
Bg lII ( 36 7 )Ec oR I (2) X h oI  (1229 )
157 
 
gatgaagccctgaaagacgcgcagactggatccttcccgccggaggtggaggagcaggatgatggcacgctgcccatgtcttgtgcccaggagagcg
ggatggaccgtcaccctgcagcctgtgcttctgctaggatcaatgtgtagctcgag 
MBP-ODC amino-acid sequence 
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAE
ITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDT
SKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIA
ATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTGSFPPEVEEQDDGTLPMSCAQESGMDR
HPAACASARINV 
 
MBP-NYV construct DNA sequence 
 
 
gaattcatgaaaactgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggtctcgctgaagtcggtaagaaattcgagaaag
ataccggaattaaagtcaccgttgagcatccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacattatcttctggg
cacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatcaccccggacaaagcgttccaggacaagctgtatccgtttacctgggatgc
cgtacgttacaacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaagatctgctgccgaacccgccaaaaacctgg
gaagagatcccggcgctggataaagaactgaaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccgctgattg
ctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttc
ctggttgacctgattaaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaa
cggcccgtgggcatggtccaacatcgacaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgttg
gcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagc
ggttaataaagacaaaccgctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgccactatggaaaacgcc
cagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtc
gatgaagccctgaaagacgcgcagactggatcccgccctgaagttaaacaaggatgctatagaacattgggtgtttttagatataagagtaggtgttat
gttggtcttgtgtggggggtccttcttacaactgaactcatagtttgggcagctagtgcttagctcgag 
MBP-NYV amino-acid sequence 
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAE
ITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDT
SKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIA
ATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTGSRPEVKQGCYRTLGVFRYKSRCYVGLV
WGVLLTTELIVWAASA 
MBP-NYV
1251 bp
MBP NYV
STOP
BamHI (1109)
BglII (367)EcoRI (2) XhoI (1244)
158 
 
Cdc4-off7 construct 
see cdc4_5GS_off7 in annex from chapter 1 
 
Cdc4-E3_5 construct DNA sequence 
 
 
aagcttatggggtcgtttcccttagctgagtttccattacgtgatatccctgttccttatagctaccgtgtgtctggcggtatagcttcctcaggtagtgtta
ctgcgcttgttactgccgctggcactcatcgaaactcgtccacggctaagacagttgagacagaagacggcgaagaagatatcgatgagtatcagagg
aaaagagcagctggttctggcgaatccactcctgaacgcagtagtttcgcagcggtagcacatgataatcacaaaaccctccatccagttaacttacag
aacaccggtgcagcgtctgtggataatgacggtctgcacaatttaacagatatatccaacgatgcagaaaaacttttgatgtctgtggatgatggttctg
ccgcaccttctacattgagtgtaaacatgggagtggcatctcataatgttgctgctcccactaccgtcaatgcggcaacaataactggcagtgatgttag
taacaatgttaatagtgctactattaacaatcctatggaggaaggagcgctgccgttatcacccactgcttcctctccaggtaccacaactcctttagcta
aaactacgaaaactatcaacaacaataataatatcgccgatttgatagaatccaaagattctataatctcccctgaatacctttctgatgagattttcag
cgcaataaacaataatctccctcacgcatacttcaaaaatttattatttagattagttgccaacatggataggagtgaactatccgacttggggacttta
atcaaggataatttaaagagggacctaataacgtctttgccttttgaaataagtttgaaaattttcaattatttgcaattcgaggatattataaattccctt
ggggtctcccaaaattggaacaaaataattagaaaatctacatcgttgtggaaaaaacttctgatatcggaaaattttgtgagcccaaagggttttaat
tctctcaatctcaaactctcccaaaaatacccaaaactctcacaacaagatcgccttagattatcttttctggagaatggatccggctcgggcgacctgg
gtaagaaactgctggaagctgctcgtgctggtcaggacgacgaagttcgtatcctgatggctaacggtgctgacgttaacgctactgacaatgatggtt
atactccgctgcacctggctgcttctaatggtcacctggaaatcgttgaagttctgctgaagaacggtgctgacgttaacgcttctgaccttactggtatt
actccgctgcacctggctgctgctactggtcacctggaaatcgttgaagttctgctgaagcacggtgctgacgttaacgcttatgacaatgatggtcata
ctccgctgcacctggctgctaagtatggtcacctggaaatcgttgaagttctgctgaagcacggtgctgacgttaacgctcaggacaaattcggtaaga
ccgctttcgacatctccatcgacaacggtaacgaggacctggctgaaatcctgcaatacccatacgatgttccagattacgcttaactcgag 
cdc4-E3_5 amino-acid sequence 
MGSFPLAEFPLRDIPVPYSYRVSGGIASSGSVTALVTAAGTHRNSSTAKTVETEDGEEDIDEYQRKRAAGSGESTPERSSF
AAVAHDNHKTLHPVNLQNTGAASVDNDGLHNLTDISNDAEKLLMSVDDGSAAPSTLSVNMGVASHNVAAPTTVNAA
TITGSDVSNNVNSATINNPMEEGALPLSPTASSPGTTTPLAKTTKTINNNNNIADLIESKDSIISPEYLSDEIFSAINNNLPHA
YFKNLLFRLVANMDRSELSDLGTLIKDNLKRDLITSLPFEISLKIFNYLQFEDIINSLGVSQNWNKIIRKSTSLWKKLLISENFV
SPKGFNSLNLKLSQKYPKLSQQDRLRLSFLENGSGSGDLGKKLLEAARAGQDDEVRILMANGADVNATDNDGYTPLHLA
ASNGHLEIVEVLLKNGADVNASDLTGITPLHLAAATGHLEIVEVLLKHGADVNAYDNDGHTPLHLAAKYGHLEIVEVLLK
HGADVNAQDKFGKTAFDISIDNGNEDLAEILQYPYDVPDYA 
  
cdc4-E3 5
159 3 bp
cdc4 E3 5
HA tag
GS linker
STOPBa mH I (108 2)
H ind III (2) X h oI (1589 )AvaI (109 0)
AvaI (1589 )
159 
 
References 
 
1. Scacheri, P.C., et al., Short interfering RNAs can induce unexpected and divergent changes in the 
levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A, 2004. 101(7): p. 1892-
7. 
2. Jackson, A.L., et al., Expression profiling reveals off-target gene regulation by RNAi. Nat 
Biotechnol, 2003. 21(6): p. 635-7. 
3. Agrawal, S. and E.R. Kandimalla, Role of Toll-like receptors in antisense and siRNA [corrected]. Nat 
Biotechnol, 2004. 22(12): p. 1533-7. 
4. Judge, A.D., et al., Sequence-dependent stimulation of the mammalian innate immune response 
by synthetic siRNA. Nat Biotechnol, 2005. 23(4): p. 457-62. 
5. Castanotto, D. and J.J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics. 
Nature, 2009. 457(7228): p. 426-33. 
6. Hershko, A. and A. Ciechanover, The ubiquitin system. Annu Rev Biochem, 1998. 67: p. 425-79. 
7. Scheffner, M., et al., The E6 oncoprotein encoded by human papillomavirus types 16 and 18 
promotes the degradation of p53. Cell, 1990. 63(6): p. 1129-36. 
8. Scheffner, M., et al., Targeted degradation of the retinoblastoma protein by human 
papillomavirus E7-E6 fusion proteins. Embo J, 1992. 11(7): p. 2425-31. 
9. Zhou, P., Targeted protein degradation. Curr Opin Chem Biol, 2005. 9(1): p. 51-5. 
10. Gosink, M.M. and R.D. Vierstra, Redirecting the specificity of ubiquitination by modifying 
ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A, 1995. 92(20): p. 9117-21. 
11. Colas, P., et al., Targeted modification and transportation of cellular proteins. Proc Natl Acad Sci 
U S A, 2000. 97(25): p. 13720-5. 
12. Fang, S. and A.M. Weissman, A field guide to ubiquitylation. Cell Mol Life Sci, 2004. 61(13): p. 
1546-61. 
13. Sakamoto, K.M., et al., Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box 
complex for ubiquitination and degradation. Proc Natl Acad Sci U S A, 2001. 98(15): p. 8554-9. 
14. Sakamoto, K.M., et al., Development of Protacs to target cancer-promoting proteins for 
ubiquitination and degradation. Mol Cell Proteomics, 2003. 2(12): p. 1350-8. 
15. Schneekloth, J.S., Jr., et al., Chemical genetic control of protein levels: selective in vivo targeted 
degradation. J Am Chem Soc, 2004. 126(12): p. 3748-54. 
16. Liu, Y.C., Ubiquitin ligases and the immune response. Annu Rev Immunol, 2004. 22: p. 81-127. 
17. Zhang, D., et al., Targeted degradation of proteins by small molecules: a novel tool for functional 
proteomics. Comb Chem High Throughput Screen, 2004. 7(7): p. 689-97. 
18. Rodriguez-Gonzalez, A., et al., Targeting steroid hormone receptors for ubiquitination and 
degradation in breast and prostate cancer. Oncogene, 2008. 27(57): p. 7201-11. 
19. Bargagna-Mohan, P., et al., Use of PROTACS as molecular probes of angiogenesis. Bioorg Med 
Chem Lett, 2005. 15(11): p. 2724-7. 
20. Tang, Y.Q., et al., Chimeric molecules facilitate the degradation of androgen receptors and 
repress the growth of LNCaP cells. Asian J Androl, 2009. 11(1): p. 119-26. 
21. Schneekloth, A.R., et al., Targeted intracellular protein degradation induced by a small molecule: 
En route to chemical proteomics. Bioorg Med Chem Lett, 2008. 18(22): p. 5904-8. 
22. Lim, M.S. and K.S. Elenitoba-Johnson, Ubiquitin ligases in malignant lymphoma. Leuk Lymphoma, 
2004. 45(7): p. 1329-39. 
23. Zhou, P., et al., Harnessing the ubiquitination machinery to target the degradation of specific 
cellular proteins. Mol Cell, 2000. 6(3): p. 751-6. 
160 
 
24. Zhang, J., N. Zheng, and P. Zhou, Exploring the functional complexity of cellular proteins by 
protein knockout. Proc Natl Acad Sci U S A, 2003. 100(24): p. 14127-32. 
25. Cong, F., et al., A protein knockdown strategy to study the function of beta-catenin in 
tumorigenesis. BMC Mol Biol, 2003. 4: p. 10. 
26. Su, Y., et al., Eradication of pathogenic beta-catenin by Skp1/Cullin/F box ubiquitination 
machinery. Proc Natl Acad Sci U S A, 2003. 100(22): p. 12729-34. 
27. Liu, J., et al., Targeted degradation of beta-catenin by chimeric F-box fusion proteins. Biochem 
Biophys Res Commun, 2004. 313(4): p. 1023-9. 
28. Cohen, J.C., et al., Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal 
development in the mouse. BMC Dev Biol, 2004. 4: p. 4. 
29. Chen, W., et al., Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 
complex suppresses tumor cell growth in vitro and in vivo. Cancer Res, 2004. 64(11): p. 3949-57. 
30. Melchionna, T. and A. Cattaneo, A protein silencing switch by ligand-induced proteasome-
targeting intrabodies. J Mol Biol, 2007. 374(3): p. 641-54. 
31. Matsuzawa, S., et al., Method for targeting protein destruction by using a ubiquitin-independent, 
proteasome-mediated degradation pathway. Proc Natl Acad Sci U S A, 2005. 102(42): p. 14982-7. 
32. Zheng, N., et al., Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature, 
2002. 416(6882): p. 703-9. 
33. Wu, G., et al., Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding 
and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell, 2003. 11(6): p. 1445-56. 
34. Orlicky, S., et al., Structural basis for phosphodependent substrate selection and orientation by 
the SCFCdc4 ubiquitin ligase. Cell, 2003. 112(2): p. 243-56. 
35. Hao, B., et al., Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) 
ubiquitin ligase. Mol Cell, 2005. 20(1): p. 9-19. 
36. Hao, B., et al., Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate 
recognition by SCF ubiquitin ligases. Mol Cell, 2007. 26(1): p. 131-43. 
37. Sambrook, J. and D. Russell, Molecular Cloning: A Laboratory Manual. third edition ed. 2001, 
Cold Spring Harbor: Cold Spring Harbor Laboratory press. 
38. Binz, H.K., et al., High-affinity binders selected from designed ankyrin repeat protein libraries. Nat 
Biotechnol, 2004. 22(5): p. 575-82. 
39. Galan, J.M. and M. Peter, Ubiquitin-dependent degradation of multiple F-box proteins by an 
autocatalytic mechanism. Proc Natl Acad Sci U S A, 1999. 96(16): p. 9124-9. 
40. Blondel, M., et al., Nuclear-specific degradation of Far1 is controlled by the localization of the F-
box protein Cdc4. Embo J, 2000. 19(22): p. 6085-97. 
41. Zhang, M., C.M. Pickart, and P. Coffino, Determinants of proteasome recognition of ornithine 
decarboxylase, a ubiquitin-independent substrate. Embo J, 2003. 22(7): p. 1488-96. 
42. Sen, N., A. Sen, and E.R. Mackow, Degrons at the C terminus of the pathogenic but not the 
nonpathogenic hantavirus G1 tail direct proteasomal degradation. J Virol, 2007. 81(8): p. 4323-
30. 
43. Zhang, M., et al., Proteasomes begin ornithine decarboxylase digestion at the C terminus. J Biol 
Chem, 2004. 279(20): p. 20959-65. 
44. van Daalen Wetters, T., et al., Polyamine-mediated regulation of mouse ornithine decarboxylase 
is posttranslational. Mol Cell Biol, 1989. 9(12): p. 5484-90. 
45. Toth, C. and P. Coffino, Regulated degradation of yeast ornithine decarboxylase. J Biol Chem, 
1999. 274(36): p. 25921-6. 
46. Interlandi, G., et al., Characterization and further stabilization of designed ankyrin repeat 
proteins by combining molecular dynamics simulations and experiments. J Mol Biol, 2008. 375(3): 
p. 837-54. 
161 
 
47. Palanimurugan, R., et al., Polyamines regulate their synthesis by inducing expression and blocking 
degradation of ODC antizyme. Embo J, 2004. 23(24): p. 4857-67. 
48. Verma, R., et al., Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields 
active S phase cyclin-Cdk. Mol Cell, 2001. 8(2): p. 439-48. 
49. Zhang, J. and P. Zhou, Ectopic targeting of substrates to the ubiquitin pathway. Methods 
Enzymol, 2005. 399: p. 823-33. 
 
 
  
162 
 
 
163 
 
 
 
References ................................................................................................................................................ 171 
 
  
Conclusions and outlook 
      
164 
 
 
  
Table 1: The table was adapted from [1]. 
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A wide variety of human diseases, including neurodegenerative disorders, cancer, inflammatory 
diseases, hypoxia, genetic diseases and muscle wasting disorder, involve the ubiquitin proteasome 
pathway [1, 2]. An overview of different aberrations in the ubiquitin proteasome system (UPS), which 
have been implicated in the pathogenesis of many inherited and acquired pathologies is given in Table 
1.  
Alterations in the expression of the UPS genes can result in uncontrolled and/or accelerated degradation 
of a substrate (loss of function). Enhanced removal of tumor suppressors, such as p53 and p27, are 
involved in the pathogenesis of malignancies. Levels of p53, the “guardian of the genome”, are mostly 
controlled by the ubiquitin ligase MDM2. A subset of human tumors has been shown to contain 
amplifications of the mdm2 gene, leading to over-expression of Mdm2 [3]. Also, a naturally occurring 
polymorphism within the mdm2 promoter, leading to increased Mdm2 protein in human populations, 
may account for variations in some individuals’ susceptibility to cancer and accelerated tumor formation 
[4, 5]. p27 is, like p53, a negative cell-cycle regulator, its  degradation by the ubiquitin ligase SCFskp2 
regulates progression into mitosis. p27 level is markedly reduced in a wide range of human cancers 
where skp2 is overexpressed [6].  
Other pathologies are due to the stabilization of a substrate that can result from mutational inactivation 
of the ubiquitination machinery involved in its degradation, or mutation of the substrate itself, which 
prevents its recognition and/or proteasomal degradation (gain of function). Autosomal-recessive 
juvenile Parkinson disease (PD) is in 50% of the patients associated to mutations and deletions in the 
Parkin gene [7]. Parkin encodes a RING-finger protein with E3 ligase activity. Recently, it was witnessed 
to form a complex with two other proteins, also linked to early onset familial form of PD,  pten-induced 
putative kinase 1 (PINK1) and DJ-1 [8], which enhanced its ubiquitin ligase activity. This PPD complex 
could constitute a novel kind of E3 ligase complex, which seemed to play an important role in promoting 
degradation of un-/misfolded Parkin substrates. Relevant substrates of Parkin are not known, but Parkin 
can protect dopaminergic cells from neurotoxicity, probably by degrading yet unknown proteins [9]. VHL 
ubiquitin ligase is mutated in all renal cell carcinomas and in von Hippel-Lindau syndrome, which is 
characterized by highly vascularized tumors. Its principal substrate, HIF1α, the hypoxia inducible 
transcription factor, is stabilized and leads to activation of hypoxia-responsive genes, in the presence of 
oxygen, such as the vascular endothelial growth factor (VEGF), which stimulates angiogenesis [2, 9]. 
Huntington disease is caused by a mutation, leading to an abnormal expansion of CAG trinucleotides in 
the gene encoding the huntingtin, a protein which may be involved in gene transcription [10]. This 
mutation confers a toxic gain-of-function on the mutant protein, as the polyglutamine tract can form 
amyloid-like fibrils, which can form aggregates in the cytoplasm and/or nucleus, a hallmark of the 
disease. Several data suggest that Huntingtin may be a proteasome substrate and that eukaryotic 
proteasomes cleave proteins with expanded polyglutamine sequences very slowly, if at all [11].  It was 
then proposed that these polyglutamine proteins would impair the UPS, but this model is controversial 
as several conflicting sets of data have been reported [10].  
Now that several components of the UPS could be linked to the initiation and/or progression of specific 
human pathologies, their potential as targets for therapeutic strategies are being investigated (Fig. 2). 
The proteasome itself was first successfully targeted by the proteasome inhibitor Bortezomib (Velcade)  
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Figure 1: Overview of the ubiquitin proteasome system (UPS) and potential sites for drug development. Protein degradation 
through the UPS is a highly regulated process, involving several steps. The first step in the cascade is ubiquitin activation by 
E1 (ubiquitin-activating enzyme) followed by ubiquitin delivery to E2 (ubiquitin-conjugating enzyme) (a). The second step 
involves complex formation by E2-Cys Ub, E3 (ubiquitin ligase) and the substrate (b). The third step (c) comprises transfer 
of ubiquitins to the substrate lysine(s) to earmark the substrate with a polyubiquitin chain. In the fourth step of the pathway 
(d), a polyubiquitylated substrate is released from E3. Proteasomes recognize the polyubiquitin chain as a signal to de-
ubiquitylate and destroy the substrate. The fifth step seals the fate of a doomed protein (e). The proteasome removes the 
ubiquitin chain, and threads the unfolded protein into the proteasome chamber, where the protease active sites are located. 
The ubiquitin molecules are recycled, and the peptides generated are used in major histocompatibility class I-coupled 
antigen presentation or degraded to amino acids that are recycled for new protein synthesis. Potential sites for drug 
development are shown in red colored boxes. MDM2, double minute 2; SCF, SKP1–Cullin–F-box; SKP, S-phase kinase-
associated protein; RBX, RING-box protein. Adapted from [9].  
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(Millenium Pharmaceuticals, Cambridge, MA) [9]. This tripeptide boronic acid (PS341) was the first UPS 
targeting drug approved by the FDA, for the treatment of multiple myeloma patients, as a second line 
therapy. Surprisingly, this reversible proteasome inhibitor showed specificity towards cancer cells, it 
seemed to downregulate the pro-oncogenic NF-κB pathway [12]. Additionally, it is thought that 
proteasome inhibition might lead to accumulation of misfolded proteins in the ER, inducing unfolded 
protein response, and cell death. Alternatively, interfering with polyubiquitin chain recognition at the 
proteasome site is another approach for inhibition of the UPS. Small-molecule inhibitors, called 
ubistatins, identified by a chemical genetic screen performed in Xenopus extracts, bind to the 
hydrophobic interface of the Lys48-linked polyubiquitin chains, and prevent recognition of ubiquitinated 
substrates by ubiquitin-chain receptors of the proteasome [13]. 
Targeting other compounds of the UPS may open the door to other therapeutic interventions.  Inhibitors 
of E1, the ubiquitin activating enzyme, through blocking access of ATP, could prevent ubiquitin 
activation, the first step of the ubiquitination cascade [9]. Otherwise, inhibiting the interaction transfer 
at the E1/E2 level could put a stop to the transfer of the activated ubiquitin molecule onto the ubiquitin 
conjugating enzyme (E2) [9]. According to previous studies, E1 inhibitors might provoke cell-cycle arrest 
and thus counteract hyperproliferative pathologies, but they might also have side-effects on other 
pathways [9].  
Regulating the activity of certain proteins via attacking E3 ligases, the specificity module for the 
ubiquitination reaction, would increase the specificity of the therapy and eliminate side-effects.  In the 
past decade, the biotech and pharmaceutical industries have sought to target specific E3 ligases by 
developing inhibitors and agonists [14]. Small molecule inhibitors, called nutlins, were identified in a 
chemical library screen, to inhibit the interaction between mdm2 and p53 [9]. Nutlins could activate 
p53-dependent cell-cycle arrest and apoptosis. However, these anti-mdm2 compounds are not specific 
for p53 and may compete with other mdm2 substrates [12]. Alternatively, another hit originating from a 
chemical library screen, called RITA, was identified to bind the N-terminus of p53 and prevent its 
interaction with mdm2. However, RITA does also affect p53 interaction with other binding partners. 
SCFskp2 is also a highly interesting pharmacological target. Preventing the interaction of the F-box subunit 
skp2 with its substrate p27 is likely to be beneficial to slow down proliferation of cancer cells [9]. On the 
other hand, promoting the activity of certain E3 enzymes could also be beneficial. SCFFbxw7 degrades 
oncoproteins, such as c-Myc or cyclin E. The binding pocket of F-box protein Fbxw7 is mutated in several 
types of cancers, leading to a high expression level of its substrates. Identifying an agonist of Fbxw7 
would be challenging, even if not as much as reactivating a mutant allele.  Restoring the activity of the 
VHL ubiquitin ligase, which fails to degrade HIF1α, which in turn promotes angiogenesis, could be of 
interest as well, to reduce tumor vascularization. The advantages in inhibiting or activating certain E3 
ligases are numerous but the strategies do need to be highly specific.  
Targeted degradation of a specific protein would offer a new strategy for the removal of oncoproteins, 
and other proteins, which the UPS fails to degrade, and can ultimately be toxic for the cell, e.g. stabilized 
substrates in neurodegenerative diseases or viral proteins. Moreover, the degradation of a key viral 
protein should not only prevent the virus multiplication but also increase the host immune response, as 
proteasome-processed viral peptides are presented onto MHC I molecules. 
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Figure 2: Schematic representation of the bimolecular complexes, designed and tested by Prakash et al [15], as substrate for 
the proteasome and their outcome. Barnase and/or Barstar are equipped with ubiquitin molecules and /or an unstructured 
region (USR). (a) Barnase lacking a USR is stable when presented to the proteasome by ubiquitinated barstar. (b) Barnase 
displaying a USR is not degraded if barstar is not ubiquitinated. (c) Ubiquitinated barstar displaying a USR is degraded by the 
proteasome, but barnase is stable. (d,e) When ubiquitinated barstar delivers a USR-displaying barnase to the proteasome, 
the barnase is proteolyzed but the ubiquitinated barstar is spared (d). Ubiquitinated barstar was capable of 'turning over' 
multiple copies of a USR-displaying barnase (in 1o-fold excess) for proteasome-mediated degradation (e). Adapted from [16]. 
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Several protein knock-out techniques were developed (as reviewed in the introduction of Chapter 3), 
but despite their promises, engineered degradation has so far been successfully applied to very few 
proteins only, and every time redesigned case by case. As almost all of them were limited by the lack of 
known binding motifs, we chose to use a common binding scaffold, DARPins, for the engineering of 
diverse effector proteins, meant to degrade a target protein. Furthermore, we wanted to design effector 
proteins, which would only minimally interfere with the cell metabolism (by not relying on existing 
molecules), and would be able to lead any kind of target protein to the proteasome. By choosing MBP, 
an exogenous stable protein as target protein, we wanted to further assess the potential of protein 
knock-out.  
The chimeric F-box strategy (described in Chapter 1) showed only limited success in yeast. As expected, 
the chimeric F-box protein seemed to be functional as it was mediating degradation of the target 
protein and, was itself degraded by the proteasome, like natural F-box proteins. To circumvent the 
ubiquitination step, which might have been too restrictive for “foreign” substrate, another strategy 
relying on DARPin-degron constructs (described in Chapter 2 and 3) was established. These molecules 
were efficiently recognized and degraded by the proteasome, but they failed to co-lead a target protein 
for degradation. Our results were thus not as convincing as those earlier described by the different 
groups, who had developed similar techniques but for however only very specific cases, not allowing any 
generality.  
A very recent study might partially explain why our attempts to increase the capacity of protein knock-
out, were not awarded. Prakash et al [17] proposed earlier that the presence of an unstructured region 
(USR) in a proteasome substrate serves as inititation site for protein degradation and could also be a 
second component of the targeting signal, in addition to the ubiquitin chain. Recently, Prakash and 
colleagues [15], further assessed the importance of these two structural features for the proteasome 
when selecting substrates in a protein complex.  They used a bimolecular complex made of barnase and 
barstar as substrate, and appended to these molecules either an ubiquitin signal and/or an unstructured 
region (USR), and monitor their fate in the presence of reticulocyte lysate or purified yeast proteasome 
(Fig. 3). A single protein bearing only one sort of signal was stable but with both signals, it was efficiently 
degraded (Fig. 3a,b,c). The USR could lead a target protein to degradation, but only if associated with an 
ubiquitin signal, present on the target protein itself or carried by the binding partner (Fig. 3c,d). 
Strikingly, the co-degradation of the ubiquitinated binding partner was occurring only, when an USR was 
also present in its sequence. In other words, they demonstrated that an ubiquitinated member of a 
complex could act in trans and catalytically (Fig. 3e), like an adaptor for the proteasome, leading 
multiple copies of USR-containing partner to degradation, but only if it did not contain itself an initiation 
site. In such a complex, the substrate specificity was then determined primarily by the presence of an 
initiation site, rather than by the location of the ubiquitin modification. Additionally, the chemical 
properties of the initiation site added another substrate selectivity level as certain unstructured regions 
were more favorable [15, 18].  
These latter results would explain why MBP, a tightly folded protein, was not co-degraded with a 
DARPin-degron construct. It is likely that both proteins could form a complex, which was brought to the 
proteasome but that the DARPin-degron construct was a much more favorable substrate for the   
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proteasome, which then spared the MBP.  It cannot also be excluded that our chimeric F-box protein, 
which was also degraded by the proteasome, and even more readily than MBP, might even have been 
competing with MBP and decreasing its degradation. In other words, the chimeric F-box protein could 
have, after mediating MBP ubiquitination and thus promoting its recognition by the proteasome, 
inhibiting its degradation in a second step.  
Protein degradation represents an underexamined dimension of proteomics. All data, which can be 
gathered regarding the ubiquitination machineries, the protesomal degradation mechanism and the 
requirements for an appropriate substrate, are urgently needed and will be determinant for better 
understanding this highly elaborated turnover system. Even so, as more and more information has 
emerged since the discovery of the ubiquitin proteasome pathway by Aaron Ciechanover, Avram 
Hershko and Irwin Rose, all awarded by the chemistry Nobel prize in 2004, the difficulty lies in 
assembling it in a comprehensible manner. Mixed signals do emerge from varying studies, it is thus likely 
that all substrates are not handled similarly by the proteasome, making it even more challenging to 
draw conclusions.  
However, the potential of protein knock-out has been long known and exploited by viruses. Since the 
observation that HPV E6 targets p53 for ubiquitination, numerous other viral proteins have been 
identified, which induce degradation of cellular proteins in order to better escape the immune response 
and ease their progragation [19, 20]. To achieve degradation, viral proteins can manipulate the host 
ubiquitination machinery [21]or bypass it and go directly to the proteasome [22]. Interestingly, while 
already working on our chimeric F-box protein strategy, poxviruses appeared to have evolved a unique 
class of F-box proteins, based on the use of the ANK repeat motif for the substrate recognition domain 
[23]. Their design is close to ours, except that the domain orientation is inverted, the ANK domain lies N-
terminally while the F-box domain lies C-terminally, and is shorter than other cellular F-box motifs 
(approximately 30 residues instead of 45). Poxvirus ankyrin repeat proteins can interact with the host 
SCF ubiquitin ligase complex and most likely use it to redirect the degradation of specific cellular 
proteins [24, 25]. Substrates have not been identified yet but one of these F-box proteins was shown to 
colocalize with NF-κB and interfere with inflammation [24].  
To conclude, it appears that reaching the gate of the proteasome, via a polyubiquitin signal or a degron 
sequence, might not be enough for accessing its safe chamber. A few candidates might success, escape 
the controls and be rewarded but most of them will be driven back, if they are not structurally adapted. 
Other stratagems may be developed, but the future potential of protein knock-out techniques will be 
most likely restricted to a certain type of protein substrates.  
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